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SUMMARY
Various studies involving D_j_ arnfieldi were undertaken to 
further existing knowledge of lungworm infection in horses and 
donkeys. These fall into two main categories: first, a number
of parasitological investigations were carried out including 
experimental and field studies of infection and second, 
immunological investigations were undertaken on the development 
of an ELISA to detect infection with arnfieldi.
In Section I, following a review of the literature 
concerning experimental arnfieldi infection, various
techniques for the culture of D_;_ arnfieldi infective larvae 
were compared.
The technique which proved most successful involved the 
Baermannisation of faeces to recover first stage larvae 
which, following washing and sedimentation to clean the larval 
suspension of faecal debris and concentrate the larvae, were then 
incubated in water in shallow flat bottomed trays for 10-14 days 
until they reached the infective L^ stage. Larvae obtained by 
this method were used for experimental infections.
Two experimental studies were conducted. In the first, ten 
naturally reared adult ponies were infected with 2,000 - 5,000 
D. arnfieldi L^. These ponies were monitored for any clinical 
response to infection and pairs of animals were examined at 
necropsy at various time intervals post-infection. While gross 
lesions were present in the lungs of the first pair of ponies
killed three weeks post-infection, no arnfieldi were found 
until the second pair of ponies were necropsied five weeks post­
infection. The lesions increased with the increase in time 
between infection and necropsy and most ponies exhibited varying 
bouts of coughing.
In the second experiment the response to arnfieldi 
infection was compared in three adult pony mares given 6,000 -
10,000 and three foals given 2,500 L^. At necropsy of one 
mare and one foal six, eight and ten weeks post-infection gross 
lesions attributable to arnfieldi infection were found and 
histologically there was overinflation, bronchitis, cellular 
infiltration and excess mucus in the lumena of the airways. These 
lesions were generally less severe in the foals than in the mares 
and the clinical signs in both groups were confined to mild 
coughing.
In the second part of Section I which deals with lungworm 
field studies the literature concerning naturally occurring 
D. arnfieldi infection is reviewed. A survey of the infection 
rate in 698 donkeys arriving at the Donkey Sanctuary, Sidmouth, 
Devon over a three-year period showed that this has fallen to 34%
compared with 73% in a previous United Kingdom survey in 1973.
This decrease was deemed to be due mainly to increased use of 
improved modern anthelmintics. In a survey of the level of
patent D^ arnfieldi infection in 681 horses and 39 donkeys in the
West of Scotland 28% of the donkeys proved positive while only
two horses (0.3%) had patent infections. Interestingly neither 
of these animals had any history of previous donkey contact. 
During the course of the latter survey an outbreak of coughing in 
a small group of horses/ponies following the introduction of two 
donkeys with patent D_^  arnfieldi infections was investigated. 
The major clinical signs were coughing and increased respiratory 
rates but none of the horses or ponies developed patent 
D. arnfieldi infections. Finally, in this section, a small study 
was undertaken to follow the pattern of faecal excretion of
D. arnfieldi L^ in three adult donkeys and two worm-free donkey 
foals grazing a paddock grazed the previous year by donkeys with 
patent arnfieldi infections. Contrary to expectations the 
foals failed to develop patent infections despite one of the 
adults in the group having a consistently positive faecal L^ 
counts.
In Section II the basic principles and various formats of 
the Enzyme Linked Immunosorbent Assay (ELISA) are outlined
followed by a description of the steps taken to develop the 
reagents necessary for a D_;_ arnfieldi ELISA. The ELISA chosen 
was an antigen capture micro ELISA utilising the 
biotin/streptavadin development system: this allowed the same
antibody to be used for antigen detection (non-biotinylated) and 
assay development (biotinylated).
To check the affinity of anti-D. arnfieldi IgG antibody
prior to use in the test, antibody fractions raised in two
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immunised rabbits were incubated with sections of D_;_ arnfieldi 
worms on slides. This showed that the antibody fractions from 
both rabbits recognised worm antigens although the serum from one 
rabbit gave better results. A comparison of the antigenicity of 
fresh versus formalin-fixed arnfieldi adult worm sections 
showed that fresh worms were more antigenic and 
immunohistochemical studies indicated that antibody recognised 
both surface and somatic antigens on the epicuticle and gut 
lining.
To investigate the composition of the arnfieldi antigen 
the following procedures were carried out: firstly the antigen
was autoclaved to destroy the tertiary structure if peptide in 
nature: secondly, periodate treatment was used to disrupt any
terminal sugars if the D_;_ arnfieldi antigen was a glycoconjugate. 
The results of these treatments suggested that 20% of the 
epitopes of the arnfieldi antigen were protein in nature while 
30% were carbohydrate.
From checkerboard titrations the optimal concentrations of - 
reagents for use in the ELISA were determined. Basically plates 
coated with non-biotinylated antibody were washed prior to 
incubation with test antigen. Following washing, biotinylated 
antibody was added, incubated, washed and streptavadin peroxidase 
conjugate added. After incubation and washing the 
chromogen/substrate was added and incubated in the dark before 
reading. Overall this enabled the detection of EL_ arnfieldi
xi
antigen down to levels of 1.2 - 2.6 ng of protein. Serum samples 
from various animals including experimental and field infections 
were tested using the ELISA. Discrepancies between faecal counts 
and optical densities by ELISA were found. These did not follow 
any set pattern - animals with negative faecal counts could give 
high ELISA readings and vice versa.
An ELISA for arnfieldi antibody was also developed and 
although this correlated well with infection in samples from 
experimental ponies this would have limited diagnostic value in 
the field.
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GENERAL INTRODUCTION
Dictyocaulus arnfieldi (Cobbold, 1884) is the only equine 
lungworm and is found in horses, donkeys, mules, hinnies and 
zebra. Although found in all five continents the only detailed 
reports of the prevalence of D_j_ arnfieldi in donkeys have been 
from the United Kingdom.
The life cycle of arnfieldi is direct. The adults, 
living in the bronchi and bronchioles, lay eggs which are carried 
by the mucocilary blanket up the trachea to the larynx and then 
swallowed. The eggs, containing first stage larvae (L^) are 
passed in the faeces and hatch within a few hours (Wetzel and 
Enigk, 1938; Round, 1972). Two moults occur to produce the 
infective third stage larvae (L^) and this stage can be reached, 
under ideal conditions, in three days. The can survive up to 
14 days in sunlight and 24 - 42 days in the shade (Borovkova, 
1948). Following ingestion by a susceptible host the moult to 
the fourth stage larvae (L^) in the intestine and migrate, via 
the mesenteric lymph nodes to the lungs where the final moult and 
maturation occur in the bronchi toward the periphery of the lobes 
(Wetzel and Enigk, 1938). Adult worms can be up to 10 cm in 
length and are thread-like. The minimum prepatent period is 
9 - 1 0  weeks (Britt and Preston, 1985).
The donkey is considered to be the natural host for 
D. arnfieldi as many animals develop patent infections which 
appear to be non-pathogenic: These may persist for the life of
the donkey if no effective anthelmintic treatment is given. In 
contrast, in adult horses most arnfieldi infections do not 
become patent but clinical signs of a chronic cough, increased
respiratory rate and rhonchi, heard on lung auscultation, usually 
accompany infection (Clayton and Murphy, 1980). Horse foals 
appear to behave more like donkeys and develop patent infections 
without clinical signs: Unlike donkeys however, the duration of
patency is limited, the maximum length of patency recorded in
the United Kingdom being 31 weeks in foals and eight months in
adult horses (Round, 1972). In parts of the Soviet Union up to 
70% of horses have been shown to have patent infections 
(Akramovskii, 1952; Borovkova, 1948; Koulikov, 1935) and the
plane of nutrition is considered to exert an influence on the
length of patency: this ranged from six to seven months for
horses on a high plane of nutrition to 21 months for animals on a 
poor diet (Akramovskii, 1952).
Round (1972) showed that donkey foals usually acquire 
infection in their first grazing season. Regardless of age or 
the time at which these foals start grazing, patent infections do 
not appear until August with the majority reaching patency in the 
autumn. This tends to support the theory that D^ _ arnfieldi 
larvae do not overwinter on pasture (Akramovskii, 1952), and that 
infection of donkey foals originates from larvae passed in the 
spring and summer by infected adult donkeys.
The level of infection in individual donkeys tends to 
increase during the first 2 - 3  years of life. After this faecal 
larval output usually remains fairly constant. It has been found 
that after anthelmintic treatment with fenbendazole and 
mebendazole, which reduces faecal larval counts to zero, adult
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donkeys are resistant to reinfection: this is not the case in
donkeys under 3 years of age (Round, 1972).
In the Soviet Union horse to horse transmission has been 
reported (Akramovskii, 1952) while in this country, although 
horse to horse transmission is possible the horse usually 
acquires infection from the donkey.
Despite the differences in clinical response between the 
donkey and the horse the pathological findings are similar 
(Nicholls, Clayton, Duncan and Buntain, 1979). At necropsy 
D. arnfieldi infection is characterised by pale, raised areas of 
overinflated pulmonary tissue, often wedge-shaped, around the 
lung periphery. These circumscribed lesions are most numerous in 
the caudal lobes, a distribution which is consistent with an 
agent arriving in the lungs via the bloodstream. In many cases 
the small bronchi supplying the overinflated areas are occluded 
by coiled worms and mucus exudate, often greenish in colour. An 
intense mucopurulent reaction with mucus, polymorphonuclear 
leukocytes and eosinophils, surrounds any hatched found in the 
bronchi while adults in the bronchi stimulate little exudation. 
There is epithelial hyperplasia with an increase in both size and 
numbers of goblet cells. The lesions tend to be localised with a 
diffuse eosinophilia being the only change in areas of lung 
exempt from gross parasitological changes.
The differential diagnosis of coughing in the horse poses a 
problem for the practising veterinary surgeon (Clayton and 
Murphy, 1980). Infection with D^ _ arnfieldi is one of the 
possible causes and although it usually produces chronic coughing
i.e. duration greater than three months, usually the veterinary 
surgeon is called in at the start of the episode and thus has to 
differentiate arnfieldi infection from other causes of acute 
and chronic coughing in the horse. Viral infections (equine 
influenza and equine herpes virus type 1) can be confirmed by 
serology and virus isolation while bacterial infections can be 
ultimately confirmed by examination of suitable material. The 
differential diagnosis of causes of chronic coughing often 
depends largely on the history. Cases of Chronic Obstructive 
Pulmonary Disease (C.O.P.D.) usually present with increased 
expiratory effort and a recent history of the horse being fed hay 
or bedded on straw which is of poor quality i.e. mouldy and dusty 
while Pharyngeal Lymphoid Hyperplasia (P.L.H.) usually occurs in 
horses up to four years of age in training and can be confirmed 
by endoscopy. Suspected cases of D_;_ arnfieldi infection present 
special problems. Although there may be a history of grazing 
with donkeys currently there is no way to confirm the diagnosis 
in the live horse. For example faecal examination by Baermann 
technique, which is suitable in donkeys where patent infections 
are the norm, is of limited value in the horse where most 
infections do not reach patency. Endoscopic examination of the 
airways is also of limited value as it is difficult to detect the 
adult worms in the lower bronchi even in heavily infected 
donkeys. When worms have been detected in the bronchi the 
infection is usually patent and larvae can be found in the faeces 
(Clayton, 1987; Fischer, Deegan and Lieske, 1982); an added
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complication is that, in the horse, there is retardation of 
development and the worms often remain less than 1 cm in length.
Examination of tracheal washings has been considered an aid 
to diagnosis of infection in horses (MacKay and Urquhart, 1979). 
On rare occasions Ih_ arnfieldi have been detected but often the 
only significant finding is the presence of eosinophils which, 
although indicative of parasitic infection, is not specific.
Obviously the finding of arnfieldi eggs, larvae or worms 
by Baermann, endoscopy or tracheal washings is proof of infection 
but a negative result is meaningless.
In many instances the diagnosis of D_j_ arnfieldi infection in 
the horse is retrospective in that if, following treatment with 
an anthelmintic effective against arnfieldi, the animal stops 
coughing then it is assumed the cough was indeed due to the 
presence of arnfieldi. In other cases diagnosis is simply 
based on coughing in association with a history of recent or 
previous grazing contact with donkeys.
Clearly this is a rather unsatisfactory situation and the 
objectives of the work presented in this thesis were first to 
provide more information on various aspects of D_^  arnfieldi 
infection and second to examine the possibility of developing a 
diagnostic test for lungworm infection in horses. In view of the 
increasing use of the Enzyme Linked Immunosorbent Assay (ELISA) 
for the diagnosis of parasitic infections in man and animals the 
ELISA was considered the test of choice. Although most ELISAs 
are used to detect antibodies, a diagnostic test for equine 
lungworm would have to differentiate current from previous
infection and therefore the ELISA would be one which could detect 
D. arnfieldi antigen.
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MATERIALS AND METHODS
PARASITOLOGICAL TECHNIQUES 
Faecal Sampling
All faecal samples were collected per rectum using separate
plastic gloves for each animal. The samples were then placed in 
plastic cartons with lids and stored in the refrigerator until 
tested.
Faecal Examination
McMaster Flotation
Faecal samples were examined by a modified McMaster 
technique (Gordon-Whitlock, 1939). In this method, 3 g of faeces 
are homogenised in 42 ml water, passed through a 100 ura mesh 
sieve, and the filtrate collected. A 15 ml flat-bottomed tube is 
filled with the well-mixed filtrate then spun in a centrifuge at 
2000 rpm for 3 min. The supernatant is poured off, the sediment 
agitated using a whirlmixer and the tube filled to the previous 
level with saturated salt (NaCl) solution. The tube is inverted 
6 times and sufficient fluid removed in a pipette to fill both
chambers of a McMaster slide. The eggs rise rapidly in the
floatation fluid hence the pipetting must be accomplished 
rapidly. The number of eggs in both chambers of the McMaster 
slide is multiplied by 50 to give the count in eggs per gram 
(e.p.g.) of faeces.
Baermann Sedimentation
The detection of Dictyocaulus spp. larvae in faeces was
achieved using the modified Baermann method of Henriksen (1965)
in which 10 g of faeces was suspended in a gauze bag in warm 
water contained in a conical measure (urine flasks). After a
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minimum of 6 hours, the supernatant was drawn off leaving a final 
volume of 10 ml and the gauze plus faeces discarded. The numbers 
of larvae in 1 ml were determined and the results expressed as 
larvae per gram of faeces.
Worm Recovery at Necropsy
Lung Examination for Recovery of D^ _ arnfieldi
A perfusion method similar to that of Inderbitzen (1976) was 
employed to recover worms from the lungs at necropsy. The 
procedure was as follows: The pericardial sac was opened to
expose the pulmonary artery in which a 2 cm incision was made. A 
rubber tube was introduced pointing towards the tracheal 
bifurcation and fixed in situ by double ligatures. The remaining 
great vessels were tied off and water from a mains supply allowed 
to enter via the pulmonary artery. The water entering the 
vascular system eventually ruptured the capillary network to 
return via the bronchial tract and out from the trachea. Twenty 
litres of washings collected from each set of lungs were filtered 
through a 37 micron aperture sieve and subsequently examined for 
worms.
This method required intact pleura. If the pleura had been 
damaged on removal from the carcase or if samples of lung tissue 
had been removed for histological examination, an alternative 
method of lungworm recovery was necessary. The method used was 
as follows: The airways were opened by cutting along the bronchi
with scissors. Each lung was then floated with the cut surface 
down for 12 hours in a bucket of warm saline, after which the
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tissue was removed and the supernatant syphoned off. The 
remainder was spun in a centrifuge at 1,500 rpm for 3 minutes and 
the sediment examined microscopically for the presence of worms. 
Culture and Administration of Dictyocaulus arnfieldi Larvae
Larval Culture
Infective third stage Dictyocaulus arnfieldi larvae (L^) 
were cultured as described (page 33). Larvae in water were 
transferred from flat glass trays into 500 ml urine flasks and 
left to sediment for a minimum of eight hours. The supernatant 
was then carefully syphoned off to leave a volume of 50 ml. The 
numbers of larvae present in each sample were determined by 
counting 5 ml (10%) of a well-mixed larval suspension using an 
Eel counting slide (Hawksley) under the dissecting microscope. 
Doses were then made up by volume to give the desired number of 
larvae.
Administration
The animals were restrained to allow the passage of a 
polythene stomach tube (Portex Ltd., Hythe, Kent, England). The 
infective dose was then poured through a funnel into this tube 
then flushed through with water.
ANIMALS
Housing
Animals were housed in a unit of ten cement-lined brick 
loose boxes with access to a concrete run-out area for part of 
the day. Where required, different groups/individuals were kept 
separately. Straw bedding was removed and the loose boxes
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thoroughly cleaned out daily: The run-out area was also swept
and hosed daily. The animals were fed hay ad lib and 
proprietery horse and pony cubes or coarse mix (Spillers). 
Worm-Free Foals
Worm-free donkey foals for the grazing study were obtained 
in the following manner. The in-foal donkey mares were wormed 
approximately every eight weeks while at grass with pyrantel 
embonate (Strongid-P, Pfizer, Kent) . Several weeks before they 
were expected to foal they were housed individually in clean 
boxes and subsequently wormed repeatedly with pyrantel every four 
weeks. The donkey mares foaled indoors and the foals were housed 
in their boxes with access to the run-out area. At weaning the 
two donkey foals were housed together with access to the run out 
area.
PATHOLOGICAL TECHNIQUES 
Post Mortem Examination
All animals were shot using a humane killer and faecal and 
blood samples were collected at this time. The larynx, trachea, 
heart and lungs were carefully removed intact.
The lungs were examined visually and by palpation. The 
number, size, appearance and distribution of any superficial 
lesions were noted.
Histological Techniques
Tissues for light microscopy were obtained at necropsy from 
the lungs and bronchi both from gross lesions and randomly from 
the caudal lobes. Blocks about 2 - 3 mm thick were collected in
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buffered neutral formalin, fixed for at least 24 hours, post­
fixed in corrosive formol, dehydrated and cleared in a double 
embedding series. Tissue blocks were finally embedded in 
paraffin wax and cut at 5 - 6 urn in a rotary microtome.
Haematoxylin and eosin (H & E) was the routine stain used 
for sections however selected sections were also stained with 
Alcian Blue/Periodic Acid Schiff (PAS) pH 2.5 for mucus and 
carbol chromotroph for eosinophils.
Scanning Electron Microscopy Techniques
Samples for Scanning Electron Microscopy (SEM) were taken 
from the following sites
1. Dorsal trachea midway between the larynx and the tracheal 
bifurcation.
2. Ventral trachea midway between the larynx and the tracheal 
bifurcation.
3. Right cranial lobar bronchus.
4. Right caudal lobar bronchus.
5. Right cranial segmental bronchus.
6. Right caudal segmental bronchus.
7. Small bronchus from the right cranial lobe of the lung.
8. Small bronchus from the right caudal lobe of the lung.
9. Lung slices from three different locations in the right
cranial lobe for examination of bronchioles, alveolar ducts 
and alveoli.
10. Lung slices from two different locations in the right caudal 
lobe for examination of bronchioles, alveolar ducts and
alveoli.
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When samples 1-4 had been taken, the right cranial lobar 
bronchus was cannulated and the cranial lobe of the lung perfused 
with Karnovsky's fixative (2.5% paraformaldehyde/2% 
glutaraldehyde). The dorsal basal segment of the caudal lobe of 
the right lung was similarly perfused via a cannula in the 
appropriate segmental bronchus.
Samples 5-10 were then taken. From all sites, pieces of 
tissue with a surface area of not more than 1 cm square and 
approximately 2 mm thick, were immersed in Karnovsky's fixative 
for 24 hours. Tissues were rinsed in 0.2M cacodylate buffer for 
four hours before dehydration through a series of acetones then 
critical point dried in liquid CC^, mounted on aluminium stubbs 
and coated with gold paladium. Specimens were examined by means 
of a Philips 501B scanning electron microscope.
Processing for Scanning Electron Microscopy
Tissue samples were treated according to the following 
regimen.
Wash the tissue gently on 0.1M Cacodylate buffer (sodium) to 
remove surface blood and mucus.
Fix in Karnovsky's EM fixative or 3% buffered Gluteraldehyde 
- a minimum of 24 hours.
Trim or slice tissue to expose the surfaces to be scanned. 
As the appearance of the tissue changes considerably during 
drying to ensure the correct surface is scanned the top 
right hand corner is cut diagonally.
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Wash in buffer (0.1M sodium cacodylate buffer) for a minimum
of 4 hours.
Wash in 70% acetone - minimum of 4 hours.
Wash in 90% acetone - minimum of 2 hours.
Wash in 100% acetone - minimum of 2 hours.
Leave in 100% acetone overnight.
Attach tissues to an aluminium stub with silver paint.
Sputter coat with gold for 4 minutes.
Store samples at 37°C.
HAEMATOLOGICAL TECHNIQUES 
Collection and storage of samples
Animals were bled by jugular venupuncture into sterile 
vacutainers (Becton-Dickinson, New Jersey, USA).
For estimations requiring serum, 10 ml of blood was drawn 
into a plain vacutainer and left to stand for several hours to 
allow the formation of a firm clot. Serum which separated was 
decanted into polythene Eppendorf tubes, frozen and stored at 
-5°C.
Samples for haematological estimations were collected in 
heparinised vacutainers and tested within a „ few hours of 
collection.
All parameters were either measured in, or the results 
converted into SI units.
Packed Cell Volume (PCV)
The packed cell volume (PCV) was determined by the 
microhaematocrit method. The heparinised blood sample was mixed
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gently before filling 2 capillary tubes, which were sealed by 
Cristaseal (Hawksley & Sons Ltd., London) at one end. The tubes 
were spun for 6 mins in a microhaematocrit centrifuge, the 
percentage PCV was then determined from the scale on a Hawksley 
Microhaematocrit Reader and converted to a 1/1 ratio.
STATISTICAL ANALYSIS
Where applicable data was analysed using the Chi square 
test. With one degree of freedom, the significance at the 5% 
level (p = 0.05) is above 3.84.
IMMUNOLOGICAL TECHNIQUES 
Preparation of Reagents
Dictyocaulus arnfieldi Antigen
All stages of D_j_ arnf ieldi present in the lungs of a 
naturally infected donkey which had been humanely destroyed for 
chronic lameness, were recovered using the modified Inderbitzen 
method described earlier (page 10). The arnfieldi worm
material was washed by centrifugation with TRIS-HC1 buffer (4 
washes at 1500 rpm for 3 min), before being frozen in a small 
volume of buffer.
At this point, the various stages of D_^  arnfieldi present 
were still intact so, following defrosting, the suspension was 
macerated using a Polytron. The suspension was kept on ice and 
"Polytroned" for 45 mins before most, but not all, of the 
parasites were disrupted. This suspension was then stored 
overnight at 4°C.
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Following overnight storage, the suspension was centrifuged 
at 4200 rpm for 20 min, the supernatant decanted, and respun at 
4200 rpm for a further 20 min. The resultant supernatant was 
decanted, the pellets resuspended using a vortex mixer, then 
combined and frozen at -5°C.
The final supernatant was then spun at 16,000 for 45 min in 
an ultracentrifuge and decanted to give the solution which was 
used as the "antigen solution". The pellet was again resuspended 
using the vortex and frozen.
The protein content of the antigen solution was determined 
by the Lowry method with precipitation (vide infra). Read at 680 
nm using the tungsten light source, the protein content was 30 
ug/ml. The antigen solution was aliquoted and frozen for later 
use.
Immunisation of Rabbits
To produce antibodies to D_j_ arnf ieldi two rabbits were 
immunised as follows
All stages of D^ _ arnfieldi, recovered from the lungs of an 
infected donkey (vide supra) were washed by centrifugation in PBS 
- four changes spun at 1500 rpm. The pellet was resuspended in a 
small volume of PBS before being transferred to a Griffiths tube, 
kept in ice, and the parasites disrupted. The final volume 
(4 ml) was mixed with an equal volume of Freund's complete 
adjuvant. This was homogenised by taping a syringe containing 
the mixture onto a whirlmixer and mixing for 30 minutes until a 
creamy coloured homogenous solution was obtained. This solution 
was split into two equal volumes, one of which was frozen (at
-5°C) for later use. The other was used immediately to immunise 
two rabbits. Each rabbit received 2 ml of the solution. This 
was administered subcutaneously at multiple sites over the 
shoulder and back region of the rabbit to stimulate the maximum 
immune response.
Six weeks later the rabbits received a similar booster 
immunisation using the Ek_ viviparus/Freunds mixture which had 
been previously frozen. Two weeks after the second immunisation 
the rabbits were bled out and their sera frozen separately. 
Purification and Concentration of anti-D. arnfieldi Antibodies 
Preparation of DEAE column
The column (Pharmacia 250 x 25) was loaded with DEAE 
prepared as follows
60 g of DEAE was added to approximately 500 ml of a 0.01M
phosphate buffer, pH 7.6 and stirred well. This was left to
equilibrate for 20 minutes at room temperature before being 
sieved through a Buchner funnel using 11mm filter paper.
The column was assembled, ensuring it was truely vertical. 
The solid DEAE retained by the filter paper was re-suspended in 
approximately 600 ml of the phosphate buffer and this was used to 
load the column. The excess fluid was allowed to drain away from 
the bottom of the column with more DEAE suspension being added at
the top. Care must be taken not to disturb the loading edge nor
to let the column dry out. When the column was full and white in 
appearance, the plug was put in and the column left overnight to 
settle.
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In the morning the column required packing before use. The 
top flow filter was inserted and the phosphate buffer flushed 
through, flow rate approximately 120 ml/hr, to pack the column. 
Prior to the chromatographic separation the ultra violet 
detection system was switched on for one hour. This allowed the 
mercury in the mercury vapour lamp to vapourise completely. 
After one hour the flow rate was reduced to 60 ml/hr. The 
plotter was allowed to warm up and the fraction collecter set to 
collect 3 ml in each tube.
After 20-30 minutes at the reduced flow rate the pump was 
switched off and the buffer allowed to drain out. When the 
bottom of the meniscus had entered the column the top flow filter 
was removed and the sample (Rabbit 1 or 2) added with a syringe 
to the top of the column. The sample was allowed to drip through 
until the meniscus had entered the column then phosphate buffer 
was added by syringe before the top flow filter was replaced. 
The pump was switched on to give a flow rate of 60 ml/hr to flush 
through the sample which was collected in the fraction collector.
Amicon - Ultrafiltration Method
The Amicon stirred cell had a volume of 60 ml. The 
filter/membrane was a YM10 which had an exclusion range of
10,000 mol weight (Diaflow Ultrafilter Membranes). Before use 
the membrane had to be treated as follows
The membrane must be handled by the edge only with care not 
to scratch the glossy surface. The membranes are pretreated with 
glycerin to prevent drying and sodium azide is added as a 
preservative. These must be rinsed off before use by floating
19
the membrane glossy side down in a beaker of distilled water for 
at least one hour, changing the water three times. For use the 
membrane is placed in the amicon chamber with the glossy side
toward the solution. For re-use the membranes should be stored 
in 10% ethanol/water solution in the refrigerator.
The amicon cell was set up in the refrigerator. The
carrying gas used was nitrogen at a pressure of 55 psi (37 atm). 
IgG Preparation by Caprylic Acid Precipitation 
To one volume of serum add two volumes of acetate buffer 
(0.06 H, pH 4) in a beaker and stir with a magnetic stirrer. 
Measure out 7.5 ml caprylic acid (also called octanoic acid) for 
every 100 ml of serum used. Slowly drip the caprylic acid into 
the serum/acetate buffer solution while stirring vigorously. 
Continue stirring for 30 minutes after the addition of all the
caprylic acid. Centrifuge the solution for 30 minutes at
2000 rpm and 20°C. Decant the supernatant and adjust the pH to
5.7 using 0.02M phosphate buffer pH 6.2. Dialyse the supernatant 
against 0.02M phosphate buffer, pH 6.2 at 4°C for two nights. If 
any precipitate has formed spin it down at 2000 rpm and 20°C for 
as long as needed. Concentrate supernatant in an amicon to give 
a small volume of high IgG concentration.
Acetate Buffer 0.06M pH 4
9.84 g sodium acetate (anhydrous)
6.2 ml glacial acetic acid
Make up to less than 2 litres and adjust pH to 4 if 
necessary. Make up to 2 litres.
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Phosphate Buffer 0.02M pH 6.2
Made as a 1 : 100 dilution of stock 2M phosphate buffer 
pH 6.2
Phosphate Buffer 2M pH 6.2
119.38 g Na2HP04 .12H20 
or 59.4 g Na2HP04 .2H20
Make up to less than 500 ml and adjust to 6.2 if necessary. 
Make up to 500 ml.
Concentration of purified anti-D. arnfieldi antibody 
solution
After the protein concentration of the fractions collected 
from the column had been calculated, all tubes with significant 
amounts of protein were selected for concentration. 
Concentration of this fluid was performed as before by 
ultrafiltration in an Amicon stirred cell ultrafilter using a 
filter of exclusion range 10,000 mol. wt. Ultrafiltration of the 
antibody solution was performed at 3.5 bar using nitrogen. Once 
the antibody solution fluid had been reduced to the desired 
level, the filtration was stopped and the concentrated antibody 
solution removed from the cell.
The cell was then washed with 40 ml distilled water and the 
filter stored in 10% ethanol. The resultant concentrated 
antibody solution was aliquoted and frozen at -20°C until use.
Protein determination using the modified Folin-Lowry 
technique
To determine the protein concentrations of the final 
antibody and antigen solutions, known dilutions of these
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were made up in distilled water to give final volumes of 1 ml. 
These dilutions were then tested for protein concentration using 
the modified Folin-Lowry technique (Sigma Kit No. P5656). This 
protocol involved the preparation of a standard curve using 
solutions of known protein concentrations then processing the 
test solutions and comparing those with the standard curve. 
Absorbence values of all solutions were read at 680 nm on a Cecil 
Digital UV Spectrophotometer (model no. CE 2922).
ELISA TECHNIQUES 
Coating of Plates
The antibody to arnfieldi raised in rabbits was diluted 
to 1:100 in 0.5H bicarbonate/carbonate coating buffer pH 9.6 
(page 23). Fifty microlitre aliquots of the appropriately 
diluted antibody were pipetted into each well of a 96 well 
microtitre plate which was then sealed with a clear adhesive 
sheet and incubated for 2 hrs at 37°C. After incubation the 
plates were washed 3 times with PBS (pH 7.2) containing 0.05% 
Tween 20 (PBST) to remove any unadsorbed antibody. Tween 20 was 
incorporated into the wash buffer because of its mild detergent 
properties, which facilitate the removal of any unabsorbed 
reagents during the washing procedures, and its ability to block 
non-specific binding of assay reagents. The plates were then 
shaken dry and stored at -30°C until use. Before use the plates 
were thawed and washed a further 3 times with wash buffer and 
tapped dry.
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The ELISA plates used throughout this study were Dynatech 
129B (Dynatech, Virginia, USA) 96 well polystyrene microtitre 
plates. The microtitre plates were of the format shown below, 
and when referring to ELISA plate formats, the notation of 
columns 1-12 and rows A-H will be used.
A 1 2 3 4 5 6 7 8 9 10 11 12
B
C
D
E
F
G
H
ELISA Buffers and Substrates
Coating Buffer (Carbonate-bicarbonate, pH 9.6)
1.50 g Na2C03
2.93 g NaHCO 3
Make up to 1 litre with distilled water. 
Wash Buffer (PBS-Tween 20, pH 7.2)
42.50 g NaCl
5.35 g NaH2P04
Na2HP04
Tween 20 (polyoxyethylene (2) - sorbitan
monolaurate)
1.95 g
2.50 ml
Make up to 5 litres with distilled water.
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This can be stored at room temperature but must be discarded 
if it becomes cloudy.
Diluting Buffer
Add 800 yil bovine serum albumin to 100 ml of wash buffer.
Store at +4°C.
Peroxidase Substrate - Stock Solution
100 mg orthophenylene diamine (O.P.D.)
10 ml absolute methanol
Mix thoroughly. Should be stable for 1-2 weeks if stored in 
the dark at +4°C.
Peroxidase Substrate - Working Solution
50 ml distilled water
24.7 ml 0.1 M citric acid
25.3 ml 0.2 M NaoHP0,
2 4
1 ml stock O.P.D.
0.05 ml 6% H 20 2 
Blocking Agents
A solution (5 or 2.5%) of dried skimmed milk (Marvel) in 
diluting buffer (page 24) was used as a blocking agent. Marvel 
acts as a blocking agent to prevent non-specific binding of test
reagents thereby reducing non-specific adsorption of serum
proteins and test reagents to the plate, which eliminates 
background "noise" in the system.
Biotinylation of Rabbit anti-D. arnfieldi Antibody
The antibody solutions were biotinylated to provide a 
suitable method for developing the proposed assay by using 
streptavidin conjugated enzymes.
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The antibody solutions were dialysed against three changes 
of 0.1M Na2HC02 at pH 8.2-8.6, then the protein concentration of 
the samples were adjusted to 1.0 mg/ml. N-
hydroxysuccinimidobiotin (Sigma H1759) was first allowed to reach 
room temperature (stored at -20°C) to prevent hydrolysis and then 
weighed out and dissolved in freshly made up dimethyl sulphoxide 
to 1 mg/ml. This was then added at 120^ul per ml of antibody 
sample and rotated at room temperature for 4 hours on a rotary 
mixer (Eschmann; Sussex, model BSM). Following this the mixture 
was dialysed against PBS (pH 7.2) overnight before being used in 
the development of the capture sandwich assay.
EDTA Treatment
Equal volumes of EDTA solution (0.2M EDTA in 0.2M Tris 1M 
HC1, pH 8) and serum were boiled for 20 minutes in a stoppered 
glass test tube. The tubes were centrifuged (15,000g, 15
minutes) and the supernatant analysed for the presence of 
D.arnfieldi antigen in the ELISA.
Autoclave Treatment
The antigen solution/serum was diluted as required in PBS 
and autoclaved at 121°C, 15 psi for 15 minutes.
Periodate Treatment
Equal volumes of antigen solution/serum and sodium periodate 
solution (100m Molar) in acetate buffer pH 5.5 were mixed in a 
stoppered glass test tube and incubated at room temperature 
in the dark overnight.
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Preparation of Dictyocaulus arnfieldi Sections
Whole IK_ arnf ieldi worms recovered from the lungs of an 
infected animal were blocked in paraffin wax to enable five 
micron sections to be cut. These five micron sections were then 
mounted on glass microscope slides.
Dewaxing of IK arnfieldi Sections
The D_j_ arnf ieldi sections mounted on glass slides in 
paraffin wax were dewaxed using a series of graded alcohols. The 
slides were immersed in each alcohol solution for three minutes. 
The initial immersion was 100% alcohol and the final immersion 
was 100% distilled water.
Dehydration of IK arnfieldi Sections
The IK_ arnfieldi sections were dehydrated using a series of 
graded alcohols. Immersion was for three minutes each time 
starting with 10% alcohol and finishing with 100% alcohol.
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SECTION 1
EXPERIMENTAL AND FIELD STUDIES WITH Dictyocaulus arnfieldi 
IN HORSES, PONIES AND DONKEYS
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INTRODUCTION - EXPERIMENTAL STUDIES
As one of the major objectives of this work was to try to 
develop a diagnostic ELISA for D_j_ arnf ieldi it was important to 
have animals known to have been infected with lungworms. It was 
necessary therefore to have a reliable method of culturing 
D. arnfieldi L^. The first part of Section I deals with the 
examination and modification of existing larval culture methods.
Subsequently two experimental studies were1 carried out in ponies
not only to provide material considered important for the 
development of a diagnostic ELISA but also to provide more basic
information on the clinical response and pathogenesis of the
infection in adult and young animals.
The results of this work will be presented under the
following headings
Laboratory Culture of D^ _ arnfieldi.
Experimental Infection with D^ arnfieldi.
Experiment 1 - Infection of adult ponies.
Experiment 2 - Infection of pony mares and foals.
LABORATORY CULTURE OF Dictyocaulus arnfieldi
There have been only a few attempts to culture D^ arnfieldi 
in the laboratory (Round, 1972; Britt and Preston, 1985) and no 
particular method has proved entirely successful with very poor 
or negative yields being a common occurrence. Previous culture 
methods described by Round (1972) have included the following:-
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(1) Faecal Thin Layer Method (Jarrett, Jennings, McIntyre, 
Mulligan and Urquhart, 1957 - D_;_ viviparus)
A 1 cm layer of faeces in a shallow plastic tray is covered by
damp butter muslin and left at room temperature for 5-6 days. 
The surface is then washed gently with water to recover the 
larvae. Yields of arnfieldi L^ by this method proved variable 
but never good.
(2) Incubation of Faeces in Jars
From infected animals faeces are put into jars with screw 
lids. Tap water may be added to a depth of approximately 1 cm 
before incubation at 15°C.
Jars with added water have produced better yields of
D. arnfieldi L^ than dry jars but maximum recoveries were only
approximately 12% of the original contents.
(3) Water Culture (Parfitt and Sinclair, 1967; Michel, 1968 - 
D. filaria).
First stage larvae are cultured in shallow trays in tap 
water at 20°C. This method gave poor recoveries for 
D. arnfieldi♦
(A) Filter Paper Method (Method cited by Round, 1972)
A thin layer of faeces containing L^ is spread on filter 
paper in a petri dish and the surface sprayed with water to keep 
the culture moist. This method proved reasonably successful for 
small amounts of faeces.
(5) Sawdust Thin Layer Method
First stage larvae recovered by the Baermann technique are 
transferred to a Petri dish and tap water added to cover the
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bottom of the dish. Sawdust is then added to cover the surface 
and to soak up all the water before the dishes are incubated at 
20°C for four days. The wet sawdust is subsequently Baermannised 
overnight to collect the infective larvae. Although this was 
the most successful method adopted by Round (1972) and Britt and 
Preston (1985) it was inconsistent and poor yields were 
occasionally obtained.
As none of these methods for the culture of arnfieldi 
proved overwhelmingly successful it was decided to try several 
other techniques used routinely to culture other species of 
nematode larvae. The source of larvae for all of these 
techniques was faeces from four naturally infected donkeys with 
counts of 40-80 EL. arnfieldi per gram of faeces. When faeces 
from more than one donkey were used these were bulked together 
and well mixed. A 10 g sample from each batch of faeces was 
examined to ensure the presence of reasonable numbers of larvae 
before setting up the cultures as follows:
(1) Approximately 100 g of faeces, pressed lightly into balls, 
were put into plastic cartons with lids. These were stored in 
the culture room at 22°C for one week. A sample of the faeces 
was then mixed with a little water in a petri dish and examined 
with the dissecting microscope before the remainder of the faeces 
were put in 30 g amounts and Baermannised. No infective larvae 
were recovered using this technique.
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(2) First stage larvae collected following Baermannisation of 
faeces were placed in lidded petri dishes with:-
(a) sawdust and water;
(b) vermiculite and water;
(c) damp filter paper.
These were incubated at 37°C and sprayed with water to keep 
the cultures moist. On examination with the dissecting 
microscope two days later all larvae present in the cultures were 
dead.
(3) The following faecal samples were cultured in lidded petri 
dishes and kept at room temperature for six days:
(a) fresh faeces, sawdust and water;
(b) homogenised fresh faeces, sawdust and water;
(c) homogenised fresh faeces, vermiculite and water;
(d) homogenised fresh faeces, charcoal and water;
(e) homogenised fresh faeces and water;
(f) homogenised fresh faeces put onto moist filter paper. 
After six days samples from all of the above were examined
microscopically by Baermannisation but no viable arnfieldi 
were found.
(4) Fresh faeces were crumbled into a bucket and mixed with 
water to enable the faeces to be spread evenly, to a depth of 
approximately 1/2", on plastic trays. The trays were put into 
plastic bags, sealed to keep the faeces moist and put into the 
culture room at 22°C. The trays were examined daily and water 
sprayed on the surface when required to keep the cultures moist. 
After six days water was added to the surface of the trays and
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faeces to try to collect any larvae. Unfortunately the faeces
formed a slurry with the water making direct examination
impossible. The slurry was therefore sieved and then filtered 
through a milk filter which was then inverted on to another milk 
filter and Baermannised. A few third stage D_;_ arnfieldi were 
found by this method but unfortunately there was gross
contamination with small strongyle (cyathostome) larvae. It 
would have been possible to eliminate the cyathostomes by 
Baermannising the original faecal sample to recover arnfieldi 
, sterilising the faeces, then adding the suspension to the 
sterile faeces and culturing as before but due to the poor 
yields the extra stages involved were not thought to be 
justified.
(5) First stage D_j_ arnf ieldi larvae recovered by the Baermann
technique were concentrated by sedimentation and put into tissue 
culture bottles with either tap water, distilled water or(Minimal 
Essential Medium (M.E.M): the culture fluid was changed twice
daily.
These cultures were left on the bench and examined daily to 
assess larval viability and stage of development. After two days 
all of the larvae in MEM were dead. In distilled water larvae 
survived for a maximum of four days while in tap water a few 
were found after one week but most did not reach this stage of 
development.
32
(6) Fresh faeces were crumbled into a bucket and enough water
added to enable the mixture to be spread onto glass pie dishes to
a depth of < 1/2 inch as follows:-
(a) faeces and moist vermiculite;
(b) faeces and moist sawdust;
(c) faeces on top of damp filter paper;
(d) faeces.
No larvae were found in samples removed from (a) and (b)
after five days while similar samples from (c) and (d) had a few
D. arnfieldi second stage larvae (l^). Further samples from (c) 
and (d) examined after seven days were negative.
(7) Faeces were mixed with warm water then passed through a 
coarse sieve. The filtrate was then poured through filter paper 
on a Buchner funnel using suction. This filter paper was then 
inverted on to a milk filter and Baermannised. The first 30 ml 
from each Baermann funnel was collected in 15 ml conical tubes 
the following morning then centrifuged at 1000 rpm for ten 
minutes. The supernatant was removed and the loose pellet of 
larvae resuspended by inverting the tube several times before 
pouring the larval suspension into a petri dish on the bench. 
The larval suspension was 'washed' by repeating this spinning 
process twice daily. Although this method did yield some clean
after 10-14 days not all of the larvae had developed to 
and many were dead.
(8) Faeces were crumbled and 'Baermannised' by placing 30 g 
samples in gauze in 250 ml urine glasses filled with tap water 
for six hours. The water was then sucked off leaving a volume
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of 25 ml. These 25 ml samples were bulked in 150 ml lots and 
transferred to 500 ml urine glasses which were then filled with 
fresh water and left to sediment overnight or for at least six 
hours. Sedimented 50 ml samples from these were then bulked 
again to 150 ml lots, transferred to 500 ml glasses, and then 
filled with fresh water. This process was repeated until the 
larval suspension was clean and when clean the suspensions were 
transferred to glass trays which remained on the bench. Water 
was added twice daily using a wash bottle to keep the depth of 
the water at approximately 1/2 inch and help aerate the cultures. 
The trays were examined regularly under the dissecting microscope 
to check for larval viability and contamination. It took 10-14 
days for the larvae to reach the stage and having reached this 
stage they remained viable for approximately two weeks. When the 
cultures had reached the stage they were bulked together in 
500 ml urine glasses and sedimented overnight before reducing to 
a volume of 50 ml. These 50 ml samples were bulked in glass 
trays.
Maintenance of larvae in water trays following 
Baermannisation and repeated sedimentation was found to be the 
most successful technique for culturing arnfieldi larvae from 
the stage present in faeces to the stage required for
infection and this was the method used to produce larvae for all 
the experimental infections. Although this method was found to 
be the most successful of those tried, it was time consuming and 
produced adequate, but not large, yields.
EXPERIMENTAL INFECTION WITH Dictyocaulus arnfieldi 
INTRODUCTION
Since there are only a few reports of experimental 
infections with D^ arnfieldi there is a paucity of detailed 
information relating to lungworm infection in both donkeys and 
horses.
Round (1972) described the results of a series of 
experimental infections mainly in ponies.
In the first using worm-free animals, two yearling ponies 
which received 6,000 were compared with two uninfected
controls. The infected animals started to cough after 17 days, 
continued to cough for ten weeks and in both the respiratory rate 
was also raised. Despite frequent examination no larvae were 
ever found in the faeces and there were no differences between 
infected and control animals with regard to haematology, serum 
protein levels or body weight gains. Ten months later all four 
ponies were infected with a dose of 12,000 and compared with a 
further two uninfected controls of the same age. The ponies 
which were experiencing a reinfection started coughing 12 days 
post challenge and had occasional adventitious lung sounds which 
were first heard on auscultation on day 13 post infection. The 
ponies undergoing primary infection were much more severely 
affected with clinical signs of severe coughing, pronounced 
adventitious lung sounds and forced respiration, from 15 days 
post-infection. In both pairs of infected ponies there was an 
increase in the number of circulating eosinophils during weeks 
three and four post infection/reinfection when compared with the
uninfected controls. None of the four infected animals developed 
patent infections and all six ponies were returned to pasture.
Eleven months later the two ponies which had been infected 
twice previously were each given a further dose of 24,000 
D. arnfieldi L^. There was no coughing or other clinical signs 
associated with infection and larvae were not detected at any 
time in the faeces.
From these experiments Round concluded that all ponies 
showed clinical signs of coughing, increased respiratory rates 
and adventitious lung sounds after their first exposure to 
infection with D_;_ arnfieldi. These signs occurred from Day 11 
and tended to be most obvious at 3-5 weeks post infection: 
Reinfection produced a diminished clinical response which Round 
suggested could be due to some form of acquired immunity.
A further experiment by Round (1972) in which 12,000 were 
administered to four worm-free mature ponies produced an increase 
in circulating eosinophils by week five and coughing, although 
mild, was persistent and notable from Day 20. Minor adventitious 
sounds were also present from Day 18 in two of the ponies but 
only persisted for a few days; these infections never became 
patent. From this study Round suggested that, in adult ponies, 
clinical signs relating to D_^  arnfieldi infection were due to 
immature stages and that the lack of patency was a result of this 
retardation of development.
Round also attempted experimental infection of younger 
animals. Eight Welsh Mountain Pony foals, naturally reared but
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considered unlikely to have had previous experience of 
D. arnfieldi were used. Seven received 7,000 D_^  arnfieldi 
orally with one animal remaining as an uninfected control. The 
intention was to carry out weekly serial kills. By seven days 
post infection there had been no clinical signs and neither 
macroscopic lesions attributable to D_j_ arnfieldi nor lungworms 
were found. By 14 days post infection only slight coughing had 
occurred which could be related at necropsy to pneumonic lesions 
of virus pneumonia; again no lungworms were found. Due to these 
negative results Round considered that the larvae used were non- 
inf ective and abandoned the experiment.
On subsequent checking of the infectivity of his larval 
culture by infection of four 20 month old ponies, increases in 
respiratory rates and mild adventitious sounds were observed in 
all animals associated in some with a circulating eosinophilia. 
This suggested that the original larval inocula may indeed have 
been infective and the six survivors from the "foal infection" 
were each given a further 10,000 from the batch used to infect 
the four 20 month old ponies. This was therefore a reinfection 
after 94 days for five animals and an initial infection for one. 
One reinfected foal was killed at 11 days post reinfection and 
patches of overinflation were seen in the diaphragmatic lobes. 
In other lung lobes there were consolidated areas which proved to 
be lesions due to infection with Streptococcus zooepidemicus. On 
dissection of the bronchi and overnight flotation of the lungs 30 
D. arnfieldi were recovered, all of which were mature. The 
single foal experiencing a primary infection was necropsied at 13
days. Although there was some emphysema no IX. arnfieldi were 
found. This indicated that the worms found in the reinfected 
animal were from the first infection of 7,000 and the
remaining four ponies were then killed on Days 18, 20, 25 and 32
after what was now in effect a reinfection. Lesions and worms 
were found in the lungs of all animals, only immature worms being 
recovered on Day 18 while subsequently both immature and mature 
worms were found. Round presumed that the mature worms found 
were from the initial infection while the immature worms were 
from the reinfection.
In a further study eight pony foals with unknown histories 
and five donkey foals - three reared worm free and two with an 
unknown history - were given 6,000 orally. Twenty-three days 
post infection four ponies and three donkeys were necropsied 
followed by four ponies and one donkey on Day 57; the remaining 
donkey was killed on Day 63. The maximum establishment achieved 
was 0.75% of the infective dose and there was no significant 
difference in the numbers of worms recovered between the ponies 
and the donkeys but there were statistically significant 
differences in the size of worms recovered. The worms recovered 
from the donkeys were larger than those from the ponies and 
parasites recovered on Day 57 were larger than those recovered on 
Day 23. On Day 23 all worms were immature < 0.5 cm. By Day 57 
the ponies had both immature and young adult worms while the 
donkeys on Day 57 and Day 63 had immatures and adults in the 
lungs which were producing . This suggested a minimum
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prepatent period of 8-9 weeks in donkeys Neither the ponies nor 
the donkeys exhibited overt clinical signs following infection.
Round (1972) also compared the response of ponies and 
donkeys to single and trickle infections with D^ _ arnfieldi L^. 
In one experiment, four worm-free ponies aged 20 months were 
used. Two received 23 doses of 1,000 orally over five weeks 
while two received a single oral dose of 24,000 during week 2 
of the experiment. All the four ponies exhibited coughing from 
week 3 and when necropsied at the end of week 6 immature worms 
were recovered from all although the lungs appeared normal. 
There were no significant differences in size or numbers of worms 
which established from the two infection regimens.
In a second experiment two yearling donkeys and two yearling 
ponies, all reared worm-free, were given five daily doses of
1,000 orally each week for six weeks. Larvae were detected in
the faeces of both donkeys on week 13 and their faecal larval 
output increased over the next four weeks at which time all four 
animals were necropsied. From the two donkeys 204 and 430 adult 
D. arnfieldi were recovered while 131 and 6 immature worms were 
recovered from the lungs of the ponies.
In a recent study Britt and Preston (1985) infected 12
yearling Fell ponies which had grazed pasture considered to be 
free from arnfieldi♦ Six animals received a dose of 20,000 L^ 
while the remaining six were infected with 12,000 L^. There was 
no coughing or other clinical signs related to infection apart 
from a slight mucopurulent nasal discharge 51-89 days post
infection. Eight of the 12 animals developed patent infections
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with lungworm larvae being detected in their faeces on at least
one occasion; the earliest appearance of larvae in faeces was 68
days post infection. A further two animals had worms present in 
the lungs at post mortem. Three from each infection group were 
treated with ivermectin (Eqvalan, MSD AGVET) and the remaining 
six were untreated. All of the animals were killed 130 days post 
infection. The six control ponies had a mean of 10.1 
D. arnfieldi (range 6-35) in their lungs at necropsy whereas no 
worms were found in the ivermectin treated group. In the animals 
which received a dose of 20,000 L^, 44.4% of the parasites
recovered were immature while in those receiving 12,000 only
2.3% had not reached maturity.
Although a few horse foals have been observed to develop
clinical disease with spasmodic cough, dyspnoea, raised 
temperature and obstructive bronchitis on auscultation (Poncet, 
1983; Lyons, Drudge, Zygmont, Twehues, Downing and Sutton, 1982) 
most reports suggest that they behave more like donkeys than 
adult horses in that most develop patent infections without 
clinical disease (Round, 1972). For example Clayton and Duncan 
(1981) grazed pony mares and foals on contaminated pasture and 
within 11 weeks, although none of the foals had shown any 
clinical signs, all had D^ arnfieldi larvae present in their
faeces: In contrast no larvae were found in the faeces of the
mares but two of the four developed a cough 4 - 6  weeks post 
turnout and in one of these, a few D_j_ arnfieldi were found in 
the lungs at necropsy.
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The lung pathology associated with D_;_ arnfieldi infection 
has been described by Nicholls, Duncan and Greig (1978) and 
Clayton and Murphy (1980). The lesions, which are similar in the 
horse and donkey, consist mainly of raised circumscribed areas of 
pale, overinflated pulmonary tissue with hyperplasia of the 
bronchial epithelium and infiltration of lymphoid cells around 
the airways which were often occluded by mucus exudate and coiled 
worms. The finding of worms in the airways is more common in the 
donkey than in the horse although the situation in the horse foal 
has not been recorded.
To examine further the pathogenesis of D_^_ arnfieldi two 
experiments were carried out to investigate the clinical and 
pathological response to infection in adult and young ponies. 
These experiments were also designed to provide serum samples at 
various stages after known infections in both adult and young 
animals for use in the development of a diagnostic ELISA for the 
detection of D^ _ arnfieldi antigen.
EXPERIMENT 1 - INFECTION OF ADULT PONIES 
Animals
Ten adult ponies of Shetland type were purchased for 
this experiment. Although their history was unknown it was 
assumed that all had previous grazing experience. The group was 
loose housed in a concrete yard with free access to straw-bedded 
shelters. Identification was by numbered cattle ear tags 
attached to individual nylon head collars. Faecal sampling and 
examination, by Baermann and McMaster techniques, showed that all
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ponies were negative for first stage larvae (L^) of D_j_ arnfieldi 
but positive for strongyle eggs. Each pony then received several 
anthelmintic treatments with fenbendazole and ivermectin which 
eliminated strongyle eggs in the faeces. During this period of 
anthelmintic treatment and faecal sampling the ponies became 
acclimatised to their surroundings and to being handled.
Table 1.1
Experimental Design: A Study of EL arnfieldi Infection in Adult
Ponies
Details of Infective Dose and Time of Necropsy
Animal Dose of D.arnfieldi Date Day of
Number
L3 Infected Necropsy
1
2
2,000 3/9/87 20
3
4
2,000 3/9/87 34
5
6
2,000 25/9/87 48
7
8
2,000 25/9/87 62
9
10
5,000 15/10/87 68
All ponies received a single dose of D^ arnfieldi L^. Due 
to difficulties in culturing large numbers of infective 
D. arnfieldi larvae simultaneously, they were infected in groups 
on three separate occasions (Table 1.1). Although from different
42
batches all infective larvae were cultured in the same manner 
from the faeces of the same two donor donkeys.
The ponies were weighed weekly, respiratory rates were 
recorded daily and blood samples taken weekly for haematology. 
The weekly serum samples were frozen at -20°C for future use in 
an ELISA test.
Faecal samples were taken weekly for examination by both 
Baermann and McMaster techniques.
Necropsies were carried out in pairs between 20-68 days post 
infection. At necropsy the lungs were removed and photographed 
immediately. Any gross lesions, for example patches of 
overinflation, were noted before the lungs were subjected to 
perfusion to recover any lungworms present.
RESULTS
Detailed results of body weights, PCV's and respiratory 
rates are given in Appendices 1.1 - 1.3.
There was no evidence of changes in body weight of five of 
the six ponies necropsied up to Day 48. One of the Day 48 ponies 
and those killed later in the experiment showed weight losses 
ranging from 7-21 kg.
No D_j_ arnfieldi L^ were found in the faeces of any of the 
ponies.
The clinical responses, lung pathology and lungworm 
recoveries at various stage post infection were as follows:
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Day 20 - Ponies 1 and 2
Although pony 1 had a higher than normal respiratory rate 
there was no increase in the respiratory rates of either animal 
nor was any coughing observed. In the lungs of both animals 
there were a few discrete areas of overinflation (Figure 1.1). 
No lungworms were recovered.
Day 34 - Ponies 3 and 4
No significant changes in respiratory rate were observed. 
Pony 3 showed mild coughing on on Days 28, 32 and 34 and pony 4
was heard to cough on Day 26 with harsh respirations on 
auscultation on Day 32.
The lungs of both animals had several discrete areas of 
overinflation (Figure 1.2 and 1.3). No worms were recovered from 
pony 4 but 16 small threadlike immature D^ arnfieldi (< 5 mm 
long) were recovered from the lungs of pony 3.
Day 48 - Ponies 5 and 6
Although there was no increase in respiratory rate in either 
pony, pony 5 showed intermittent coughing from Day 7 until 
Day 32. Pony 6 was only heard to cough on Days 35 and 36.
The lungs of these animals had numerous overinflated areas 
which were much more marked than those observed earlier 
(Figures 1.4 and 1.5). On perfusion, 38 and 36 D^ arnfieldi 
(< 1 cm long) were recovered from ponies 5 and 6 respectively.
Day 62 - Ponies 7 and 8
Fairly persistent coughing was observed in pony 7 from 
Days 17-34 associated with an increased respiratory rate between
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Figure 1.1
Gross appearance of the lungs of a pony on Day 20 post-infection 
with 2,000 arnf ieldi L^. A few discrete areas of
overinflation are evident
Figure 1.2
Gross appearance of the lungs of a pony on Day 34 post-infection 
with 2,000 D^ arnfieldi L^. Several discrete and obvious 
areas of overinflation are present
Figure 1.3
Areas of overinflation evident in the lung of a pony on Day 34 
post-infection with 2,000 arnfieldi
Figure 1.4
Well defined areas of overinflation in the lungs of a pony 
on Day 48 post-infection with 2,000 D^ arnfieldi
Figure 1.5
Marked areas of overinflation in the lung of a pony on Day 48 
post-infection with 2,000 D_^  arnfieldi
Figure 1.6
Marked areas of overinflation in the lungs of a pony on Day 62 
post-infection with 2,000 EK arnfieldi
Days 25-33. Sporadic coughing was heard until Day 50. Pony 8 
showed no change in respiratory rate but was heard to cough on 
Day 24 and 26 and between Days 40 -43.
The lungs showed marked areas of overinflation (Figure 1.6) 
and 24 and 12 D_^  arnfieldi (< 2 cm long) were recovered from 
pony 7 and pony 8 respectively.
Day 68 - Ponies 9 and 10
Pony 9 showed an increased respiratory rate from Day 32 
onwards and although heard to cough on Day 33, coughing was more 
frequent from Days 41-64. Pony 10 showed an increased respiratory 
rate from Day 18 onwards and coughing, first noted on Day 5, was 
relatively persistent from Day 20 until necropsy.
At necropsy the lung lesions were similar to those observed 
in the Day 62 ponies, although they were less severe in pony 9 
than in pony 10: One and 102 young adult D^ arnfieldi (< 4 cm
long) were recovered from the lungs of ponies 9 and 10 
respectively.
DISCUSSION
Although Round (1972) reported a consistent increase in 
respiratory rate preceded by coughing from around 2-3 weeks after 
a primary Eh_ arnfieldi infection, which increased in severity 
between three and five weeks, the clinical response to infection 
in this experiment was variable. For example although coughing 
was noted in all eight ponies necropsied from 34 days onwards in 
only three of these animals (ponies 7, 9 and 10) was coughing
marked and accompanied by increases in respiratory rate. These
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signs were most evident from three weeks post infection and 
tended to increase towards the end of the experiment. The most 
severe clinical response was seen in one of the two ponies 
(pony 10) which received the dose of 5,000 and the highest 
number of worms (102 EL_ arnfieldi) was recovered from this animal 
at necropsy. The variation in clinical response between this 
study and Round's is most probably a reflection of variability in 
larval challenge, infectivity and worm establishment.
Despite the fact that no clinical signs were observed up to 
20 days post infection and no worms were recovered from the two 
ponies necropsied at this time, grossly visible areas of 
overinflation were found in the lungs of both animals. The fact 
that worms were not recovered is probably due largely to the 
technical difficulty associated with recovery of a low number of 
very small worms from their situation in the lung parenchyma. In 
one of the remaining ponies (pony 4 - Day 34) no worms were 
recovered but gross lesions, typical of D^ arnfieldi infection, 
were found at necropsy of all eight animals. The severity of the 
pulmonary lesions, which consisted of overinflated areas located 
on the periphery of the lung lobes, appeared to increase with the 
increasing period of infection becoming larger, more numerous and 
distributed over a wider area of the lung. No histopathology was 
possible since an intact pleura was required for worm recovery by 
perfusion and this technique completely disrupts the lung tissue.
None of the worms recovered in this study were sexually 
mature although this is not surprising since the minimum 
prepatent period reported for EL_ arnfieldi is 68 days (Britt and
46
Preston, 1985) and in other studies it has been found to be 
significantly longer at 91 days (Round, 1972). In general the 
size of the worms recovered during this experiment increased with 
time after infection : very small thread-like worms were
recovered on Day 34 while immature adult worms were present in 
the animals necropsied on Day 68 post infection.
In essence this experiment confirmed previous reports of the 
response of adult animals to experimental D^ arnfieldi infection. 
A second experiment was then designed to compare the response to 
infection in young and mature ponies and to examine the 
associated pathology in more detail.
EXPERIMENT 2 - INFECTION OF PONY MARES AND FOALS 
Animals
Three adult Dartmoor mares and their foals were used.
Although the history of the mares was unknown, they were semi­
wild and it was assumed they had spent most if not all of their 
lives, outdoors. The mares were in foal when purchased and on 
arrival they were treated with ivermectin. When they were close 
to foaling they were moved into individual clean straw-bedded 
concrete loose-boxes with daily access to a concrete yard. Hay
and water were available ad lib. The mares foaled indoors and
the foals were reared under conditions designed to prevent
helminth infection. The foals were weaned around six months of 
age at which time the mares were treated with fenbendazole. A 
minimum period of two weeks elapsed post weaning/treatment before 
any animal was infected.
Table 1.2
Experimental Design: A Study of IK arnfieldi Infection in Pony
Mares and Foals 
Details of Infective Dose and Time of Necropsy
Animal Dose of Date Date of
No. D.arnfieldi Infected Necropsy
13 mare 6,000 13/11/88 42
14 foal 2,500 13/1/88 42
11 mare 10,000 24/12/87 56
16 foal 2,500 29/1/88 56
12 mare 10,000 24/12/87 70
15 foal 2,500 13/1/88 70
All ponies received a single dose of IK_ arnfieldi by
stomach tube. Due to the difficulties in culturing large numbers 
of infective IK_ arnfieldi larvae simultaneously they were 
infected on three separate occasions as indicated in Table 1.2. 
Although from different batches all infective larvae were
cultured in the same manner from the faeces of the same two donor 
donkeys.
Respiratory rates were recorded daily but due to 
difficulties in handling these semi-wild ponies regular 
auscultation of lung fields and collection of blood and faecal 
samples was not undertaken.
Necropsies of one mare and one foal were carried out at 42, 
56 and 70 days post infection: In the previous experiment no
histological examination of the lungs was possible as the 
perfusion technique used to recover D_^  arnfieldi completely
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disrupts the lung tissue. In this experiment the lungs were 
carefully divided, leaving the pleura intact, and only one lung 
was used to recover worms, the other providing samples for 
histology and scanning electron microscopy. Where perfusion was 
not possible because the pleura had been damaged at necropsy, the 
lung was dissected following the respiratory tree and any visible 
worms picked out manually. The lung tissue was then floated in a 
bucket of saline overnight and the sediment examined for the 
presence of worms.
RESULTS
A summary of the major clinical findings and pathology 
together with worm recoveries at necropsy is presented for each 
animal in Table 1.3.
Clinical Signs
Respiratory Rate (RR)
All of the mares but only one foal (foal 15) showed an 
increased respiratory rate. Individual respiratory rates are 
detailed in Appendix 1.4.
The RR of the foal increased from Day 11 with the 
marked rise over Days 17-26.
Mare 11 showed a marked rise in RR from Day 34 while mare 12 
showed an increase from Day 18 with a more marked rise from 
Day 34. The RR of mare 13 showed an increase from Day 10 with a 
more marked increase from Day 14. In all three mares the RRs 
remained elevated until necropsy.
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Coughing
Only foal 15 was noticed to cough and only on one occasion
(Day 35) while two of the mares both showed fairly persistent
marked coughing from Day 34. Although both of the mares 
exhibited bouts of harsh, dry coughing at no time did any animal 
appear in respiratory distress. No nasal discharge was detected 
in any animal.
Worm Recoveries
Worms were only recovered from the single lungs examined 
from two animals. Seven worms were found in mare 11 and two 
worms in foal 15.
Pathology
Gross lesions indicative of D_^  arnfieldi infection were 
found in the lungs of most animals. They were least severe in 
foals 14 and 16 (Figures 1.7 and 1.8) and most marked in mares 13
and 11 (Figures 1.9 and 1.10). In contrast, in the animals
necropsied on Day 70 both had obvious gross lesions. The lesions 
consisted of circumscribed patches of overinflated lung tissue 
which were mainly found towards the caudal border of the lung.
Histopathology
Histopathological changes associated with gross lesions were 
found in only three animals. Mare 13 showed moderate 
overinflation (Figure 1.11). Mare 11 showed overinflation, 
chronic bronchitis in the small bronchi with lymphocytes and 
eosinophils in the interstitium (Figure 1.12) while foal 15 
showed mild overinflation, eosinophilia (Figure 1.13), bronchitis 
and bronchiolitis (Figure 1.14) and mucus was present in the
51
Figure 1.7
Grossly normal lung of a pony foal 42 Days post-infection 
with 2,500 Ek arnfieldi
Figure 1.8
Grossly normal lung of a pony foal 56 Days post-infections 
with 2,500 EK arnfieldi
Figure 1.9
Marked areas of overinflation in the lung of a pony mare 
42 Days post-infection with 6,000 EK arnfieldi
Figure 1.10
Gross appearance of the lung of a pony mare 56 Days post­
infection with 10,000 EL arnfieldi showing marked 
areas of overinflation
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Figure 1.11
Histological sections of normal bronchiole and surrounding 
alveolar pattern (left) compared with mild bronchiolitis in an 
area of moderate overinflation (right) in a pony mare necropsied 
on Day 42 post-infection with 6,000 arnfieldi L^. H & E x 25.
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Figure 1.12
Histological sections of small bronchi (left) compared with a 
small bronchus showing chronic bronchitis and a dense infiltration 
of lymphocytes, plasma cells and some eosinophils (right) in a 
pony mare necropsied on Day 56 post-infection with 1,000 
D. arnf ieldi L^. H & E x 10.
Figure 1.13
Histological section of a bronchiole with mucus and eosinophils 
in the lumen and lymphocytes, plasma cells and eosinophils in 
lamina propria from a foal necropsied on Day 70 post-infection 
with 2,500 D^ arnf ieldi L^. H & E x 100.
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Figure 1.14
Histological sections of a normal bronchiole (left) compared with 
a severe bronchiolitis with thickening of the bronchiolar wall 
due to infiltration by lymphocytes and plasma cells with some 
eosinophils in a foal necropsied on Day 70 post-infection with 
2,500 D_^  arnf ieldi (right). H & E x 25.
lumen of the airways.
Scanning Electron Microscopy (SEM)
The SEM appearance of the airways in ponies infected with 
D. arnfieldi resembled those of normal horses (Pirie, Pirie,
Cranston and Wright, 1990). The surface of the trachea, lobar 
and segmental bronchi were regularly folded and mucus, in
varying amounts, was present. The surface cells were well 
ciliated and protruding from among the cilia were mucus-secreting 
cells, singly or in small groups (Figure 1.15). Small patches of
non-ciliated microvillous cells (Figure 1.16), which have been
seen in the larger respiratory passages of normal horses, were 
found in the trachea of mares 13 and 12. Similar patches
occurred in foal 15 in the trachea and small bronchus from the 
caudal lobe of the lung. The latter site was usually well 
ciliated although the presence of non-ciliated cells gave a
rather "moth-eaten1* appearance (Figure 1.17). The surface of the 
small bronchi had shallow folds and some mucus was present. In 
the bronchioles, alveolar ducts and alveoli, the number of
ciliated cells gradually decreased towards the terminal
passages. On the other hand the non-ciliated bronchiolar 
epithelial (Clara) cells became more numerous until they were the 
dominant cell in the terminal bronchioles. The latter cells, 
which were dome-shaped and projected into the bronchiolar lumen, 
often had clefts on their surfaces (Figure 1.18). Under low 
power the alveolar surfaces appeared relatively smooth and 
interalveolar pores (of Kohn) were easily identified.
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Figure 1.15
Scanning electron micrograph of the ciliated surface of airways 
in a pony experimentally infected with arnfieldi
Figure 1.16
Scanning electron micrograph of the trachea of a pony mare 
experimentally infected with 6,000 arnf ieldi showing a 
patch of non-ciliated microvillous cells
Figure 1.17
Scanning electron micrograph showing patches of non-ciliated 
cells in a bronchus of a foal experimentally infected 
with 2,500 arnfieldi
Figure 1.18
Scanning electron micrograph showing non-ciliated epithelial 
(Clara) cells in a terminal bronchiole of a foal experimentally 
infected with 2,500 D_^  arnf ieldi
DISCUSSION
Worm recoveries at necropsy in most previous studies of 
experimental D^ _ arnfieldi infections have been generally variable 
and low (Round, 1972). In the previous study reported here 
(Experiment One) low numbers of worms were recovered from seven 
of the ten adult ponies infected, the three negative recoveries 
being from the lungs of animals killed three and five weeks post­
infection, when any lungworms present would have been very small. 
The mares and foals in this experiment were necropsied in pairs 
at six, eight and ten weeks post-infection but very few worms 
were recovered from only one mare (mare 11 - seven worms) and one 
foal (foal 15 - two worms). The simplest explanation for this is 
poor infectivity of the D_j_ arnf ieldi larvae used in this study: 
This appears to have been a recurring problem in most 
experimental lungworm studies.
Despite the low worm establishment however, all three mares 
showed raised respiratory rates following infection and in two 
(mares 11 and 12) fairly persistent coughing was noticed from 
Day 34 until necropsy. The foal from which two worms were 
recovered showed a milder reaction with a slightly raised 
respiratory rate and occasional cough between three and five 
weeks post-infection.
Although these differences in response between the mares and 
foals in this experiment may have been related to the larger 
infective dose administered to the mares (6,000 - 10,000 L^)
compared with the foals (2,500 L^) the findings tend to agree 
with a previous report of Clayton and Duncan (1981) where, after
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exposure to natural infection, adult ponies developed marked 
clinical signs while foals grazing the same pasture showed no 
signs although they, unlike the adults, developed patent 
D. arnfieldi infections.
In spite of the apparent poor worm establishment in this 
experiment gross lesions of overinflation, commonly associated 
with D_j_ arnf ieldi infection in both horses and donkeys (Nicholls 
et a_l, 1979; Clayton and Murphy, 1980), were found in the lungs 
of the animals necropsied six and eight weeks post-infection 
although they were minimal in the foals. In contrast both the 
mare and foal necropsied at ten weeks (mare 12, foal 15) had 
obvious gross lesions of overinflation. Where present 
histopathological changes including overinflation, bronchitis, 
cellular infiltration and excess mucus production generally 
reflected the severity of both the gross lesions and clinical 
response and confirmed previous reports of lesions found in 
association with arnfieldi infection (Clayton and Murphy,
1980). An exception was the mare necropsied at ten weeks 
(mare 12) in which no significant microscopical changes were 
detected despite the fact that this animal showed the most marked 
clinical response and gross lung pathology. This latter finding 
together with the lack of significant changes attributable to 
D_;_ arnf ieldi in the lung tissues of all animals examined by 
scanning electron microscopy in this study may simply reflect the 
limited pathology associated with these infections or may be due 
to technical difficulties in location and selection of suitable
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material from the distal airways and lung parenchyma.
The limited conclusions of this experiment are that adult 
ponies react more severely both clinically and pathologically to 
experimental EL_ arnfieldi infection although the results 
emphasise the unpredictability of infection and inconsistency in 
relationship between clinical response and underlying pathology.
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INTRODUCTION - FIELD STUDIES
In 1952 Akramovski reported a high prevalence of patent
D. arnfieldi infections in horses in the Soviet Union which was
unrelated to any contact with donkeys. From the information on 
the epidemiology of D_j_ arnf ieldi infection in the Soviet Union it 
is suggested that larvae do not overwinter on pasture 
(Akramovski, 1952) hence infective stages of IK_ arnf ieldi are not 
found until May each year : these larvae are derived from
infected horses which are housed during the winter and
contaminate the pasture when allowed out to graze the following 
spring. New patent infections are then seen in young horses
from August with the majority appearing in September and October. 
This is the same timing to that found by Round (1972) in his
study of when D_j_ arnf ieldi first appeared in the faeces of 
donkey foals in England. Round (1972) also reported the results 
of a limited survey of the prevalence of infection in equines in 
the U.K. Around this time the overall prevalence of infection in 
donkeys was found to be 73% although on one of the 
establishments where the horses and donkeys all grazed together, 
80% of the donkeys had patent infections and 6% of the horses 
were patent. In contrast eight mature hinnies kept with the
infected donkeys were found to be negative for D^ arnfieldi
infection on faecal examination. However one hinny colt
introduced to infected donkeys when it was only a few weeks old 
subsequently developed a patent D_j_ arnf ieldi infection with a 
higher larval output compared with donkeys of a similar age
(Round, 1972). Round (1972) also examined 57 Thoroughbred
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horses, which had no known contact with donkeys and none of which 
exhibited any clinical signs of arnfieldi infection and found 
three (5%) were passing D_^  arnfieldi larvae in their faeces.
Of 55 horses examined at post mortem in Brazil (Ribeiro, 
Larangeira and Paiva, 1979) five animals (9%) were positive for 
D. arnfieldi with an average of 2-4 worms being recovered from 
their lungs. More recently in a post mortem survey of 488 horses 
in Kentucky (Lyons, Tolliver, Drudge, Swerczek and Crowe, 1985) 
11% had arnfieldi present in the lungs. The average number
of worms recovered was six and these were mainly fifth stage 
larvae (immature adults). Thirty per cent of those with 
D. arnf ieldi in the lungs also had D_j_ arnf ieldi on examination of 
the faeces however the low numbers of arnfieldi found tends
to suggest that although the potential for horse to horse 
transmission exists, it is low. In contrast six mature infected 
donkeys examined at post mortem (Tolliver, Lyons and Drudge, 
1985) were found to have between 3 - 315 worms in the lungs.
In the Netherlands, Boersema and Kalis (1978) found 51% of 
249 donkeys with an existing D_j_ arnf ieldi infection. No donkey 
under five months of age had a patent infection and although the 
number of larvae excreted increased with increasing age the 
percentage of infected animals did not show any such increase.
Of 423 donkey lungs examined at necropsy over a period of 
one year in Morocco 48% were found positive for D^ arnfieldi 
(Pandey, 1980). Although D^ _ arnfieldi infection was observed 
throughout the year there was evidence of increased incidence and
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level of infection in donkeys in autumn and winter and to a 
lesser degree in June. These peaks appeared to be closely related 
to periods of rainfall and relatively low temperatures.
In a study of 176 donkeys kept on 59 premises in Denmark 
87.5% had patent D_j_ arnfieldi infections (Anderson and Fogh, 
1981). Thirty-four of a total of 106 horses from 30 of these 
premises were hospitalised with dyspnoea and coughing although no 
patent D_;_ arnf ieldi infections were detected. Also in Denmark a 
group of horses was reported to have exhibited chronic coughing 
of five years duration which appeared three weeks after the 
arrival of a donkey. Three horses and the donkey had patent 
D. arnfieldi infection and lungworms were found in the bronchi at 
post mortem examination of all animals (Nielson and Anderson,
1981).
In Germany, faecal samples from 106 donkeys on 52 farms were 
taken every 6-8 weeks during 1982 (Heil, 1983). Examination of 
these showed that patent D_j_ arnf ieldi infections were lowest in 
yearlings (less than 40%) while 57% of 6-10 year olds were 
infected; only 28% of animals over ten years of age were positive 
for p_j_ arnf ieldi ♦
These studies indicate that D^ arnf ieldi is worldwide in 
distribution and, with the exception of the Soviet Union where 
there are large horse farms, the donkey appears to be the most 
significant host in the epidemiology of infection. Also from the 
information available it appears that retardation of development 
of D^ arnfieldi occurs frequently in the horse regardless of 
breed or geographical location. As D_j_ arnf ieldi larvae
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apparently cannot overwinter on pasture in temperate areas the 
donkey is undoubtedly important as a reservoir of infection 
(Heil, 1983).
In donkeys, the number infected with arnfieldi increases 
during the first two years of life after which time the number 
infected tends to remain static while the magnitude of the 
infection increases over the next few years. Round (1972) 
reported that 62% of donkey foals developed patent infections 
while donkeys over three years of age were resistant to 
reinfection following effective anthelmintic treatment, although 
an age immunity per se is not thought to occur. The earliest age 
at which Round found a foal to have a patent infection was 101 
days and no patent infections were observed in foals before 
August of the year of their birth. Development of patency in 
foals tended to be synchronous and independent of the precise age 
of the foal. In a later study, Clayton and Duncan (1981) grazed 
four pony mares and foals and two infected donkey mares and foals 
together on D^ arnfieldi contaminated pasture. In early August, 
within 11 weeks of turnout, all of the pony and donkey foals were 
positive for Eh_ arnf ieldi upon faecal examination. The general 
impression from these studies was that adult donkeys with patent 
infections continued to pass larvae for very long periods while 
those which did not have patent infections remained negative 
despite exposure to pastures grazed by heavily infected donkeys.
From the above it is obvious that, as with experimental 
infections, there is limited information on naturally occurring
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D. arnfieldi infection. In order to assess the current situation 
in donkeys and horses in the UK two major surveys were 
undertaken. In the first, the Donkey Sanctuary in Devon was the 
main source of material and information. In the second survey, 
carried out in the West of Scotland, the majority of animals were 
horses or ponies but a few donkeys resident with these animals 
were included. During the Scottish survey there was an 
opportunity to investigate an outbreak of coughing, in a group of 
horses and ponies, which followed the recent introduction to the 
pasture of two donkeys with patent D^ _ arnfieldi infections. 
Finally a small field study was carried out using donkeys 
resident at the Glasgow University Veterinary School in an 
attempt to provide more information on the acquisition of 
D. arnfieldi by young donkeys at pasture.
RESULTS
Donkey Sanctuary Survey
Detailed results of the faecal examinations for D^ arnfieldi 
infection of all new arrivals at The Donkey Sanctuary from 1986 - 
1988 are shown in Appendix 1.5. Of the total of 698 donkeys 
sampled 34% were positive and over the 3-year sampling period 
there was a decrease in the numbers positive from 40% in 1986 to 
35% in 1987 and 23% in 1988 (Table 1.4). This reduction in 
positive cases in 1988 compared with 1986 and 1987 was 
significant (p < 0.05). When the numbers of positive animals 
within different age groups were compared (Table 1.5) these 
ranged from 30% 42% but there were no significant trends.
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Table 1.4
Donkey Sanctuary Data for Three Years Showing Total Numbers 
of Donkeys Tested, Numbers Positive, Percentage Positive and 
Mean Faecal Dictyocaulus arnfieldi Larval Counts
Number
Tested
Number
Positive % Positive
Mean D. arnfieldi 
Larval Count 
(L^/50 g Faeces)
1986 264 105 39.8 80
1987 258 90 35.3 705
1988 176 41 23.3 783
Total 698 239 34.2 -
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Table 1.5
Donkey Sanctuary Data over a Three-Year Period showing Total 
Numbers of Animals of Different Age Groups Tested, 
the Numbers and Percentage Positive and the Mean
Faecal Dictyocaulus arnfieldi Larval Counts
Age
Number
Tested
Number
Positive
%
Positive
Mean D.arnfieldi 
Larval Count 
(L^/50 g Faeces)
0 - 2 41 15 36.6 931
3 - 5 78 26 33.3 323
6 - 1 0 117 49 41.9 213
11 - 15 125 50 40.0 160
16 - 20 117 36 30.8 284
21 - 25 75 24 32.0 1221
26 + 121 36 29.7 481
Unknown 25 2 8.0 314
Total 698 239 34.2 -
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Although some statistically significant differences were 
found when age groups within sample years, age groups between 
sample years or season of sampling were compared (data presented 
in Table 1.6), no relevant trends emerged.
These results suggested that the Chi Square test was not an 
ideal method of statistical analysis especially as the number of 
variables examined required numerous repetitions hence increasing 
the risk of errors. A more accurate method of analysis to cope 
with the variables - age, year and season of testing - is log 
linear analysis, but this is a complex test and was not 
considered appropriate for the basic analysis of the results 
obtained in this survey.
West of Scotland Survey
To try to establish the prevalence of patent arnfieldi
infections in a random equine population a survey was conducted 
of animals in various types of horse establishments in the West 
of Scotland : these included riding schools, livery yards, stud
farms and dealers' yards as well as private stables each with a 
minimum of three resident animals. Fresh faecal samples were 
collected and examined by both Baermann and McMaster techniques. 
Although detailed histories were not available, all animals were 
known to have been at pasture at some time.
A total of 720 animals were sampled. Of these 681 were 
horses or ponies and 39 were donkeys. Eleven of the donkeys 
(28%) had patent D^ _ arnfieldi infections, while samples from two 
horses (0.3%) proved positive for D_j_ arnf ieldi larvae. Fifty- 
three (8%) of the horses in the survey were known to have had
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contact with donkeys but none of these proved positive for 
D. arnfieldi while the two horses with patent infections, as far 
as was known, had no previous contact with donkeys and neither 
had shown any clinical signs of infection.
Investigation of an Outbreak of Coughing in Horses Associated 
with Donkeys Infected with arnfieldi
During the period of the West of Scotland survey reported 
above an outbreak of coughing occurred in a small group of five 
horses grazing with two donkeys. The donkeys had been purchased 
from a market in September four weeks prior to the first 
appearance of clinical signs in the horses. All seven animals
were clinically examined and blood and faecal samples collected
before they were treated by the owner with fenbendazole at 
7.5 mg/kg daily for five days: the donkeys were then moved to
separate grazing. Two weeks after they were first seen all seven 
animals were re-examined. A chestnut hunter gelding had been 
introduced into the field with the donkeys between visits but on 
examination no clinical abnormalities associated with
D. arnfieldi infection were detected in this animal.
The results of the clinical and faecal examinations are 
presented in Table 1.7.
These limited observations suggest that the donkeys 
introduced Eh_ arnfieldi infection to this group of horses which 
resuled in clinical signs which responded to the owners treatment 
with five daily doses of fenbendazole. Treatment reduced
strongyle egg counts in all the animals and D_j_ arnf ieldi larvae 
in the faeces of the one donkey from which a post-treatment
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sample was obtained. The possibility remains, however, that 
transmission of some other respiratory pathogen from the donkeys 
to the horses may have been involved and that the apparent 
clinical response to anthelmintic treatment was fortuitous.
Donkey Grazing Study
The animals used in this experiment were three adult 
donkeys, all of which had a known grazing history and two donkey 
foals, nine and ten months old, which had been reared worm free. 
Although only one of the adults (No. 20A) had a current patent 
D. arnfieldi infection the other two were known to have had 
patent infections within the last three years. All animals had 
been housed over the winter and were turned out together, on 6th 
April, 1988, into a two acre paddock which had been grazed by 
infected donkeys the previous year.
The donkeys had blood and faecal samples taken weekly. The 
blood samples were stored for later use in the D_^  arnfieldi ELISA 
while the faecal samples were examined for arnfieldi and
strongyle eggs. If the faecal strongyle egg counts became high 
the donkeys were treated with pyrantel embonate (Strongid-P, 
Pfizer, Sandwich, Kent), which is not effective against 
D. arnfieldi, at a dose rate of 19 mg/kg bodyweight. The donkeys 
were observed daily for any signs of respiratory disease.
The faecal strongyle egg counts and IL_ arnfieldi larval 
counts are shown in Table 1.8.
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No clinical signs were observed in any of the five donkeys 
during the 4 - 5  month observation period. The adult animal with 
the patent D_;_ arnf ieldi infection remained positive throughout 
while the remaining two adult donkeys and the two donkey foals 
which were initially negative for D^ arnfieldi, remained negative 
until the end of the study.
DISCUSSION
Recent surveys of the prevalence of D^ _ arnfieldi infection 
in donkeys from different parts of the world show that, with the 
exception of one report from Denmark where Anderson and Fogh 
(1981) reported an 87.5% infection rate, this appears to be 
decreasing from the 73% level reported by Round in 1972. For 
example Boresema and Kalis (1978) found a prevalence of 51% in 
The Netherlands, Pandey (1980) found 48% of donkeys to be 
infected in Morocco while Heil (1983) in Germany found patent 
infections in less than 40% of yearlings, 57% of 6-10 year olds 
and only 28% of donkeys over ten years old. The overall 
prevalence found in the Donkey Sanctuary survey reported here was 
34% and although, as reported by Heil (1983), the 6-10 year old 
group had the greatest proportion of animals positive (42%) and 
the younger donkeys the least (1-2 year olds - 37% and 3-5 year 
olds - 33%), the decrease to 28% found by Heil in animals over 
ten years of age was not seen in the U.K. survey where the 
percentage infection rates were - 11-15 years - 40%; 16-20 years
- 31%; 21-25 years - 32% and over 26 years - 30%.
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As both the U.K. surveys were based on the detection of 
larvae in faeces by the Baermann technique the considerable 
decrease in the level of infection between 1972 and 1986/88 
cannot be attributed to differences in technique. The most 
likely explanation for the lower level of infection is the 
increased awareness of the importance of anthelmintic treatment 
of animals combined with the availability of new and effective 
anthelmintics which were not available in 1972.
In the early 70's the most modern anthelmintics commercially 
available were diethylcarbamazine, tetramisole/levamisole and 
some of the early benzimidazole compounds. Round (1972) found 
diethylcarbamazine by intramuscular injection, which was 
effective against viviparus in cattle, to be ineffective while 
tetramisole at 15 mg/kg gave variable reductions in faecal larval 
excretion. Thiabendazole, used at 440 mg/kg proved the most 
effective. A single dose gave promising but inconsistent results 
but two doses given 24 hours apart gave a reduction in larval 
output of 90-100% in samples taken 14 and 28 days post treatment.
At the same time trials using levamisole and cambendazole 
were carried out in donkeys in Germany (Enigk and Weingartner, 
1973): a single oral dose of 15 mg/kg of levamisole produced a
78% reduction in faecal larval counts 41 days post treatment 
while intramuscular doses at 5 and 10 mg/kg gave reductions of 
94% and 98%, although the higher doses produced slight reactions 
at the injection sites. Two intramuscular doses of levamisole at 
5 mg/kg, 3-4 weeks apart, proved the most effective while 
cambendazole, given orally at 30 and 40 mg/kg, was unsuccessful
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in eliminating infection.
In subsequent trials, oxibendazole was found to have no
activity against arnfieldi (Kates, Colglazier and Enzie, 1975)
while mebendazole, used at 15-20 mg/kg, was 99% effective in 
eliminating arnfieldi larvae from the faeces (Clayton and 
Neave, 1979).
In studies to define an effective therapeutic regimen
against D^ _ arnfieldi infection in donkeys to reduce the risk of
transmitting infection to horses and, by removing worms from the 
lungs, to reduce the donkey's apparent susceptibility to other 
respiratory pathogens, Clayton and Trawford (1981) proposed 
minimum doses of 15 mg/kg mebendazole for five days. Mebendazole 
also proved effective in the treatment of yearling horses when 
two doses of 20 mg/kg given one month apart eliminated larvae 
from the faeces of these animals (Rickard and James, 1976).
Febendazole (FBZ) has been used in a number of anthelmintic 
trials in horses and donkeys (Enigk and Dey Hazra, 1976). A 
single dose of 7.5 mg/kg FBZ is effective against intestinal 
parasites in both donkeys and horses but neither single doses of 
30 mg/kg nor two consecutive daily doses of 15 mg/kg eliminated 
adult lungworm infection in donkeys; both, however, produced a 
temporary 50-70% reduction in larval output but this had 
increased to pre-treatment levels within three weeks (Urch and 
Allan, 1980).
Duwel (1983) reported further studies on FBZ in donkeys at 
dose rates of 7.5 - 10 mg/kg for five days. This regime was 
superior to single doses but, in some cases, reduction in larval
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output was less than 95%. Duwel suggested that the presence of 
mucus in the bronchi protected the worms from the action of the 
drug.
Perhaps the most significant development in anthelmintic 
therapy of D_;_ arnf ieldi was the recent introduction of
ivermectin. When used in a trial involving 12 ponies
experimentally infected with arnfieldi, mature arnfieldi
were found in all six of the untreated controls at necropsy while 
no D_j_ arnf ieldi were found in the six ponies which had received 
ivermectin at 200 mcg/kg 15 days prior to necropsy (Britt and 
Preston, 1985). It is likely that over the last five to 15 
years, the use of anthelmintics, especially ivermectin, has 
resulted in the observed decline in the prevalence of 
D. arnfieldi infection.
In our survey of horses and donkeys in the West of Scotland
28% of the donkeys but less than 1% of horses had patent
infections. A surprising finding was that the horses with patent 
infections had no current or recent known contact with donkeys 
and that some of the horses with patent infections had not shown 
any coughing. Although horses can harbour patent infections 
without signs of disease, the history of the field outbreak was 
more typical: in this, the horses and ponies started coughing
within a month of the introduction of the infected donkeys. This 
was not surprising since climatic conditions at the time 
(September) with moderate temperatures and adequate moisture, 
were ideal for the rapid development of larvae to the infective 
stage and, as shown by the experimental studies, lesions are
present in the lungs by three weeks post infection. This study 
reflected the variability in response to D_j_ arnfieldi infection 
with some of the animals showing severe clinical signs while 
others in the group had either very mild or no clinical signs. 
As these animals were not necropsied it can only be assumed from 
the history, clinical signs and response to treatment that 
D. arnfieldi was responsible for the disease syndrome shown.
In the donkey grazing study the adult donkeys behaved as 
expected from previous studies (Clayton and Duncan, 1981; Round, 
1972) in that the donkey with the patent infection (20A) 
maintained this with only minor fluctuations in output while the 
other two adult donkeys, known to have had previous exposure to 
D. arnfieldi infection, remained non patent throughout. In 
contrast the two naive young donkeys (23F and 24F) did not behave 
as expected in that they did not acquire detectable patent 
infections in late summer or by the end of September when the 
experiment was ended. Although the number of animals used in 
this experiment was small, the pasture was deliberately 
'overgrazed' to try to ensure exposure to EL_ arnfieldi infective 
larvae by all the animals. It is possible that due to weather 
conditions, no infective larvae were available on the pasture 
during the grazing period which, although unlikely, makes the 
results difficult to interpret. Alternatively, since it was not 
possible to necropsy these donkeys to check for worms in the 
lungs, there is the possibility that the young animals, in which 
were not detected in the faeces, could have behaved like
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horses and developed non-patent infections with retardation of 
development of D_;_ arnf ieldi.
The failure of these young donkeys to develop patent 
infections while grazing alongside an infected animal on pasture 
grazed by infected donkeys the previous year, was unexpected. 
One possible explanation is that the donkey 'foals' in this study 
were born the previous year and were around nine months old at 
turnout. Their initial exposure to infection, if it occurred,
was therefore a lot later than most foals which graze alongside
their dams from birth: also these 'foals' started grazing
immediately upon turnout in April rather than gradually acquiring 
the grazing habit. Another possibility is that, due to the 
colder weather at this time, only few infective D_j_ arnf ieldi
larvae were available which allowed these older donkey foals to
acquire some immunity by trickle exposure without developing 
patent infections. Whatever the reasons, the fact that these 
young donkeys failed to show evidence of Dj_ arnfieldi infection 
makes it impossible to draw any firm conclusions from this study.
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SECTION 2
STUDIES ON THE DEVELOPMENT OF AN ENZYME LINKED IMMUNOSORBENT ASSAY 
(ELISA) FOR THE DETECTION OF Dictyocaulus arnfieldi INFECTION
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INTRODUCTION
Due to difficulties in the clinical diagnosis of lungworm 
infection in horses, an immunoassay was sought to provide a 
diagnostic laboratory test for D_j_ arnf ieldi infection. Two types 
of immunoassay, enzyme immunoassay (EIA) and radioimmunoassay 
(RIA), are currently used in the study and diagnosis of 
infectious diseases although EIA is rapidly superseding RIA. The 
first EIA was reported in 1971 and since that time EIAs have 
provided an extremely sensitive and precise method of analysing 
large numbers of samples rapidly for a variety of biological 
parameters including infectious disease agents such as viruses, 
bacteria, fungi and parasites. In general, EIA and RIA have 
similar sensitivities but the greater versatility and simplicity 
afforded by the EIA (Table 2.1) has led to its rise in popularity 
and it is now the assay of choice for detection and 
identification of disease agents; discrimination of disease 
agents; quantification of a disease agent; identification of 
specific antibodies and quantification of specific antibody 
isotypes. The difference between RIAs and EIAs is in their 
detection system; whereas RIAs use radionuclides which decay, 
EIAs use enzymes which are biological catalysts. EIAs operate 
via an enzyme attached to one of the reagents used in the test 
which, on addition of the appropriate enzyme substrate solution, 
then produces a colour change which can be measured by eye or by 
spectrophotometer. In most EIAs the solid phase is a plastic, 
onto which proteins and carbohydrates can be passively adsorbed; 
these are known as Enzyme Linked Immuno-Sorbent Assays (ELISAs)
Table 2.1
Comparison of Enzyme Immunoassay (EIA) and Radioimmunoassay (RIA)
Handling of Reagents 
Disposal of Reagents 
Storage of Reagents 
Reading
Reading Time
Availability of 
Reagents for 
Infectious 
Diseases
Flexibility
Kits
Expense
Training for Use
Field Use
Labelling in 
Laboratory
EIA RIA
Caution
Strict Legislation
Half-life dependent
Sophisticated
machines
Slow
Poor
Some mutagenic substances
No control
Stable long term
By eye/Sophisticated 
machines
Rapid
Good
Flexible Flexible
Good Poor
Moderate/Low High
Simple Simple
Yes No
Simple Difficult
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and the most common format is a 96 well microplate for use in the 
96 well micro ELISA. The advantage of the solid phase is that 
one of the components can be attached to it, further reagents 
added and, following suitable incubation, unreacted reagents 
washed away giving a simple separation of bound and free 
reagents. Assays involving such a separation step by washing are 
heterogeneous assays.
The basic principles which apply to all ELISAs are listed.
(a) Adsorption of antigen/antibody to the plastic solid phase 
(coating).
(b) Addition of sample and subsequent reagents.
(c) Incubation of reagents.
(d) Separation of bound and free reactants by washing.
(e) Addition of enzyme labelled reagents (conjugates).
(f) Addition of colour development system/enzyme detection 
(substrates).
(g) Reading of assay - visual or spectrophotometric.
Utilising these basic principles there are four types of
ELISA.
ELISA FORMATS
(1) Direct ELISA (Figure 2.1)
Antigen or antibody is adsorbed onto the solid phase and 
reacted directly with enzyme labelled antiserum or enzyme 
labelled antigens. The disadvantages of this assay are, with
labelled antibody, low levels of antigen adsorption from crude 
samples due to competition for plastic sites by contaminants also
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F i g u r e  2.1
Direct ELISA using labelled antibody 
or labelled antigen.
1. Passive adsorption of 
antigen/antibody 
to the plate
> -
WASH
2. Addition and incubation 
of enzyme labelled 
antibody/antigen.
WASH
3.
O
Addition and incubation 
of colour development 
system. £
/■>
o.
°o
X  X  /
READ
all sera raised against different antigens have to be labelled 
giving poor applicability to diagnostic problems: In general
antigens are rarely labelled.
(2) Indirect ELISA - (Figure 2.2)
The antigen is adsorbed onto the solid phase and any non­
adsorbed antigen is washed away before the addition of serum 
containing antibodies against the antigen in a blocking buffer 
which prevents the non-specific adsorption of protein onto any 
unoccupied sites on the plastic. After incubation any unbound
antibodies are washed away enabling bound antibody to be
detected, following incubation, with a single optimal dilution of 
anti-species antibody conjugated to an enzyme. The amount of 
specific antibody binding to the antigen is quantified after 
addition of the colour development system. This type of assay is 
used for the detection of specific antibodies present in serum 
samples. The specificity is dependant upon the purity of the 
antigen attached to the solid phase. Indirect assays have the 
advantage over direct assays in that only a single anti-species 
enzyme conjugate is required.
(3) Direct Sandwich ELISA - (Figure 2.3)
Antibody (igG Fraction of whole serum) is attached to the 
solid phase at a constant optimal dilution and, following
incubation, unadsorbed antibody is washed away before antigen is 
added in a blocking buffer. After incubation unbound antigen is 
washed away to enable the detection of bound antigen by the
addition of enzyme labelled antibody specific for the 'captured' 
or 'trapped' antigen. This antibody can be the same as that used
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Figure 2.2. Indirect ELISA
« Passive adsorption of antigen.
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against antigen.
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4.
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Addition of colour 
development system.
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Figure 2.3 • Direct Sandwich ELISA
1. /  Passive adsorption
^  of antibody.
WASH
2. « Addition of antigen.
WASH
3.
— &
Addition of enzyme 
labelled antibody against 
antigen.
WASH
4.
° < y  \  •
S v »
I Addition of colour 
development system.
READ
on the solid phase, produced in the same or a different species 
as the trapping antibody. After incubation and washing away of 
unbound conjugate, the colour detection system is added and the 
test read. This type of assay enables the detection of some 
antigens which, due to scarcity or contamination, cannot be 
attached directly to the solid phase. The 'trapping' antibody 
must bind specifically to the antigen to be detected which itself
must contain a minimum of two epitopes to permit the formation of
the 'sandwich'. The disadvantage is that all detecting antisera 
have to be enzyme conjugated, however this can be overcome by 
using an indirect sandwich ELISA (Figure 2.4) in which the second 
antibody is produced in a different species from the trapping 
antibody. This second antibody can be detected using a species 
specific antiserum conjugate which does not react with the 
antibody on the plastic. Any disadvantage of this extra step is 
outweighed by the advantage that many second antibodies may be 
titrated using one conjugate.
(4) Competition ELISA
(a) Direct Antibody Competition - (Figure 2.5)
Adsorption of antigen onto the solid phase is followed by
washing and the addition of specific antibody labelled with 
enzyme at a pre-titrated dilution to ensure the saturation of 
antigenic sites so none remain available for further antibody 
competition. This acts as a positive control. In this ELISA the 
interaction is disrupted by prior mixing of the test sample (non­
labelled) with the labelled antibody. The non-labelled
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Figure 2.4. Indirect Sandwich ELISA
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Figure 2*5. Direct Antibody Competition ELISA
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4. /  . \  /  q Addition of colour
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(competing) antibody, at a range of dilutions, replaces some or 
all of the conjugated antibody. After washing and development of 
the assay, the amount of 'competing' antibody is read as a 
reduction in the colour expected compared to the colour obtained 
without the addition of the non-labelled competing antibody. 
This type of assay is gaining in importance with the increase in 
the use of monoclonal antibodies (mAbs). Any species can provide 
the serum to be used as the competitor.
(b) Direct Antigen Competition - (Figure 2.6)
In this assay, antigen is the competing substance for pre­
titrated conjugated antibody. If the labelled antibody reacts 
with the competitor antigen in the liquid phase it will not bind 
to the solid phase antigen and will be washed away after 
incubation, hence labelled antibody is no longer present to react 
with the antigen in the solid phase. This will reduce the 
expected colour.
(c) Indirect Antibody Competition - (Figure 2.7)
This is the same as the indirect ELISA except for the 
addition of competing (test) antibody to the solid phase antigen 
before or together with the pre-titrated specific antibody. The 
competing antibody must be produced in a different species from 
the pre-titrated antibody to .prevent the anti-species conjugate 
reacting with both. The binding of the competing antibody to the 
antigen prevents the pre-titrated (labelled) antibody binding and 
thus reduces the colour produced. The greater the amount of 
antibody in the test sample the less colour will be produced.
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Figure 2.6. Direct Antigen Competition ELISA
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Figure 2.7. Indirect Antibody Competition ELISA
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o
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(d) Indirect Antigen Competition - (Figure 2.8)
In this type of assay, antibody is pre-titrated against the 
solid phase antigen by the use of anti-species conjugate. The 
addition of antigen in the liquid phase provides the competition 
which appears as a reduction in the colour produced.
THE arnfieldi ELISA
As helminth parasites are among the most complex infectious 
disease agents infecting mammals, the host's antibody response to 
helminth infection is the most diverse with the production of 
antibodies of all isotypes - IgA, IgE, IgG and IgM. Antibodies 
are produced against various antigens; those present within the 
parasite-somatic antigens; those on the outer surfaces - surface 
antigens; those contained in helminth excretions and/or 
secretions - excretory secretory (ES) antigens. The first 
components of the parasite to be recognised as foreign by the 
host i.e. to form the first host-parasite interface, are the 
surface antigens and ES antigens. Unlike the surface antigens 
which are of a more finite quantity, the ES antigens are produced 
for the life of the worm and so a more abundant antibody response 
might be expected. The somatic antigens do not form part of the 
host parasite interface until after the death of the worm when 
they become exposed and elicit an antibody response. 
Antigenicity is defined as the ability of proteins, carbohydrates 
or lipids to elicit the induction and production of antibodies 
which bind in a predetermined manner to the antigen. The region 
of the antigen to which the antibody binds is the antigenic
Figure 2.8* Indirect Antigen Competition ELISA
1. Passive adsorption of antigen.
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determinant or epitope. Antibody specifically binds to the 
epitope of the antigen by multiple non-covalent interactions 
electrostatic, hydrogen bonds, Van der Waals forces and 
hydrostatic forces. The multispecificity of antibody molecules 
is dependent not only on the heterogeneity of the epitope in 
question but also on the molecular construction of the antigen 
reactive sites (paratopes) of the antibody molecules. The 
strongest binding occurs when the paratope matches the epitope 
exactly - "best fit".
In the early stages of an infection there is little antibody
available so an antigen excess prevails. This stage is normally
superseded by antigen-antibody equivalence - a state which 
favours the formation of immune complexes. Stable antigen- 
antibody complexes can result when there are a sufficient number 
of short range interactions between both regardless of total fit. 
In the later stages of infection (chronic infections) the long 
term antigen challenge or exposure produces elevated levels of 
circulating antibody. As arnfieldi infection, like many
helminth infections will be chronic at the time of diagnosis, it 
is most likely that a state of antibody excess occurs.
Due to commonness of some internal antigens e.g. enzymes,
the more individually specific antigens are surface expressed.
These antigens often show less cross-reactivity hence are more 
specific and therefore more useful for diagnosis. Antigens 
collected or extracted from stages of the parasite which do not 
occur in the final host are unlikely to be of use for detecting
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antibodies to the parasite in that host.
Host ELISAs in current use in the veterinary field have been 
developed to detect antibody. As the serum of the host reflects 
the heterogeneous collection of immunoglobulin molecules produced 
in reponse to previous antigenic stimuli, the detection of 
antibodies to D_^  arnfieldi in a single sample would, due to the 
chronicity of the antibody response, only prove previous exposure 
which, since the horse is a grazing animal, may not be that 
uncommon. Such a result would be of little value in diagnosis of 
current infection. For this reason an antigen detection test for 
use on individual samples, would be superior.
While the most accessable body fluid to test is blood, the 
ELISA test can be used with a variety of fluids. Although it was 
considered that respiratory associated secretions would be the 
best source of antigens attempts to collect nasal secretions 
(Rouse and Angulo, 1970) from arnfieldi infected horses and 
donkeys proved to be impracticable. Serum was therefore chosen 
as the most readily available sample for use in the D_;_ arnf ieldi 
ELISA.
The ELISA selected was the antigen capture micro ELISA with 
a 96 well flat bottomed plate format. Flat bottomed wells were 
chosen as they give less steric interference when 
spectrophotometric reading is employed to assess colour 
development (Crowther and Smith, 1986). As only rabbit anti- 
D. arnfieldi antibody was available for use in the ELISA it was a 
prerequisite that the same antibody could be used for detection 
and, after biotinyiation, development of the assay.
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IMMUNOHISTOCHEMICAL LOCALISATION OF D^ _ arnfieldi ANTIGENS 
Reactions with anti-D, arnfieldi Antibody Fraction Raised in 
Rabbits
This procedure was undertaken to ensure the anti- 
D. arnfieldi IgG antibody fraction (FrR) raised in rabbits 
recognised D_j_ arnfieldi antigen, prior to using this antibody in 
the ELISA test. The FrR was reacted with sections of 
D. arnfieldi worms as follows:-
Five micron sections of 10% formalin fixed adult 
D. arnfieldi worms blocked in wax were mounted on glass 
microscope slides and ringed with a diamond marker. The sections 
were then de-waxed and the slides air dried and outlined with 
yellow paint (Texpen, Marktex, Englewood, New Jersey) to contain
the reactants. The sections were then covered with FrR at a
range of dilutions (1:10 - 1.80) in phosphate buffered saline 
(PBS -pH 7.2, 100 mM) and incubated at room temperature for 30
minutes in a humid chamber. The slides were washed in three 
changes of PBS, each change lasting five minutes. The conjugate, 
sheep anti-rabbit IgG antibody conjugated to horseradish 
peroxidase (Sigma), at dilutions of 1:100 and 1:50 in PBS was 
added and incubated for 30 minutes as above. The slides were 
washed in PBS three times as above. The colour development
system (50 ml PBS, 16 jil 30% {substrate}, 15 mg DAB
{diaminobenzidine}) was incubated on the slide for a maximum of 
30 minutes, an insoluble brown colour product indicating a 
positive reaction.' The reaction was stopped by rinsing the
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slides in distilled water. Slides were then dehydrated by 
immersion through a series of alcohol concentrations 
counterstained with haemalum for less than a minute, blued in 
Scotts tap water substitute (pH 8), cleared in xylene and mounted 
with DPX (Distrene Plasticizer Xylene).
Summary of Procedure
(1) Apply antibody solution (FrR) to sections for 30 minutes.
(2) Wash three times with PBS.
(3) Apply conjugate for 30 minutes.
(4) Wash three times with PBS.
(5) Apply colour development system - colour - in 30 minutes.
(6) Stop with distilled water.
(7) Dehydrate through alcohols.
(8) Counterstain with haemalum.
(9) Mount.
RESULTS
The results of incubating D_j_ arnfieldi sections with the 
primary antibody at either 1:10 or 1:20 dilution with 1:100 
conjugate dilution are presented in Table 2.2 and the results 
with 1:50 conjugate dilution are presented in Table 2.3.
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Table 2.2
Incubation of arnfieldi Section with Primary Antibody 
(1:10 - 1:20) then 1:100 Conjugate
Rabbit Dilution of Antibody Solution Degree of Brown
Reaction
1 1:10 ++
1 1:20 +
2 1:10 ++
2 1:20 ++
No primary antibody - 100 PBS nil
Table 2.3
Incubation of D^ arnfieldi Sections with Primary Antibody 
(1:10 - 1:80) then 1:50 Conjugate
Rabbit Dilution of Antibody Solution Degree of Brown
Reaction
1 1:10 ++
1 1:20 ++
1 1:40 ++
1 1:80 +
2 1:10 +++
2 1:20 +++
2 1:40 ++
2 1:80 ++
no primary antibody nil
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When the conjugate was used at a dilution of 1:50 a dark 
brown reaction was produced with FrR^ at dilutions from 1:10 - 
1:40. At a dilution of 1:80 the brown reaction product was less 
intense although still clearly visible. At the same dilution of 
conjugate (1:50) Frl^ produced a very dark brown reaction product 
(see Table 2.3) at dilutions of 1:10 and 1:20. At the higher 
dilutions of 1:40 and 1:80 the intensity of the coloured product 
was reduced but still clearly visible.
CONCLUSIONS
The appearance of the brown product indicated a positive 
reaction. The colour was due to the reaction between DAB and 
hydrogen peroxide which was catalysed by horseradish peroxidase 
in the conjugate. To achieve this positive reaction the anti­
rabbit antibody component of the conjugate must have reacted with 
the rabbit component of the anti-D. arnfieldi antibody which had 
bound to antigens present in the D_^  arnfieldi worm sections. 
This is in effect a modified type of indirect assay (Figure 2.9). 
In the control slides where no antibody solution was added, no 
brown reaction product was produced. The positive reaction in 
all the slides which had the antibody solution added indicated 
that the IgG fraction isolated from the serum of both rabbit 1 
and rabbit 2 (FrR^ and FrR2 respectively) contained antibodies 
which recognised and reacted with antigenic sites on the 
D. arnfieldi sections. The more intense colour produced by FrR2 
compared with FrR^ suggested the antibodies raised by rabbit 2 
and present in FrR2 had either a greater affinity for the
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Figure 2.9.
Diagram of the indirect assay used in the 
immunohistochemical localisation of Dictvocaulus arnfieldi 
reacting with anti-Dictvocaulus arnfieldi IgG 
antibody fraction raised in rabbits.
Dictyocaulus arnfieldi 
antigen
anti-Dictyocaulus arnfieldi 
antibody raised in rabbits
Sheep anti-rabbit IgG
Horseradish peroxidase
antigenic sites or greater avidity for binding or were present at 
a higher titre than the antibodies present in FrR^.
Reactions of anti-D. arnfieldi Antibody Fractions with Antigens
of Fresh and Formalin Treated Worm Sections
The aims of this experiment were to establish the location 
of the antigens recognised by the FrR to enable an assessment as 
to whether the host animal (horse or donkey) was likely to have 
been exposed to these antigens in a natural D_j_ arnf ieldi 
infection and to examine the effect formalin treatment of the 
worms had upon recognition of its antigenic sites by the 
antibodies present in FrR^ and FrR2»
To determine the location of antigenic sites recognised by
the antibodies in FrR^ and FrR^ within D_j_ arnf ieldi adults 
further experiments were performed using either sections of
formalin fixed (Slides 1-5) or unfixed worms (Slides 6-10) 
mounted on glass microscope slides. The worms were ringed as
before and the slides dewaxed through a graded series of
alcohols. The biotinylated FrR^ and FrR^ (FrR^B and FrR2B) were 
applied onto sections of worms at dilutions of 1:10 and 1:20 in 
PBS and incubated in a humid chamber for 30 minutes at room 
temperature. Slides were then washed three times in PBS (as 
before) following which conjugate (streptavidin peroxidase 
Sigma) at 1:1000 was added and the slides incubated as before. 
Slides were washed three times in PBS and the colour development 
system (50 ml PBS, pH 7.2, 0.1M; DAB {diaminobenzidene} 17 ug;
^2^2 ^  was added and incubated for 30 minutes to allow
the brown reaction product to develop. The reaction was stopped
by rinsing the slide in distilled water and the sections 
dehydrated by immersion through a series of graded alcohols (10 - 
100%), counterstained and mounted as before.
Summary of Procedure
(1) Add FrRB to section of arnfieldi worm on slide.
(2) Rinse with PBS three times.
(3) Add streptavidin peroxidase.
(A) Rinse with PBS three times.
(5) Add colour development system.
(6) Stop reaction with distilled water.
(7) Dehydrate slides.
(8) Counterstain and mount.
RESULTS
The results of incubating either formalin fixed or unfixed 
D. arnfieldi sections with either 1:10 or 1:20 dilution of FrRB 
and conjugate dilution 1:1000 are presented in Table 2.4.
CONCLUSIONS
All positive slides produced a brown reaction product. A 
more intense colour was produced in the slides with sections of 
the unfixed worm than with those with sections of formalin fixed 
worms indicating that more antigenic sites were available and 
accessible for binding with the antibodies present in FrR in the 
unfixed worm sections. The colour produced with the formalin 
fixed sections (Slides 1-4) showed no variation regardless of 
antibody source or dilution.< In contrast the colour produced
90
Table 2.4
Incubation of Either Formalin Fixed or Unfixed D. arnfieldi
Sections with FrRB
Slide
Source of 
Antibody
Dilution of 
Antibody
Intensity of Brown 
Reaction Product
1 FrR1B 1:10 ++
2 FrR1B 1:20 ++
3 FrR2B 1:10 ++
4 FrR2B 1:20 ++
5 none 100% PBS ni 1
6 FrRjB 1:10 +++
7 FrR1B 1:20 +++
8 FrR2B 1:10 ++++
9 FrR2B 1:20 ++++
10 none 100% PBS nil
Footnote:
1 - 4  Worm sections fixed in 10% Formol Saline
5 Negative control
6 - 9  Fresh worm sections
10 Negative control
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with the unfixed sections was much more intense with Frl^B than 
with FrR^B although there was no variation in colour product at 
the different dilutions. From this it appeared that the formalin 
exerted a detrimental effect upon some D_^  arnfieldi antigens 
reducing their interactions with antibodies present in FrRB. 
This may have been due to formalin cross-linking protein epitopes 
thus rendering them unavailable for the antibody paratopes. As 
diluting the FrRB from 1:10 to 1:20 had no effect upon the 
intensity of coloured product which developed, the antibodies 
must have been in excess hence the availability of epitopes on 
the worm sections was the limiting factor.
Microscopic examination revealed the brown reaction product 
located on the epicuticle and gut lining of arnfieldi adults 
(see Figure 2.10) indicating that antibodies raised in the 
rabbits recognised both surface and somatic antigens. The 
finding that the antibodies in FrR recognised IK_ arnfieldi 
surface antigens increased the expectation that these antigens 
would be detectable in and recognised by the host as these 
surface antigens provide an extensive host-parasite interface. 
The antigens located on the gut lining of the worm could be part 
of the fabric of the worm or could be excretory/secretory 
antigens, in which case a greater immunological response would be 
expected as ES antigens are the first antigenic compartment 
recognised by the host's immune system and, unlike somatic 
antigens, ES antigens can be produced in large amounts within the 
host hence increasing the amount of antigen to which the host 
might be exposed.
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Figure 2.10
Photomicrograph of a section of an adult EK arnf ieldi 
showing a brown colourisation indicating the recognition by 
antibodies of both epicuticle and gut antigens
COMPOSITION OF THE arnfieldi ANTIGEN
Having ascertained by immunohistochemical localisation that 
a circulating antibody response was produced in the immunised 
rabbits, further biochemical characterisation of the D_j_ arnfieldi 
antigen was undertaken.
Antigens can consist of a variety of substances e.g. 
proteins, glycoconjugates, nucleic acids, carbohydrates or 
polysaccharides etc. It was assumed that the D^ _ arnfieldi 
antigen to be tested for would be present in serum either in an 
uncomplexed (free) form or as soluble immune complexes but there 
was also the possibility that D_j_ arnfieldi antigens might form 
insoluble complexes with antibody.
EDTA Treatment
To separate D^ _ arnfieldi antigen from any immune complexes 
in serum, samples were boiled with EDTA to disrupt the bonding 
between antibodies and antigens. It was hoped that separation of 
any immune complexes into their constituent parts would leave 
epitopes in a form recognised by the antibody used in the ELISA 
as it was unlikely that any paratope of the FrR would be able to 
bind very successfully with large immune complexes due to steric 
hindrance. Binding capacity could also be reduced by m  vivo
formed antibodies masking epitopes rendering them less or
unavailable for binding (see Figure 2.11).
If, following EDTA treatment, the optical densities (ODs) 
obtained with the ELISA were increased compared with the ODs
obtained prior to treatment then it would imply that the
D. arnfieldi antigen was present as immune complexes. However,
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Diagram of Immune Complex
y
A<o>-<
\ /
/ \
Dictyocaulus arnfieldi 
antigen.
Host antibody.
as the process also involves heating the sample, it is possible 
that treatment would expose more heat stable epitopes. If no 
increase in ODs were observed it could indicate either that 
immune complexes were absent or that the epitopes were damaged 
when the complexes were separated and thus were no longer 
recognisable by the paratopes.
Autoclave Treatment
This was carried out to destroy the tertiary structure of 
the arnfieldi antigen if it was peptide in nature. A
reduction in the ODs following autoclave treatment would 
therefore indicate the D^ arnfieldi antigen was protein in 
nature, however the exposure of more heat stable peptide epitopes 
could confuse the picture. Disruption of the tertiary structure 
obviously alters the topography of the antigenic entity which 
might reduce or eliminate the 'best fit* needed for optimal 
binding between antigen and antibody.
Periodate Treatment
This treatment would disrupt any terminal sugars if the 
D. arnfieldi antigen extract was a glycoconjugate and so bring 
about a reduction in ODs. In this instance periodate was used 
under harsh conditions which are designed to completely disrupt 
the structure of the saccharide unlike mild periodate treatment 
where only the most vulnerable bonds are cleaved. Periodate 
oxidation of exposed sugars oxidises vicinal dihydrols of the 
reducing terminal of an oligo or polysaccharide.
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RESULTS
Autoclave and periodate treatment of the arnfieldi
antigen reduced the sensitivity of detection by 19% and 27% 
respectively when compared with untreated antigen (Figure 2.12).
CONCLUSIONS
The reduced sensitivity following autoclave and periodate 
treatment indicated that approximately 20% of the epitopes were 
protein in nature and 30% carbohydrate.
ELISA PROCEDURE FOR D^ _ arnfieldi ANTIGEN DETECTION
The ELISA adopted was a 96 well heterogeneous antigen 
capture MICRO ELISA (Figure 2.13). The same polyclonal antibody 
was used both to capture the antigen and to develop the reaction. 
This was accomplished by utilising the biotin-streptavidin 
system, whereby only the development antibody was biotinylated. 
The development of an ELISA necessitates the optimal dilution of 
all reagents. To this end certain recognised procedures were 
followed to establish the necessary parameters. Detailed results 
of these procedures are given in Appendices 2 . 1 - 2 . 6 0 .  To 
ensure reproduceability of the ELISA the following parameters 
were analysed:
(1) Concentration of capture antibody required to coat the 
plate.
(2) Concentration of development (biotinylated) antibody.
(3) Concentration of streptavidin peroxidase.
When calculating the concentration of capture antibody 
required to coat the plate to ensure optimal trapping of antigen,
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Figure 2.12
Optical densities obtained in the D. arnfieldi 
ELISA with untreated, periodate treated and 
autoclaved D. arnfieldi antigen
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Figure 2 . 13 . Diagrammic representation of the ELISA 
for Dictyocaulus arnfieldi antigen.
1.  /  Passive adsorption of antibody onto plate.
\  Rabbit anti-Dictyocaulus arnfieldi (FrR).
>
WASH
Addition of antigen.
WASH
Addition of enzyme labelled antibody 
raised against antigen. Biotinylated rabbit 
anti-Dictyocaulus arnfieldi (FrRB).
WASH
9 ^ Addition of conjugate - 
Streptavidin peroxidase.
4.
WASH
5. Addition of colour 
development system.
READ
the fact that on average an ELISA well can only adsorb
approximately 300 ng of IgG is taken into account (Crowther and 
Smith, 1986). Both antibody solutions (FrR^ and FrR^) were 
purified by salt fractionation and column chromatography and 
concentrated by ultrafiltration to a protein concentration of
1 mg/ml. The plate was coated with varying concentrations of 
antibody (1:25 -1:3200) and a standard amount of antigen solution 
(protein concentration 30 /ig/ml) sufficient to ensure an antigen 
excess was used. The optimal concentration of non-biotinylated 
antibody for coating the plate was found to be 1:100.
Due to the scarcity of available materials it was decided to 
biotinylate the FrR to allow the use of the same antibody to
capture antigen and develop the colorimetric reaction. Since
both capture and development antibodies were raised in rabbits 
the problems of cross reactions between species were eliminated. 
The concentration of biotinylated antibody to be used was 
calculated by titrating various dilutions (range 1:10 - 1:1280) 
with the concentrations of both capture antibody and antigen 
being kept constant. An antibody excess is required to ensure 
all available binding sites on the antigen are saturated. The 
optimal concentration of biotinylated antibody was found to be 
1:100.
The colour development system utilised in this ELISA was 
streptavidin peroxidase as the enzyme conjugate. The substrate 
contained hydrogen peroxide and the chromogen was orthophenylene 
diamine (O.P.D.). Initially the streptavidin peroxidase had been
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titrated for use in another ELISA system and was being used at a 
1:5000 dilution. When used at this dilution in the D_;_ arnfieldi 
ELISA the colour development was unacceptably slow and 
insufficient only producing a maximum O.D. after 45 min 
development time of 0.085 when read at 492 nm after stopping with 
2M I^SO^. The streptavidin peroxidase was re-titrated to 1:1000 
which produced a more rapid and intense colour development giving 
a maximum O.D. after 30 min development time of of 0.790 at 
492 nm.
In summary, the following procedure was defined for the 
ELISA for D_;_ arnfieldi antigen.
(1) Coat plate with non biotinylated FrR at a dilution of 1:100 
in coating buffer, adding 5 0yal per well.
(2) Incubate plate for two hours at 37°C.
(3) Wash plate three times with wash buffer and tap dry.
(4) Add antigen, 50^ul per well, incubate at 37°C for 30 
minutes.
(5) Wash plate three times with wash buffer and tap dry.
(6) Add biotinylated FrR (FrRB) at a dilution of 1:100 in 
diluting buffer, 50 ji 1 per well. Incubate at 37°C for 30 
minutes.
(7) Wash plate three times with wash buffer and tap dry.
(8) Add conjugate, streptavidin peroxidase, at a dilution of
1:1000 in diluting buffer, 50ji\ per well. Incubate at 37°C 
for 30 minutes.
(9) Wash plate three times with wash buffer and tap dry.
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(10) Add substrate/chromogen, 50^ul per well. Incubate at 37°C 
for 30 minutes in the dark.
(11) Read at 450 nm.
(12) Stop with 2M I^SO^, 50yil per well.
(13) Read at 492 nm.
Although 30 minutes was the average time required for 
suitable colour development, with the colour change being easily 
detectable by eye, the visual assessment of stopping time was 
backed up by reading the plates at 450 nm. If the control
positive well had an OD of 0.3 - 0.47 at 450 nm the reaction was
then stopped by the addition of acid. The plates were stopped to 
prevent any further change in the OD after the development time. 
Stopping produces a change in the coloured product which changes 
the optimal wavelength required for measurement. It is very 
important for maximum accuracy that a standard volume of each 
reagent is added to each well especially the last two additions 
(substrate and acid) as the volume in the well influences the OD. 
Antigen Titration
Having defined the parameters for the ELISA for D^ _ arnfieldi 
antigen the level of antigen detection had to be ascertained. 
There was some background noise (O.D. readings not attributable
to the presence of D_;_ arnfieldi antigen) in the test due to non­
specific adsorption of proteins from the antigen solution/serum 
samples onto any unoccupied plastic sites, i.e. spaces in the 
ELISA well where no FrR had bound. This background noise can be 
reduced by the addition of blocking agents to the buffer 
solutions. The blocking agents are immunologically inert
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substances (for the system used) which compete with the non­
specific factors, for the available binding sites of the plastic 
plate and hence reduce the amount of non-specific binding to the 
wells (Figure 2.14). Examples of blocking agents in common use 
are BSA (bovine serum albumin), horse serum and dried skimmed 
milk (Marvel, Cadbury). Another method of blocking is the use of 
non-ionic detergents which prevent non-specific adsorption by 
preventing any non-covalent and non-ionic interaction between the 
surface of the plastic and the proteins which would adsorb non- 
specifically onto the surface of the well. One such agent is 
Tween 20 (polyoxyethylene sorbitan monolaurate). Any agent or 
combination of agents used must not have any detrimental effect 
upon antigen, antibody or antigen/antibody interaction.
Antigen solution with a protein concentration of 30^ig/ml 
was used in a variety of diluents, each containing a blocking 
agent, to try to minimise non specific binding.
In diluting buffer - which contained 0.05% Tween 20 and 
0.2 - 1% BSA - antigen appeared detectable down to dilutions of 
1:1600. Below this, background reaction made it impossible to 
differentiate a positive reaction.
The addition of Marvel (range 1 - 5%) to the diluting buffer 
reduced the background noise further. The optimal concentration 
was a solution of 2.5% Marvel.
The goal for this ELISA was the detection of active 
infection in the living horse/donkey by the detection of 
D. arnfieldi antigen in equine serum. To reduce any non-specific
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Figure 2 .14. Diagrams showing action of blocking agent
Plate coated with FrR.
Plate coated with FrR 
and non-specific 
proteins binding.
Blocking agent (BSA, Marvel) 
occupying 'spare' sites on 
plastic and preventing 
non-specific proteins from 
binding.
reactions due to common immunological factors which could be 
present in horse serum, bovine serum was used as a vehicle for 
the antigen. The possibility that a common 'equine' component of 
the serum could be recognised by the FrR existed because the 
D. arnfieldi worms used to raise antibodies in the rabbits were 
recovered from donkey lungs and, despite vigorous washing, some 
equine blood or mucus may have been present in the final worm 
homogenate used to immunise the rabbits. Following detection of 
D. arnfieldi antigen in bovine serum at dilutions down to 1:800, 
antigen solution was added to inactivated horse serum (Gibco, 
Glasgow, Scotland). The amount of non-specific reaction did 
increase with the horse serum, however antigen in horse serum was 
definitely detectable down to dilutions of 1:80 which is a 
protein level of 1.5 ng. Overall antigen was detectable down to 
levels of 1.2 - 2.6 ng which is the equivalent of approximately 
0.01 of an adult worm. This was judged to be a satisfactory 
sensitivity.
USE OF THE ELISA FOR DETECTION OF IK arnfieldi ANTIGEN IN EQUINE 
SERUM SAMPLES
Having determined the basic parameters for the ELISA for the 
detection of IK_ arnfieldi antigen and having detected antigen in 
spiked samples down to levels of 1.5 ng the next step was to use 
the test to try to detect antigen in serum samples taken from 
horses, ponies or donkeys which were either known or suspected to 
have been exposed to infection. These samples fell into four 
main groups.
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(1) Samples from donkeys at the Donkey Sanctuary in Devon.
(2) Samples from ponies experimentally infected with 
D. arnfieldi.
(3) Samples from donkeys resident at Glasgow Veterinary School.
(4) Samples from clinical cases where lungworm infection was 
suspected.
In the ELISA, 50jil of both neat (undiluted) serum and serum 
treated with EDTA prior to testing were used: Both untreated and
EDTA-treated samples were tested on the same plate.
Samples taken from animals at Glasgow were aliquoted into 
polythene eppendorfs (Alpha Laboratories, Eastleigh, Hampshire) 
until required. Samples taken from animals elsewhere were posted 
to Glasgow and aliquoted and frozen as above: These samples
tended to have thawed if they had been frozen prior to posting.
(1) Samples from the Donkey Sanctuary in Devon.
Serum samples were taken routinely from donkeys on arrival 
at the Sanctuary at the same time as they were given a general 
medical check over and had faecal samples taken for examination 
for parasite eggs or larvae. The results of the faecal 
examinations were supplied together with the serum samples. 
Although the history of these donkeys was mostly unknown it would 
be reasonable to assume all had been at grass previously.
(2) Samples from ponies experimentally infected with 
D. arnfieldi.
The experimentally infected mature ponies (Section 1.3) had blood 
samples samples taken on arrival and then at regular intervals
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thus providing known pre- and post-infection samples. The
experimentally infected mares and foals (Section 1.4) only had 
blood samples taken at necropsy thus providing a known post­
infection sample.
(3) Samples from donkeys resident at Glasgow Veterinary School. 
Resident donkeys provided blood samples over a three year
period under a variety of conditions.
(i) Adult donkeys with patent arnfieldi infections
either while grazing infected pasture or while housed,
(ii) Adult donkeys without patent arnfieldi infections
either while grazing infected pasture or while housed, 
(iii) Donkey foals housed from birth under worm-free
conditions until turnout onto infected pasture.
(4) Samples from clinical cases where lungworm infection was 
suspected.
Veterinary surgeons in practice provided blood samples from 
cases of chronic coughing in horses and ponies. These were 
usually accompanied by a faecal sample. None of the horses or 
ponies had evidence of D_j_ arnfieldi infection on faecal 
examination but samples from one outbreak of coughing were from 
animals known to have had grazing contact with donkeys which had 
patent D_^  arnfieldi infections.
RESULTS
(1) Samples from Donkeys at the Donkey Sanctuary in Devon.
The results from samples sent to the laboratory together 
with data provided by the Donkey Sanctuary are displayed in
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Figure 2.15. From these it can be seen that there is little 
correlation between the faecal arnfieldi larval recoveries and 
the ODs achieved in the ELISA for D^ _ arnfieldi antigen. In 
general the untreated serum gave marginally greater ODs than the 
EDTA treated samples at the same dilutions indicating an adverse 
effect on antigen availability by either heat or EDTA treatment. 
These samples from the Donkey Sanctuary were single samples taken 
from a large number of animals with unknown histories. As they 
were taken on a 'one-off' basis it was not possible to 
investigate any trends in D^ _ arnfieldi antigen detection over a 
period of time.
(2) Samples from Animals Experimentally Infected with 
D. arnfieldi
(a) Mature Ponies.
The results of the ELISAs on repeated samples from individual 
animals used in Experiment 1) are shown in Figure 2.16.
Pony I and Pony 2
No larvae were recovered from the faeces of either pony and, 
although lesions characteristic of infection were present in the 
lungs of both, no D^ arnfieldi were recovered. In both ponies 
there was no change in the ODs obtained following infection.
Pony 3 and Pony A
No larvae were detected in the faeces of either pony but 
lesions characteristic of D_j_ arnfieldi infection were present in 
the lungs of both. No D^ arnfieldi were recovered from the lungs 
of Pony A but 16 D^ arnfieldi were recovered from Pony 3 by lung
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Figure 2.15
The optical densities using raw and EDTA-treated serum in the 
ELISA for arnfieldi together with larval counts in 
50 grams of faeces (Da/50 g) from the donkeys admitted to the 
Donkey Sanctuary from 1986 - 1988
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Figure 2.16
The optical densities using raw and EDTA-treated serum in the 
ELISA for arnfieldi in mature ponies experimentally- 
infected with 2,000 (Ponies 1-8) or 5,000 (Ponies 9 and 10)
D. arnfieldi
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perfusion. There was no change in the ODs after infection in 
either pony.
Pony 5. and Pony 6^
No larvae were detected in the faeces of either pony but 38 
and 36 arnfieldi were recovered by lung perfusion from
Ponies 5 and 6 respectively. In both ponies there was no marked 
change in the ODs obtained post-infection.
Pony ]_ and Pony 8
No larvae were detected in the faeces of either pony and 
although 12 and 24 arnfieldi were recovered at necropsy from
Ponies 7 and 8 respectively there was no appreciable change in 
the ODs post-infection.
Pony 9 and Pony 10
No larvae were detected in the faeces of either pony but 1 
and 102 D_j_ arnf ieldi were recovered at necropsy of Ponies 9 and 
10 respectively. There was no appreciable change in the ODs 
post-infection despite the marked coughing shown by Pony 10.
(b) Mares and Foals.
The results of the ELISA ODs of individual mares and foals 
are shown in Figure .2.17. Blood samples were only taken from 
these animals on one occasion - at necropsy 6 weeks (13M and 
14F), 8 weeks (11M and 16F) and ten weeks (12M and 15F) post 
infection. Only two animals (11M and 15F) had D^ _ arnfieldi 
recovered from their lungs. The ODs of the samples from the mare 
(11M) and the foal (15F) were of the same order as those of the 
other animals where no D. arnfieldi were recorded. There was no
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Figure 2.17
The optical densities using raw and EDTA-treated serum in the 
ELISA for D. arnfieldi in mares and foals experimentally 
infected with 6—10,000 and 2,500 D. arnfieldi respectively
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difference in the ODs of the mares compared to the foals. In two
animals (11M and 13M) there were differences between ODs of the
untreated and EDTA treated sera. With 11M the untreated serum 
gave an OD value of 0.1 greater than the EDTA treated serum 
value. In contrast 13M gave an untreated serum value of 0.15 
less than the EDTA treated serum.
(3) Samples from Donkeys Resident at Glasgow Veterinary School.
Results of the ELISA ODs on repeated samples from six
donkeys maintained in Glasgow for up to two years are shown in 
Figure 2.18.
Donkey 20A was an adult mare sampled over a two year period. 
Throughout this time she had a patent D_;_ arnfieldi infection with 
fluctuations in faecal larval counts from 10 - 220 lpg. The
D. arnfieldi larval counts were greater during the grazing period 
of the second year. In all but one occasion the OD obtained with 
untreated serum was greater than with the EDTA treated serum but 
there was no correlation between any of the ODs and faecal 
larval output. Generally the ODs of the untreated serum were in 
the range 0.3 - 0.5 irrespective of whether the donkey was housed 
or grazing infected pasture.
Donkey 21A was an adult mare, again sampled over a two year 
period. Initially this animal had low numbers of D_;_ arnfieldi in 
the faeces which, on one occasion, was associated with an ELISA 
OD of 0.8 with untreated serum. Only one further faecal sample 
was positive for lungworm. Generally the untreated serum gave 
slightly greater ODs than the EDTA treated serum but overall the 
ODs were around 0.3 with no change after turnout despite the
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Figure 2.18
The optical densities using raw and EDTA-treated serum in the 
ELISA for D_;_ arnfieldi together with faecal D_^ arnf ieldi 
larval counts (l.p.g.) from donkeys at Glasgow Veterinary School
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fact that this animal was grazing pasture contaminated with 
D. arnfieldi larvae.
Donkey 22A, like the previous animal, was an adult mare 
sampled over a two year period. For the first four months of 
the study, while housed, the mare had a patent D_j_ arnfieldi 
infection ( 1 - 6  lpg faeces) and over this period the ODs were 
greater than 0.5 on a few occasions. However over the two year 
observation period there was no apparent correlation between 
ELISA ODs and either patency or exposure to infection from 
contaminated pasture. Although there was a slight increase in the 
untreated serum ODs after turnout in Spring, 1988.
Donkey 23F is the foal of donkey 21A. Donkey 21A had become 
non-patent for D_;_ arnfieldi before 23F was conceived, 23F being 
foaled indoors and reared worm free. It is therefore very 
difficult to explain the OD of > 1 with the EDTA treated serum 
taken when the foal was only a few days old as there is no 
passive transfer of D^ arnfieldi infection from dam to offspring. 
There was no increase in the ODs on turnout onto contaminated 
pasture along with infected donkeys in Spring, 1988. Towards the 
end of the grazing period (July, 1988) a slight increase in the 
ODs, especially with the untreated serum was shown but this began 
to tail off in August.
Donkey 24F was the foal of mare 20A which had a patent 
D. arnfieldi infection throughout this study. This foal was born 
and reared indoors until turned out to graze contaminated pasture 
with the other donkeys in April, 1988. The ODs were almost all
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less than 0.3 except for one occasion in July. In general, and 
in contrast to the previous animals, the ODs with the EDTA
treated serum were marginally greater than those obtained with 
untreated serum.
Donkey 25A was an adult mare which had a patent Eh_ arnfieldi 
infection over a period of approximately 18 months. In contrast 
to Donkey 20A, which also had a persistent infection, in this
animal there appeared to be some correlation between increases in
D. arnfieldi larval output in faeces and the ELISA ODs and
overall the ODs obtained in samples from this donkey were greater 
than with those obtained from the donkeys which did not have 
patent infections. As with most of the other donkeys, the ODs 
with untreated serum were greater than the ODs with the EDTA 
treated serum.
(4) Samples from horses and donkeys in some of which lungworm
infection was confirmed or suspected.
These were essentially samples taken from animals 
referred to Glasgow University Veterinary School or sent in by 
practitioners. Most had a known history which in some included a 
recent coughing episode. Several animals were sampled on more 
than one occasion. The results are illustrated in Figure 2.19.
Of the 29 animals sampled, five showed patent D_j_ arnfieldi 
infections all of which were donkeys . The ODs of serum samples 
from these five animals varied from 0.1 - 0.6 and were not 
significantly different from those obtained with the sera from 
the other donkeys and horses included in this survey.
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Figure 2.19
The optical densities using raw and EDTA-treated serum in the 
ELISA for arnfieldi together with faecal larval 
D. arnfieldi counts (l.p.g.) from animals referred 
to Glasgow Veterinary School
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In the case of Donkey Y whose faecal D_;_ arnfieldi larval
counts were 4 lpg and zero in samples taken one week apart, the
ODs with untreated or EDTA treated serum samples were both < 0.2. 
In the remaining four donkeys where patent IK. arnfieldi 
infections were confirmed (B8, B30, NM6 and NM7) the OD's varied
from < 0.2 - 0.6.
No EL_ arnfieldi larvae were evident in the faeces of the
other animals in this survey but this does not rule out the
possibility of infection as retardation of development often 
occurs in horses/ponies. In the animals in the NM group which
had been grazing with the two infected donkeys and were
clinically ill prior to treatment, the initial ODs were > 0.3: 
All these animals showed a decrease in ODs in samples taken one 
week after anthelmintic treatment. The four animals for
which only untreated serum was tested were horses with no known 
history of lungworm infection or exposure to |K_ arnfieldi within 
the preceding 18 months. Two of these animals (Jim and Pat) had
ODs greater than 0.3 when read at 492 nm.
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USE OF AN ELISA FOR DETECTION OF Dictyocaulus arnfieldi 
ANTIBODIES
Although the main aim of the ELISA used in this work was to 
diagnose current infection by detecting |K_ arnfieldi antigen, a 
test was also carried out on sera from animals known to have been 
exposed to infection to find out if it was possible to detect 
antibodies to IK. arnfieldi.
The format used was a 96 well microelisa plate which was 
coated with D^ arnfieldi antigen solution at varying dilutions. 
Serum from a mare which was known to be infected with 
D. arnfieldi (D. arnfieldi worms were recovered from the lungs at 
necropsy) was tested using FrR^ as the positive control and serum 
from a naive horse foal, which had never had access to pasture, 
as a negative control. Following incubation and washing, the 
plate was developed using anti-rabbit IgG peroxidase for the FrR^ 
and anti-horse Ig peroxidase (affinity isolated antibody-Sigma) 
for the test sample and the negative control. Following 
incubation and washing, the substrate and chromogen (hydrogen 
peroxide and OPD respectively) were added, the plate incubated in 
the dark for 30 minutes before reading at 450 nm prior to 
stopping the reaction with acid and re-reading at 492 nm.
Summary of Procedure
(1) Coat plate with D^ arnfieldi antigen in coating buffer 
(50 ^ il per well).
(2) Incubate plate for two hours at 37°C.
(3) Wash plate three times with wash buffer and tap dry.
(4) Add antibody (sample-test or control), 50 jil per well.
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(5) Incubate plate for 30 minutes at 37°C.
(6) Wash plate three times with wash buffer and tap dry.
(7) Add appropriate anti-species IgG peroxidase (1:500 in 
diluting buffer, 5 0 per well).
(8) Incubate plate for 30 minutes at 37°C.
(9) Wash plate three times with wash buffer and tap dry.
(10) Add substrate/chromogen, 50 ^ ul per well.
(11) Incubate for 30 minutes at 37°C in the dark.
(12) Read at 450 nm.
(13) Stop with 2MH2SO^, 50jil per well.
(14) Read at 492 nm.
RESULTS
This test detected antibody in the serum of the mare down to 
dilutions of 1:320 with the plate coated with antigen at a 
dilution of 1:40.
Following this successful detection of arnfieldi antibody 
in one animal, serum samples obtained at necropsy from all the 
animals used in the experimental infection of mares and foals 
(Section 1 Experiment 2) were tested (Table 2.5 and Figure 2.20). 
The plate was coated with antigen at a dilution of 1:40 and a 
naive foal was used as a negative control. Serum was tested in a 
range of dilutions - undiluted, 1:10, 1:20 and 1:40. The
aforementioned procedure was followed.
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Table 2.5
Mean Optical Densities Obtained Using the ELISA for D^ arnfieldi 
Antibody at Varying Serum Dilutions
Animal
Mean 0. 
serum
D. obtained 
dilutions
at varying 
at 492 nm Weeks
Undiluted 1:10 1:20 1:40
post
infection
13 M .402 .377 .373 .351 6
14 F .327 .416 .404 .378 6
11 M .449 .436 .408 .390 8
16 F .290 .291 .245 .202 8
12 M .345 .354 .356 .340 10
15 F .319 .344 .334 .313 10
Naive
Foal .156 .151 .135 .125
The results of this small experiment showed that it was 
possible to detect serum antibodies to D_^  arnfieldi by an ELISA 
test. While refinement of the test could improve the low optical 
densities achieved, for reasons stated previously antigen 
detection is still preferable as a diagnostic test for equine 
lungworm infection. The slightly lower optical densities shown 
by two of the foals compared with the mares could be related to 
the generally less severe clinical respone shown by the infected 
foals.
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Figure 2.201
Mean optical densities obtained using the ELISA for 
D. arnfieldi at varying dilutions of serum from mares and 
foals experimentally infected with D. arnfieldi 
(Section 1 - Experiment 2) and a D. arnfieldi-naive foal
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DISCUSSION OF ELISA STUDIES
Despite the successful development of tests to detect both 
lungworm antigen and antibody to D^ arnfieldi, the results of the 
antigen detection assay in terms of the optical densities 
obtained by the ELISA did not correlate well with the 
parasitological findings, e.g. the detection of D^ arnfieldi 
larvae in faeces. For example in 21 animals which were positive 
on faecal examination for lungworm larvae the serum ELISA ODs of 
18 of these animals were > 0.3 while in the remaining three they 
were < 0.3. Also in a further 131 animals which were not found 
to be excreting lungworm larvae on faecal examination, 92 had
serum ELISA ODs > 0.3 while in the remaining 39 the ODs were 
> 0.5.
There is no obvious explanation for these discrepancies but 
similar problems have been encountered with ELISA tests for
Dictyocaulus viviparus (Boon, Kloosterman and Brink, 1982) and
Trichinella spiralis (Saunders, Clinard, Bartlett and Saunders, 
1977) although both of these tests detected antibody. The test
for D_^  viviparus had poor specificity due to a large proportion 
of false positives, which included some naive calves. It was
suggested that this may have been due to colostral antibodies or 
minimal infections acquired via hay. There was an additional 
problem of a low level of cross reactions with gastrointestinal 
nematodes. Overall however, the specificity and sensitivity of 
the ELISA for antibodies to IK. viviparus was sufficient for herd 
screening for infection but not for diagnosis of infection in the 
individual animal. In trichinosis the ELISA was successful in
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the detection of antibodies to T^ _ spiralis in experimental 
infections but when used in commercial pigs at slaughter, a 15% 
level of false positive reactions occurred. These false 
positives were found to be due to non-specific serum factors 
which bound to components of the crude antigen preparation used 
in this ELISA. Another ELISA used to detect T^ _ spiralis also 
produced false positives but in this case the genetic backgrounds 
of the pigs were considered to have some effect (van Knapen, 
Franchimont, Skovgaard, Guildal and Henriksen, 1984). The 
apparent lack of correlation in the arnfieldi antigen ELISA 
could be due simply to technical difficulties in detecting low 
levels of D_j_ arnfieldi larvae in faeces. A similar explanation 
was given by van Knapen, Franchimont and Ruitenberg (1981), who 
suggested that some increases in specific antibody titres in the 
ELISA for trichinellosis could be accounted for by low numbers of 
Trichinella parasites infecting the pigs, which were not detected 
by classical parasitological means. Another explanation is that 
the D_^  arnfieldi ELISA was detecting non-patent infections as 
prepatent D^ _ viviparus infections have given positive results by 
ELISA in calves (Bos, Beekman-Boneschanscher and Boon, 1986). 
In this cattle study a different response to larval and adult 
worm antigens was found as anti-larval titres appeared 
approximately one week earlier than anti-adult titres which 
appeared coincidentally with patency. However in an ELISA 
developed for detection of antibody to Fasciola hepatica in 
cattle (Burden and Hammet, 1978), antigen prepared from adult
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flukes proved useful in the detection of prepatent infections. 
With D_;_ arnfieldi there is the additional problem of retardation 
of development of the parasites which therefore do not mature to 
produce patent infections.
The Eh_ arnfieldi antigen used in these studies was a crude 
antigen obtained from a homogenate of worms which included all 
lung dwelling stages and, unavoidably, some mucus and other lung 
secretions. An advantage of this crude antigen was that it 
included a wide, if not entire, range of parasite stages and
secretions liable to be found in the host. The wide range of
stages included in the antigen extract ensured that only those 
parasite antigens which occured in the host were used to raise 
antibodies in the rabbits. The disadvantage of the crude antigen 
was that there was the possibility of host tissues contaminating 
the worm homogenate thus the rabbits could have produced
antibodies against some equine proteins as well as against
D. arnfieldi antigens. This would increase the likelihood of non­
specific reactions leading to false positives due to recognition, 
by the antibodies raised in the rabbits, of epitopes in the 
equine test serum. If a more specific antigen had been used to 
raise antibodies, a narrower spectrum of epitopes would have been 
detected in the ELISA which may in turn have reduced the 
background in the negative controls and thus eliminated some of 
the false positive reactions. In the development of an ELISA for 
the diagnosis of human hydatidosis (Farag, Bout and Capron, 
1975), two antigens were used - whole hydatid fluid and purified 
hydatid antigens. Using the purified hydatid antigens the
overlap between infected patients and uninfected controls, which 
was evident when whole hydatid fluid was used as antigen, was 
eliminated; the ELISA values were also higher with the purified 
hydatid antigen. A similar situation occurred in the ELISA assay 
for antibodies in schistosomiasis (Huldt, Lagerquist, Phillips, 
Draper and Voller, 1975) where the use of a purified egg antigen 
produced considerably better differentiation between positive and 
negative samples than that achieved when using crude S^ _ mansoni 
antigen. However, until it is determined which parts of the 
antigenic repertoire of arnfieldi are responsible for the 
immunopathogenesis of disease, it is possible that a highly 
purified antigen might not contain some essential epitopes and 
thus reduce antigen detection.
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GENERAL DISCUSSION
Although arnfieldi is the sole equine lungworm and is 
worldwide in distribution, apart from the relatively detailed 
studies of Round (1972) there has been little research on this 
parasite. This is no doubt due in part to the fact that unlike 
the bovine lungworm viviparus which may cause severe disease 
with fatalities, the equine lungworm is considered of limited 
importance in horses and although known to be a common parasite 
of the donkey, it apparently causes few respiratory problems in 
this host. In horses however arnfieldi has been incriminated 
in cases of chronic coughing but confirmation of diagnosis of 
lungworm infection in such cases has posed major problems. This 
is due to the fact that the parasites do not often mature to the 
adult stage in horses and first-stage larvae cannot therefore be 
detected on faecal examination. The major thrust of the work 
reported in this thesis was to develop a test which would confirm 
the presence of an active lungworm infection by the detection of 
D. arnfieldi antigens and thus be a useful aid to diagnosis.
A pre-requisite for a number of studies proposed in this 
project was a reliable source of lungworm larvae. To this end 
various methods of laboratory culture of arnfieldi from 
present in faeces to infective third stage larvae were
attempted but most gave inconsistent or disappointing results. 
Faeces were incubated in water with sawdust, vermiculite, filter 
paper or charcoal; they were also spread in shallow layers on 
trays with and without the addition of moist sawdust, vermuculite 
or filter paper but none of these methods produced significant 
yields of and most were contaminated. Attempts to reduce this
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contamination by sieving (38 ^ 1) or filtering through milk filters 
at various stages in the culture process led to unacceptable 
larval losses. The most satisfactory method developed in this 
laboratory, involved the baermanisation of infected faeces in 
urine glasses followed by sedimentation of arnfieldi .
Larval rich fractions were then combined, fresh tap water added 
and several washing and sedimentation cycles carried out, to 
obtain a clean concentrated suspension of D_j_ arnf ieldi larvae. 
Once clean samples of D_j_ arnf ieldi larvae were obtained, they 
were incubated in shallow water in flat bottomed dishes for
several weeks prior to use. This method was a modification of 
that used by Britt and Preston (1985) and although time-consuming 
and requiring a lot of space, the results were acceptable and
relatively consistent.
In the initial experimental infection of mature ponies 
(Experiment 1) one animal showed a marked clinical response, the 
remainder exhibiting only intermittent coughing and slightly 
raised respiratory rates; this was similar to the findings of 
Round (1972) who attributed the lack of response to low
infectivity of larvae. However the results of necropsies in 
Experiment 1 and in a study by Britt and Preston (1985) in 12 
naturally reared Fell ponies which failed to show any significant 
clinical signs after infection, confirmed that IK. arnf ieldi worms 
were present in most of the ponies indicating that the lack of 
clinical signs was not due to failure of the experimental 
infections to establish. This lack of clinical response after
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single or repeated experimental infections of lungworm larvae is 
in contrast to reports of marked coughing in horses and ponies 
which have been exposed to EL_ arnfieldi infection when grazing, 
usually through contact with infected donkeys. Such a situation 
was observed during the course of the West of Scotland survey of 
lungworm infection when two ponies from a group of five showed 
increased respiratory rates, frequent coughing and harsh lung 
sounds four weeks after the introduction of two IK_ arnfieldi 
infected donkeys to share the same grazing. Mackay and Urquhart
(1979) also recorded increased respiratory rates, moist 
productive coughing and wheezes and crackles on auscultation in a 
group of horses which had grazed with lungworm infected donkeys 
for two months while in 1981, Neilson and Anderson reported 
chronic coughing in several horses which commenced three weeks 
after the arrival of an infected donkey: at necropsy of these
animals EK_ arnfieldi were found in the bronchi. A more unusual 
report (Rickard and James, 1976) was the finding of |K_ arnfieldi 
larvae in the faeces of two yearlings which were showing clinical 
signs of pulmonary infection which did not respond to antibiotics 
but resolved following anthelmintic treatment.
The apparent absence of significant clinical signs in 
experimental infections compared with 'naturally acquired' 
infections is difficult to explain. One explanation could be 
that the majority of naturally acquired infections in horses are 
also sub-clinical and only a few clinical outbreaks are reported 
after investigation by a veterinary surgeon. Another factor 
which could influence the occurrence of clinical signs is
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exercise. Ponies kept under experimental conditions are not 
usually exercised and therefore not subjected to the sustained 
respiratory effort required by the average pleasure horse which 
receives regular exercise at slow and fast paces.
Despite the mild clinical response of the ten mature ponies 
in Experiment 1 there were lesions suggestive of lungworm 
infection (Nicholls at al, 1978) in the lungs of all the animals 
at necropsy and the severity of these lesions was more pronounced 
with the increased duration of infection. The lack of a clinical 
response could be related to the level of experimental challenge 
but the pathological changes observed could have been expected to 
produce more obvious clinical signs. One factor mentioned 
previously which could have had an influence on the clinical 
response was the lack of exercise or stress in this group of
ponies. These animals had been housed together and allowed to
settle in their accommodation for several weeks before the start 
of the experiment. As they had access to shelter and hay ad lib
there was no stress due to adverse weather conditions or
competition for food, and as the pecking order had been 
established previously, bullying was not a problem. The concrete 
run out area gave the ponies ample room to walk about but not to 
take fast exercise which could have induced more coughing. The 
effect of exercise on the clinical manifestations of D_;_ arnf ieldi 
infection has not been examined.
The only report of severe clinical signs associated with 
experimental lungworm infections was in ponies which had been
120
reared indoors, worm-free (Round, 1972): it was suggested
however, that other infectious agents might have been involved in 
the observed clinical response. Also this is somewhat at 
variance with the finding that horse foals infected with 
D. arnfieldi during grazing develop patent infections without 
clinical signs (Clayton and Duncan, 1981): in this case the
level of exposure was probably important with establishment 
following repeated daily ingestion of low numbers of larvae in 
young susceptible animals.
In the experimental infection of the pony mares and foals 
(Experiment 2) minimal clinical signs were observed in the foals 
compared with the mares. There is a general belief that 
horse/pony foals behave more like donkeys than their adult 
counterparts and tend not to develop clinical disease with 
D. arnf ieldi infection. Similar findings were reported in a 
field study by Clayton and Duncan (1981) when pony mares coughed 
while their foals remained clinically normal although all animals 
were kept together on infected pasture. This could have been 
related to differences in the level of challenge, however there 
are reports of horse foals developing clinical signs due to 
D. arnfieldi♦ For example in Kentucky, Lyons et al (1982) 
reported the case of an Arab foal which first exhibited 
respiratory disease when only a few months old after being 
pastured, with its dam, in a paddock occupied by a donkey with a 
patent D_j_ anfieldi infection. This foal was clinically ill 
showing an increased respiratory rate, dyspnoea and a raised 
temperature. This was attributed to D_;_ arnf ieldi infection since
D. arnfieldi larvae were repeatedly found in the tracheal 
washings. Following effective anthelmintic treatment
(thiabendazole 440 mg/kg) the foal recovered and became 
clinically normal with no lasting respiratory impairment. Poncet 
(1983) also reported a case of a six month-old foal which 
developed respiratory problems after grazing with donkeys. This 
foal had a spasmodic cough, raised temperature and an increased 
respiratory rate. Unlike the foal in Kentucky this foal was 
found to be passing arnfieldi larvae in its faeces. Again,
following effective anthelmintic treatment, the foal recovered.
The pathological changes in the lungs of the infected foals 
in Experiment 2 were much less severe than those observed in the 
infected mares or in the mature ponies in Experiment 1. This 
could be related simply to the lower dose of larvae used to 
infect the foals but it is also possible that the young animals 
could be showing a diminished immunological response to infection 
and, as much of the pathology associated with infection is 
thought to be related to the immune response to arnf ieldi , 
this resulted in fewer lesions and a minimal clinical reaction.
The latest reported survey of D^ arnf ieldi in the U.K. 
equine population was conducted by Round in 1972. He found an 
overall prevalence of infection in donkeys of 73%. Our survey of 
700 donkeys admitted to the Donkey Sanctuary in Devon showed a 
considerable decline in the prevalence of infection to 34%. In 
recent years the widespread use of new and improved anthelmintics 
has pobably played a key role in the decrease in the numbers of
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infected donkeys in U.K. and in other parts of the world 
(Boersema and Kalis, 1978; Pandey, 1980; Heil, 1983).
Over the course of these studies there was the opportunity 
to examine faecal samples from donkey mares under a variety of 
conditions e.g. while housed, during grazing, during pregnancy 
and lactation and after weaning. None of these factors exerted 
any noticeable influence on the faecal larval output of these 
donkeys. This is in contrast to the seasonal peaks of infection, 
in autumn and winter, recorded in donkeys in Morocco by Pandey
(1980) but similar to the findings of Round (1976) who showed 
that although there were fluctuations in the faecal larval output 
of individual donkeys, these were of minor significance and were 
not apparently influenced by season of the year or any other 
factors. One donkey, which had a patent infection at the start 
of the observations described here subsequently became non-patent 
and never resumed patency despite almost constant contact with 
the other infected donkeys. Although Pandey (1980) thought 
patency was maintained due to reinfection and there was no age 
immunity, the continued lack of patency in adult donkeys exposed 
to reinfection after "self cure" or effective anthelmintic 
treatment. (Round, 1976) suggests that some animals develop an 
effective immunity. It is possible, however, that these donkeys 
could be behaving like some horses and harbouring non-patent 
infections since heavy lungworm burdens have been found in 
donkeys which had no demonstrable larvae in their faeces (Pandey, 
1980). Another possible explanation for discrepancies between 
lungworm burdens and faecal larval recoveries is that the present
parasitological methods of faecal examinations for EL_ arnfieldi 
are fairly crude and that many infections therefore go 
undetected. To resolve the question of the extent of non-patent 
infections in donkeys a large number of lungs from animals with 
known histories would need to be examined at necropsy.
One of the main problems in studies of arnfieldi in 
horses arises from the individual nature of the host. With 
D. viviparus the problem has a herd basis and it is therefore 
possible to study large numbers of animals of a similar age kept 
under identical management conditions. In contrast studies on 
D. arnfieldi tend to involve small groups of animals of widely 
different ages and breeds kept under varied management 
conditions. Again there is little doubt that a great deal of 
information regarding Eh_ arnfieldi infection in the horse could 
be gained by routine examination of lungs at necropsy. This 
would increase our knowledge of various aspects of D_j_ arnf ieldi 
infection and could contribute information which would be useful 
in its control in the equine population.
The experimental and field studies reported in Section 1 
provided some information on the prevalence, pathogenesis and 
clinical response to D_;_ arnf ieldi infection. They were also 
designed to provide material for use in the development of a 
diagnostic test for equine lungworm infection and in Section 2 
the procedures adopted in the establishment of ELISAs to detect 
D. arnfieldi antigens and antibodies are described. Using 
antibodies raised in rabbits to all stages of arnfieldi found
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at necropsy of a naturally infected animal, ELISAs were 
successfully developed which detected both lungworm antigens and 
antibodies. Unfortunately the ELISA for arnfieldi antigen 
gave variable results in animals of known lungworm status
including a large proportion of false positive reactions in 
animals with no known exposure to infection. This indicated that 
further refinements of the test were required to achieve a 
diagnostic test for current infection.
It is possible that a system using excretory/secretory (ES) 
antigens rather than somatic/surface antigens would have been 
more specific as ES antigens form the first host/parasite 
interface. For example in an ELISA for the detection of swine 
trichinosis (Gamble, Anderson, Graham and Murrell, 1983) the 
nature of the antigen used in the test was considered the most 
important determinant in the occurrence of false positive
reactions. The use of ES antigens in this ELISA eliminated all 
positive reactivity in the sera of farm-raised pigs. This 
increase in specificity was due to the lack, in the ES fraction, 
of a number of high molecular weight proteins present in the 
crude extract which gave rise to non-specific reactions. An 
ELISA using Toxocara ES antigens (de Savigny, Voller and 
Woodruff, 1979) was highly sensitive in the detection of 
toxocaral antibodies and it was predicted that any antibody 
responses to parasite ES antigens would be better indicators of 
active or recent Toxocara infection than responses to somatic 
antigens. If an animal has specific antibodies to ES antigens,
the parasite must have been present recently in a viable form
within the animal as only live parasites produce ES antigens. 
Excretory/secretory antigens were not used in the ELISA for 
D. arnfieldi as it was found impossible to maintain arnf ieldi 
parasites for any length of time in culture. No such culture 
problems are presently encountered with Toxocara and Ascaris and 
ES antigens of the stage as well as the lung stages (L^/L^) 
have been compared with the body fluid of adult Ascaris for 
antigenicity. Antibody responses to body fluid were inferior to 
those against ES antigens which were found to be both stage 
specific and targets of considerable host antibody response 
(Kennedy and Qureshi, 1986). As there is systemic distribution 
of the ES components in the host this makes them ideal candidates 
for the detection of antigen in sites distant from the infection 
site. The origin of these ES antigens is unclear but they are 
likely to be a composite of surface secretions and excretions of 
the parasite as well as fluids released by the parasite during 
moulting.
In this study antiserum was raised in rabbits by injecting 
D. arnfieldi homogenate in Freund's complete adjuvant, 
subcutaneously at multiple sites. Due to the limited 
availability of worm antigen, the rabbits only received a second 
dose of homogenate also in Freund's complete adjuvant which had 
been premixed and stored at -20°C for four weeks. A more usual 
immunisation schedule would have been to give the second dose of 
D. arnfieldi homogenate in Freund's incomplete adjuvant followed 
at a later date with a boost of arnfieldi antigen only. After
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this final boost the rabbits would then have been 'test bled', to 
determine from a rise in titre, the best time to bleed out to 
obtain the maximum yield of high affinity and avidity antibodies. 
Due to the scarcity of antigen together with the fact that a 
suitable test for D_^  arnf ieldi antibody was not available at that 
time, it was not possible to test bleed the immunised rabbits to
determine their optimal response in terms of high avidity
antibody. With the antibody test developed during the course of 
these studies and assuming a continued availability of 
D. arnfieldi antigen, it would now be possible to test bleed the 
rabbits to determine the peak response.
It is also the case that had more refined D^ arnf ieldi 
antigens been used to immunise the rabbits, the antibody 
responses might have been more specific as they would have been
directed against fewer and more defined epitopes.
Antibody responses are usually directed against the most 
immunogenic worm components and, as mentioned previously, it is 
most likely that maximum antibody responses are directed against 
worm excretions and secretions rather than somatic components. 
If these 'target' antigens could be isolated and used, a more 
avid antibody with a higher affinity could be raised which would 
enhance the sensitivity and specificity of the assay. Part of 
the importance of ES antigens is that they are continually 
produced/renewed by the living worm hence giving a greater 
biomass. As D_j_ arnf ieldi migrate from the intestine to the 
lungs, they are likely to continually shed ES antigens and each 
'depot' of ES antigen is equivalent to a microimmunisation of the
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host. Only after the death of the parasite are the somatic 
antigens exposed to form the second host parasite interface. 
Obviously, the quantities of somatic antigen are finite and 
cannot be renewed.
While the assay for D_;_ arnf ieldi did not always correlate 
with the detection of ]X_ arnf ieldi larvae in faeces, the ELISA 
which was developed was robust and the results, with samples of 
known antigen content were reproducible. It is vital in any 
ELISA that the binding involved is irreversible or that there is 
minimal leeching and desorption of antigen/antibody from the 
plate or antigen from antibody especially in the presence of 
detergents. This was achieved in the arnfieldi ELISAs
described in this thesis.
ELISAs with greater affinities are produced utilising the 
blocking properties of detergents. By incorporating detergents 
in the buffers, antibodies with low affinities are prevented from 
binding in the assay, hence only those antibodies with the 
greatest affinity bind which increases the specificity of an 
assay. With further refinements, a reduction of the optical 
densities of negative samples could be achieved and thus any 
overlap between positive and negative samples is reduced if not 
eliminated. Other favourable aspects of ELISAs are their 
simplicity and the rapidity with which results can be obtained. 
For example the ELISA for Trichinella spiralis in pigs 
(Ruitenberg, Steerenberg, Brosi and Buys, 1976) enables a spot 
diagnosis to be carried out at the slaughterhouse. Also large
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numbers of samples can be tested in one day. This has been 
demonstrated using a semiautomated ELISA for Toxoplasma gondii 
when 4,000 samples were tested daily (Walls, Bullock and English, 
1977). Other advantages are the small quantities of sera 
required which are relatively cheap and the fact that expensive 
equipment is not required for.the test.
Although most ELISAs used in human and veterinary medicine 
are for antibody detection e.g. Malaria, African Trypanosomiasis, 
Chagas disease, Amoebiasis, Toxoplasmosis, Babesiosis, 
Leishmaniasis, Schistosomiasis, Hydatid disease, Trichinosis and 
Onchocerciasis (Voller, Bartlett and Bidwell, 1976; 1978), in
view of the nature of D_^  arnf ieldi infection in grazing horses
and donkeys, an antibody detection test would only indicate 
exposure, either previous or current, to arnfieldi. To be of 
use diagnostically, a quantitative antibody test using a minimum 
of two successive samples would be required to determine whether 
there was a rising titre indicating current infection. Such a 
quantitative test would obviously be more complicated than a 
simple positive/negative test for antigen. Unlike the situation 
with viviparus. infections with D_;_ arnfieldi may be
longstanding before investigations are initiated. It is unlikely 
therefore that antibody profiles would show the classic rising 
titre associated with the acute stage of infection. Another 
factor complicating the diagnosis of D_j_ arnfieldi infection is
that it is usually an individual rather than a herd problem so
ELISAs which are adequate for herd or population diagnosis e.g. 
in bovine dictyocauliasis (Boon et a_l, 1982) or trypanosomiasis
(Ruitenberg and Buys, 1977; Luckins, 1977), are inadequate in the 
case of Ih_ arnfieldi. The lack of a rising titre is further 
compounded by the lack of multiplication of lungworms within the 
host which in turns affects the host's immune response. Also in 
the case of Ih_ arnfieldi it is likely that antibody production 
will have reached a plateau by the time of testing which makes 
interpretation of results difficult.
While the detection of antigen would be confirmation of a 
current, active infection, there are problems concerning antigen 
detection. It would be expected that free antigen would be most 
abundant during the acute phase of infection or reinfection and, 
in the ELISA for the detection of toxoplasmosis (van Knapen and 
Panggabenn, 1977), it was only possible to detect, circulating 
antigen during the short period of the active phase of infection. 
In animals chronically infected with arnfieldi the amount of 
free circulating antigen is likely to be very small and present 
as immune complexes which, in this case would hinder antigen 
detection. However in an ELISA for Toxoplasma antigen (van 
Knapen, Panggabean and van Leusden, 1985), circulating immune 
complexes could be detected coincidently with antibodies and 
remained detectable for several weeks. In this case the 
detection of immune complexes represented an amplification of the 
detection of free circulating antigen as both followed the same 
pattern although the levels of free Toxoplasma antigen were too 
low to be detectable by the ELISA.
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Apart from any technical limitations of the test, the 
discrepancies between the arnfieldi serological and
parasitological results could be due to a number of factors. It 
is possible that, especially with the samples sent by post, 
freezing and thawing had an adverse effect on the D_;_ arnfieldi 
antigen. In an ELISA for detection of Entamoeba histolytica in 
faecal specimens (Ungar, Yolken and Quinn, 1985), it was found 
that the antigenicity of the specimens varied with repeated 
freezing and thawing. Freezing and thawing can disrupt the 
bonding of antigens which are either polypeptide or carbohydrate 
in nature. Also if samples are transported in plastic tubes some 
antigen may bind to the tubes thus reducing the total amount of
antigen available to react in the ELISA.
In the animals where no necropsies were performed and the
only data available were the faecal larval counts, the possible
existence of non-patent D_^  arnfieldi infections could account for 
the varied positive optical densities associated with negative 
faecal larval counts. Positive serological results linked with 
negative parasitological results could also be due to the 
detection of blood borne immune components shortly after initial 
infection and before the detection of larvae in faeces which are 
produced by sexually mature adult arnfieldi in the lungs. 
This development from infective larva to adult parasite takes a 
minimum of 12 weeks, hence the ELISA could be detecting prepatent 
D. arnfieldi infection. In the case for the ELISA test for 
Trichinella spiralis in pigs (Ruitenberg, Steerenberg, Brosi and 
Buys, 1974) positive results are obtained prior to the
demonstration of larvae in the muscles.
A more specific test for D_;_ arnfieldi infection in horses 
might be developed using monoclonal antibodies (Mabs). By their 
nature, Mabs have a precise and predefined paratope which ideally 
reacts with an individual epitope. At the present time it is not 
known which of the epitopes involved in the immunogenic response 
to arnfieldi would be the most potent and specific to choose
for use in a detection test utilising Mabs. A more novel
technique, which may be feasible to develop as a detection assay 
for Ih_ arnfieldi is the use of single domain antibodies (Dabs). 
These are very small regions of the heavy chain of the IgG 
molecule which contain the configurations necessary for binding
antigens of high affinity with only a 10% reduction in binding
compared with that obtained using the whole molecule (Austin, 
1989; Anon, 1989). Dabs possess the same ability as Mabs to 
recognise specific epitopes of antigens in a mixture but they
have the advantage in that they can be produced in bulk from
bacteria within a few days while large quantities of Mabs require
extensive tissue culture which is slow and expensive (Ward, 1989;
Wilkes, 1989).
Finally variations in the degree of antigenicity of 
different antigens may have an indirect effect on the success of 
an ELISA. In the case of D_^  arnfieldi. if the antigens are 
highly immunogenic, a strong host antibody response might be 
initiated which would remove worm antigens from the circulation 
very rapidly thus interfering with their detection. On the other
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hand, if D^ _ arnfieldi antigens are only weakly immunogenic, a 
lesser response might be mounted by the host leaving antigens in 
the circulation for a longer period which would facilitate their 
detection by both Mabs or Dabs. In practice however, various 
stages of D^ _ arnfieldi and their secretions are likely to be 
composed of a range of antigens with differing antigenicities. 
Characterisation of these antigens together with refinement and 
development of the basic arnfieldi ELISA described here should 
make it possible to produce an accurate, reliable and specific 
diagnostic test for equine lungworm infection.
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APPENDICES
Appendix 1.1
Individual Body Weights in Kilogrammes of Mature Ponies Experimentally
Infected with D. arnfieldi
Day
Post
Infection
1 2 3
]
4
Pony number 
5 6 7 8 9 10
0 158 188 150 158 168 123 117 115 157 180
7 166 189 157 163 167 121 119 114 160 188
14 165 190 154 162 165 125 121 111 149 181
21 156 161 169 126 116 110 146 174
28 153 164 170 129 117 115 152 163
35 170 126 114 113 149 159
42 148 125 109 114 149 161
49 110 95 151 160
56 107 94 149 158
63 150 160
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Appendix 1.2
Packed Cell Volumes of Mature Ponies Experimentally Infected with D.arnfieldi
Day
Post
Infection
1 2 3 4
Pony numbe 
5
r
6 7 8 9 10
0 26 29 28 32 25 31 28 26 27 26
7 28 28 28 30 30 28 27 26 27 26
14 28 29 29 30 26 27 26 24 24 27
21 33 28 27 27 38 26 28 33
28 35 31 28 28 29 27 27 30
35 25 26 24 29 28 28
42 23 27 27 31 28 32
49 27 30 29 29
56 31 27 29 26
63 33 29
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Appendix 1.3
Respiratory Rates of Mature Ponies Experimentally Infected with arnfieldi
Day
Post
Infection
1 2 3
Pony number 
4 5 6 7 8 9
0 20 18 15 18 12 15 12 12 15
1 24 15 15 18 9 12 12 12 12
2 18 18 15 21 9 15 12 12 15
3 21 15 18 18 15 15 12 12 12
4 18 15 15 21 9 12 12 12 15
5 15 12 18 18 12 15 15 18 15
6 18 21 15 18 9 9 18 12 12
7 18 18 18 15 12 c 15 12 9 15
8 15 21 15 18 15 15 12 12 12
9 18 18 15 21 12 15 15 18 18
10 15 21 18 18 12 c 12 15 19 15
11 18 21 18 18 15 12 12 15 18
12 15 15 18 18 15 15 12 18 15
13 18 15 15 15 15 15 12 18 15
14 15 18 18 15 12 12 15 9 15
15 15 15 18 18 15 12 15 12 12
16 21 15 18 18 15 c 15 18 15 12
17 15 18 18 15 15 c 15 18 c 12 15
18 18 15 21 18 12 15 24 9 12
19 24 12 18 21 12 c 18 15 c 18 15
20 24 12 21 24 15 18 15 c 18 21
21 18 18 12 12 15 15 12
22 12 12 15 15 15 c 18 12
23 12 12 12 12 18 c 15 15
24 12 12 12 12 18 c 15 c 12
25 9 12 12 15 21 c 15 9
26 20 12 c 15 18 21 c 18 c 15
27 12 15 15 15 18 18 18
28 12 c 12 15 15 27 c 15 15
29 15 18 15 c 18 27 c 15 18
30 12 18 15 15 24 c 18 18
31 15 18 15 15 24 c 15 18
32 12 c 12 hr 18 c 18 21 c 21 21
33 12 15 15 18 24 c 18 21 c
34 15 c 15 18 15 15 c 21 30
35 12 18 c 18 18 18
36 15 18 c 15 18 15
37 15 18 18 c 21 15
38 12 15 15 18 18
10
15
15
18
15
15
15
15
15
15
15
18
18
18
18
18
15
18
21
36
39
42
33
33
33
30
21
24
27
30
27
30
27
24
21
26
21
12
18
27
c - cough
hr - harsh respirations
Appendix 1.3 (Cont'd)
Day Pony number
Post 1 2  3 4 5 6 7 8 9 1 0
Infection
39 18 18 18 c 21 15 33 c
40 21 21 18 18 c 30 24
41 15 18 15 18 24 c 21
42 15 21 15 c 18 c 24 30
43 12 18 18 18 c 27 24 c
44 15 15 15 15 27 c 24 c
45 12 12 18 c 12 24 21 c
46 15 15 12 18 21 21
47 18 21 24 30
48 15 c 15 24 c 30
49 12 18 27 c 27 c
50 12 c 15 27 24
51 15 18 24 24 c
52 18 15 24 c 27
53 18 18 21 c 24
54 15 15 27 27 c
55 18 18 21 27
56' 15 12 2? 33
57 15 15 21 c 33 c
58 18 12 /24 c 30 c
59 15 12 27 30
60 21 15 21 c 27
61 27 27 c
62 24 c 27 c
63 24 c 27
64 27 c 30
65 21 30 c
66 24 27
67 24 30
68 21 27
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Appendix 1.4
Respiratory Rates of Mares and Foals Experimentally 
Infected with D. arnfieldi
Day Post 
Infection
Mare
13
Foal
14
Mare
11
Foal
16
Mare
12
Foal
15
0 12 12 12 12 12 12
1 12 12 12 12 12 12
2 12 12 12 12 15 12
3 12 12 12 12 12 12
4 12 12 12 12 12 12
5 12 12 12 15 12 12
6 12 12 15 12 12 15
7 12 12 12 12 12 12
8 15 12 12 15 12 12
9 12 15 12 12 15 12
10 15 15 12 12 12 12
11 15 15 12 15 12 15
12 18 12 12 15 12 15
13 15 15 12 12 15 15
14 21 15 15 15 15 18
15 15 12 12 12 12 18
16 15 15 12 15 13 15
17 18 15 12 12 12 18
18 18 15 12 15 15 18
19 18 15 12 15 15 18
20 21 15 12 15 15 18
21 21 15 12 15 15 15
22 18 15 15 12 15 18
23 18 15 12 12 12 15
24 18 12 12 12 15 15
25 18 15 15 12 15 18
26 21 15 12 15 15 18
27 21 12 12 12 12 15
28 18 15 15 15 12 15
29 18 12 12 12 15 12
30 18 12 15 12 15 15
31 18 15 12 12 15 12
32 18 15 12 12 15 15
33 21 12 12 12 12 15
34 18 15 15C 15 18C 15
35 15 12 15 12 21 15C
36 18 15 18C 15 18 15
37 18 12 18C 12 15 15
38 15 15 18 12 15 12
39 18 12 18C 12 18C 12
40 21 15 18 15 18C 12
41 18 12 18C 12 15C 12
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Appendix 1.4 (Cont'd)
Day Post 
Infection
Hare
13
Foal
14
Mare
11
Foal
16
Mare
12
Foal
15
42 15 12 18 12 18C 15
43 15 12 18 12
44 18C 12 15C 15
45 18C 12 15C 12
46 15 12 18 12
47 18 12 15 15
48 15 15 18C 12
49 15 12 15C 12
50 15C 12 18C 12
51 15C 15 18C 12
52 18 12 18C 12
53 18 12 18C 12
54 15 15 15 15
55 18 12 15C 12
56 15 12 15 12
57 18C 15
58 15 12
59 15C • 12
60 18C 15
61 15 12
62 18 12
63 18C 12
64 18 12
65 18C 12
66 18C 15
67 15C 15
68 15C 12
69 15C 12
70 15C 12
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Appendix 1.5
Parasitological Data of Donkey Sanctuary Donkeys 86 - 88 
Donkeys Aged 0 - 2  Years
Donkey
Number
Lungworm/50g Strongyles e.p.g.
2609 -ve -ve
2610 42 408
2647 -ve 596
2679 -ve -ve
2683 -ve 1
2707 5 160
2713 -ve -ve
2735 131 151
2736 12 1620
2737 -ve 8
2748 -ve 98
2762 -ve 38
2764 332 252
2859 -ve -ve
• 2864 -ve -ve
2887 -ve 45
2933 12 10
2954 -ve -ve
2967 -ve -ve
2989 5 62
3012 56 252
3015 -ve 509
3028 52 357
3066 -ve -ve
3075 -ve 236
3090 -ve 123
3109 1484 321
3118 -ve 158
3119 -ve 440
3123 74 60
3165 -ve 1
3190 . -ve -ve
3201 -ve 1
3295 -ve 25
3354 5 47
3364 385 210
3420 -ve 8
3470 -ve 17
3533 -ve -ve
3545 1230 2
3547 10146 23
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Appendix 1.5 (Cont'd)
Donkeys Aged 3 - 5  Years
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
2578 -ve -ve
2603 23 550
2620 342 467
2645 -ve 434
2663 -ve -ve
2668 -ve 10
2680 -ve 69
2681 219 419
2687 43 274
2689 81 61
2696 153 501
2703 -ve -ve
2712 128 16
2725 -ve 260
2727 -ve 316
2732 -ve 35
2733 -ve -ve
2765 131 202
2771 -ve 42
2790 66 14
2810 -ve 112
2822 -ve -ve
2831 16 20
2832 -ve 356
2865 -ve 91
2883 44 1
2910 -ve 1
2918 6 69
2919 -ve 64
2920 52 195
2934 -ve 66
2935 -ve 236
2936 -ve 320
2947 94 61
2950 -ve 88
2959 67 65
3004 55 102
3006 -ve 7
3011 3642 76
3034 -ve 53
3051 -ve 105
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Appendix 1.5 (Cont'd)
Donkeys Aged 3 - 5  Years
Donkey
3 - 5  yrs 
Limgworm (50g) Stronglyes e.p.g.
3060 -ve 1
3110 3067 512
3114 4158 371
3122 390 106
3124 -ve 574
3131 -ve 137
3135 -ve 5
3138 -ve -ve
3149 -ve 385
3151 883 1935
3152 6 192
3156 -ve 122
3170 36 61
3180 -ve 6
3181 -ve 2
3189 -ve -ve
3194 -ve 1
3209 -ve 1
3232 118 307
3242 -ve -ve
3280 -ve 2
3281 -ve 604
3282 -ve 267
3294 -ve 40
3296 3 11
3337 -ve -ve
3350 -ve 34
3353 -ve 79
3384 -ve 1
3426 -ve 391
3435 -ve 109
3456 -ve -ve
3255 -ve 36
3548 -ve 140
3560 -ve 3
3590 297 30
3598 -ve -ve
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Appendix 1.5 (Cont'd)
Donkeys Aged 6 - 1 0  Years
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
2577 -ve 35
2579 -ve -ve
2581 1 232
2584 25 131
2591 -ve 6
2594 136 242
2598 -ve 240
2600 36 470
2607 152 115
2608 1 -ve
2615 56 381
2617 -ve 596
2622 -ve -ve
2623 -ve -ve
2625 532 139
2627 139 208
2646 182 142
2653 -ve 194
2664 -ve -ve
2676 -ve 758
2690 26 149
2693 4 216
2702 -ve 27
2714 -ve 15
2716 215 27
2720 9 502
2728 93 501
2730 -ve 2496
2740 3 181
2742 100 130
2749 -ve 58
2750 -ve -ve
2751 -ve 1394
2775 -ve 1
2788 -ve -ve
2798 -ve -ve
2799 -ve 106
2800 -ve 95
2807 134 176
2808 19 112
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Appendix 1.5 (Cont’d)
Donkeys Aged 6 - 1 0  Years
Donkey Lungworm (50g) Stronglyes e.p.g.
Number
2809 -ve 109
2812 -ve 104
2817 44 37
2818 79 142
2821 -ve -ve
2827 -ve -ve
2830 -ve 22
2837 -ve 224
2843 2 28
2848 -ve 56
2856 -ve 11
2860 11 25
2861 13 121
2866 -ve -ve
2874 91 25
2877 -ve 226
2889 -ve 572
2905 -ve 76
2932 9 28
2949 15 97
2956 138 99
2961 1 95
2966 -ve -ve
2998 22 27
2999 434 23
3003 -ve 167
3008 42 556
3013 62 132
3014 -ve 502
3027 16 135
3031 330 167
3035 -ve 11
3050 -ve 109
3054 97 323
3081 -ve 178
3107 317 248
3134 494 260
3136 -ve 107
3142 -ve -ve
3154 496 86
3173 1099 49
3182 -ve -ve
3184 -ve 21
3188 -ve -ve
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Appendix 1.5 (Cont'd)
Donkeys Aged 6 - 1 0  Years
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
3200 24 20
3202 474 321
3207 -ve 600
3210 -ve 1
3220 -ve 6
3230 -ve 339
3243 2401 126
3269 1484 69
3273 -ve -ve
3290 -ve 75
3292 -ve 105
3293 -ve 5
3297 7 214
3336 5 113
3358 10 12
3376 283 313
3377 -ve 5
3382 -ve -ve
3430 -ve 239
3434 -ve 97
3478 -ve 18
3167 -ve 310
3291 -ve 3
3360 -ve 2
3588 -ve 151
3592 -ve -ve
3605 -ve 4
3608 -ve -ve
3610 -ve -ve
3611 -ve -ve
3621 -ve 126
3629 74 100
3630 -ve 2520
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Appendix 1.5 (Cont'd)
Donkeys Aged 11 - 15 Years
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
2574 -ve -ve
2580 -ve -ve
2583 -ve 168
2585 -ve 43
2586 -ve 363
2587 -ve 355
2595 1 224
2597 128 2125
2605 58 365
2613 26 252
2639 3 14
2643 78 308
2648 -ve 45
2651 490 120
2665 113 219
2669 -ve -ve
2695 -ve 37
2697 17 4
2698 -ve 47
2706 50 176
2726 -ve 701
2747 40 1580
2757 -ve 565
2758 -ve 803
2763 819 283
2766 -ve -ve
2767 -ve 283
2782 33 1480
2784 14 8
2785 -ve 222
2789 -ve 325
2826 2 52
2828 34 35
2829 169 50
2833 -ve 200
2834 -ve 80
2835 376 5
2851 -ve 5
2852 62 727
2857 -ve 192
2858 -ve -ve
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Appendix 1.5 (Cont'd)
Donkeys Aged 11 - 15 Years
Donkey
Number
Lungworm (5Og) Stronglyes e.p.g.
2862 29 10
2863 -ve 361
2875 -ve -ve
2876 -ve 152
2878 -ve 41
2881 32 129
2886 54 76
2891 -ve 515
2897 1 259
2911 -ve -ve
2939 217 365
2940 134 73
2952 -ve 265
2953 52 212
2968 -ve -ve
2975 -ve 90
2983 4 359
2986 -ve -ve
2987 -ve 96
2988 -ve 133
3005 927 347
3010 -ve 25
3024 -ve 78
3029 1 7
3039 352 17
3061 -ve -ve
3071 -ve 17
3074 1 7
3078 -ve 33
3079 -ve 63
3092 358 454
3139 -ve -ve
3147 2 135
3155 -ve 100
3159 140 285
3163 -ve 1
3169 16 34
3185 -ve 71
3191 -ve -ve
3192 -ve 19
3193 -ve -ve
3195 -ve 2
3196 158 2
3198 -ve 131
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Appendix 1.5 (Cont'd)
Donkeys Aged 11 - 15 Years
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
3217 -ve 131
3218 688 252
3229 453 277
3237 -ve -ve
3240 -ve -ve
3245 25 161
3246 -ve 3
3284 -ve -ve
3289 -ve -ve
3323 2 49
3330 -ve -ve
3342 -ve 29
3370 -ve 387
3379 -ve 45
3477 3 57
3494 -ve -ve
3505 -ve 2
3525 -ve 169
3530 -ve 8
3535 -ve 12
3536 -ve -ve
3546 300 69
3554 52 62
3556 -ve 55
3569 -ve -ve
3572 -ve 23
3575 -ve 1
3579 66 62
3582 -ve 254
3591 -ve -ve
3596 7 117
3597 -ve 1
3599 145 163
3600 145 163
3613 -ve 123
3614 186 230
3616 5 232
3617 -ve 60
3641 -ve 141
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Appendix 1.5 (Cont'd) 
Donkeys Aged 16 - 20 Years
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
2571 -ve 21
2596 -ve 128
2599 16 547
2601 1 349
2604 -ve 556
2611 -ve 211
2626 42 10
2628 -ve 143
2629 -ve 31
2630 -ve 16
2631 -ve 12
2644 -ve 238
2649 -ve 11
2650 408 30
2652 -ve -ve
2656 -ve 72
2667 2 277
2672 -ve -ve
2677 8 12
2678 104 -ve
2692 3 540
2708 -ve 10
2710 -ve 37
2724 -ve 120
2729 -ve 654
2752 -ve 195
2753 54 196
2755 -ve 746
2756 -ve 600
2774 -ve 5
2776 -ve 1
2783 -ve 242
2787 -ve 5
2791 -ve 452
2794 6 686
2806 2 -ve
2816 -ve 50
2824 4 81
2836 -ve 15
2838 414 896
2844 5 598
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Appendix 1.5 (Cont'd)
Donkeys Aged 16 - 20 Years
Donkey Lungworm (50g) Stronglyes e.p.g.
Number
2885 20 136
2888 5 122
2902 -ve 1
2904 -ve 24
2907 -ve 173
2909 -ve -ve
2913 -ve 21
2917 7 53
2941 -ve 27
2943 -ve 140
2951 -ve 204
2964 39 135
2972 257 60
2974 -ve 89
3007 104 42
3030 49 80
3037 -ve 367
3040 847 127
3043 -ve 317
3058 -ve 17
3059 -ve 53
3072 -ve 46
3080 -ve 80
3085 -ve 18
3088 -ve 42
3091 6 345
3096 -ve 134
3098 -ve 2
3099 -ve 36
3111 1238 231
3125 23 150
3127 296 351
3158 15 186
3162 -ve 3
3168 1 88
3183 -ve 1
3205 41 204
3233 -ve 13
3238 1 210
3239 107 34
3247 -ve 136
3271 -ve 138
3287 -ve 4
3310 -ve -ve
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Appendix 1.5 (Cont’d)
Donkeys Aged 16 - 20 Years
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
3319 -ve 137
3326 -ve 31
3328 147 115
3333 -ve 135
3338 6 91
3339 -ve 145
3348 -ve -ve
3359 4 6
3367 -ve -ve
3380 184 10
3386 -ve 24
3421 -ve 49
3448 -ve 122
3449 -ve 3
3514 -ve 24
3521 -ve 95
3527 -ve -ve
3528 -ve -ve
3532 -ve -ve
3537 -ve 890
3543 5785 87
3549 -ve 76
3561 -ve 3
3578 -ve -ve
3584 -ve 52
3585 -ve 2
3594 -ve -ve
3602 , -ve 192
3609 -ve -ve
3612 -ve 191
3635 -ve 6
3498 -ve 1
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Appendix 1.5 (Cont'd)
Donkeys Aged 21 - 25 Years
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
2585 -ve 82
2662 130 25
2670 -ve -ve
2675 -ve 696
2682 -ve 374
2704 -ve -ve
2705 40 320
2773 14 120
2779 -ve 1
2780 -ve 3
2786 -ve -ve
2792 -ve 231
2805 -ve 18
2825 -ve 238
2850 44 65
2871 -ve 1
2882 163 140
2900 5 216
2908 25 40
2916 -ve 0
2921 -ve -ve
2922 -ve 22
2937 -ve 23
2955 -ve -ve
2965 -ve -ve
2976 288 26
2992 3 415
3026 70 124
3055 14 20
3065 26460 245
3076 -ve -ve
3087 61 528
3089 -ve 223
3097 -ve 118
3116 -ve 422
3141 63 545
3144 -ve 105
3197 6 26
3203 -ve 56
3221 -ve 151
3244 110 116
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Appendix 1.5 (Cont'd)
Donkeys Aged 21 - 25 Years
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
3248 -ve -ve
3252 -ve 46
3257 -ve 90
3258 347 -ve
3265 -ve 31
3270 -ve 548
3279 -ve -ve
3286 -ve 175
3331 -ve -ve
3355 -ve 51
3371 -ve 237
3372 -ve 161
3422 26 108
3452 -ve 72
3467 -ve 2
3473 -ve 198
3506 -ve 448
3516 -ve -ve
3526 34 182
3529 -ve 3
3534 221 557
3541 254 321
3553 -ve 454
3555 -ve 65
3558 -ve 1
3573 584 53
3577 -ve 15
3583 -ve 10
3606 118 62
3622 -ve 82
3623 -ve 31
3625 -ve 125
3633 -ve 281
3634 239 52
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Appendix 1.5 (Cont'd)
Donkeys Aged 26 Years or More
/
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
2575 -ve -ve
2576 1 317
2593 -ve -ve
2602 12 195
2606 -ve 198
2612 2 216
2616 7 93
2618 36 89
2619 101 385
2621 3 679
2624 27 198
2640 -ve 54
2661 136 79
2666 7 602
2691 -ve 82
2699 -ve 78
2721 27 263
2722 -ve 251
2731 -ve 1506
2745 -ve 10
2746 -ve 12
2761 1 15
2772 8 190
2815 -ve 12
2849 44 1212
2867 -ve 315
2868 1 398
3869 13 125
2893 -ve 5
2914 -ve -ve
2915 -ve 24
2924 -ve 12
2925 -ve 16
2927 -ve 270
2938 -ve 186
2942 2 73
2944 -ve 2
2946 46 678
2963 6000+ 236
2970 -ve 49
2971 -ve 3
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Appendix 1.5 (Cont'd)
Donkeys Aged 26 Years of More
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
2984 -ve 109
2991 7 237
3001 -ve -ve
3006 -ve 16
3038 -ve 196
3042 -ve 1
3052 -ve 72
3053 -ve 265
3063 -ve 338
3064 -ve 991
3077 -ve 3
3093 -ve 26
3100 -ve 149
3102 -ve 51
3115 -ve 30
3120 58 1053
3121 2 981
3132 -ve 1
3137 -ve 101
3143 -ve 15
3166 2 318
3199 -ve 49
3204 51 26
3211 -ve 109
3223 -ve 5
3228 -ve 6
3241 -ve 24
3253 -ve -ve
3272 6 75
3278 -ve -ve
3283 44 165
3285 -ve 1
3288 -ve 5
3298 -ve 250
3299 -ve 413
3300 -ve 48
3301 -ve 47
3322 161 181
3325 -ve 30
3335 3 377
3340 -ve 65
3341 1271 158
3343 10 107
3347 -ve —ve
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Appendix 1.5 (Cont'd)
Donkeys Aged 26 Years or More
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
3357 -ve 73
3362 -ve 380
3363 65 114
3366 -ve -ve
3369 -ve 1
3373 -ve 17
3375 -ve 23
3385 -ve 191
3418 -ve 28
3431 -ve 328
3446 -ve 101
3447 766 -ve
3453 -ve 126
3455 -ve -ve
3466 -ve 533
3469 -ve -ve
3492 -ve -ve
3493 -ve -ve
3495 -ve -ve
3515 -ve 164
3517 929 107
3518 -ve 583
3540 -ve 353
3568 -ve 116
3576 -ve -ve
3581 450 11
3593 -ve -ve
3601 5000 455
3603 -ve 423
3604 -ve 513
3607 -ve 79
3618 -ve 60
3631 -ve 373
3636 2040 57
3637 -ve 183
3639 -ve 132
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Appendix 1.5 (Cont'd)
Donkeys of Unknown Age
Donkey
Number
Lungworm (50g) Stronglyes e.p.g.
2637 -ve 171
2671 -ve 121
2711 -ve 15
2811 -ve 82
2993 -ve -ve
3009 -ve 85
3082 -ve 3
3083 -ve 245
3164 -ve 1
3175 -ve -ve
3176 -ve -ve
3179 -ve 26
3471 -ve 98
3472 -ve 143
3483 -ve -ve
3484 -ve -ve
3489 2 81
3497 -ve -ve
3465 -ve 203
3538 -ve 112
3539 -ve 313
3574 -ve 2
3619 -ve 8
3628 -ve 590
3632 627 181
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Appendix 2.1
ELISA - Titration of IK arnfieldi Antibody and also IK arnfieldi
with R^B and R 2 B Using Streptavadin Peroxidase at 1:5000
All volumes 50 jil/well.
1. Coat plate antibody.
Initial dilution 1:50 column 2. Doubling dilutions — -^
Incubate 37°C 2 hr.
Wash
2. Add IK_ arnfieldi antigen 1:1000. Columns 4-11. Doubling dilutions 
Incubate 37°C< 30 min.
Wash.
3. Add biotinylated antibody - plate 1 R,B)
) 1:100. Columns 3-10.
plate 2 R2B)
Incubate 37°C 30 min.
Wash.
4. Add streptavadin peroxidase 1:5000. Columns 2-9.
Incubate 37°C 30 min.
Wash.
5. Add substrate. O.P.D. all wells.
Incubate in dark 37°C 40 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.2
ELISA - Titration of arnfieldi Antigen with R^B Using
Streptavadin Peroxidase of 1:1000
All volumes 50 jil/well.
1. Coat plate arnfieldi antigen.
Initial dilution 1:100 Column 2. Doubling dilutions 
Incubate 37°C 2 hr.
Wash.
2. Add biotinylated antibody (R^B). Columns 4-11. Doubling dilutions 
Incubate 37°C 30 min.
Wash.
3. Add Streptavadin peroxidase 1:1000 columns 3-10.
Incubate 37°C 30 min.
Wash.
4. Add substrate O.P.D. all wells.
Incubate in dark 37°C. 1 hr 15 min.
5. Stop with acid. Read 492 nm.
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Appendix 2.3 
ELISA - Titration of D;_ arnf ieldi R^B Using 
Streptavadin Peroxidase at 1:500
All volumes 50 jil/well.
1. Coat plate arnfieldi antigen starting column 1.
Initial dilution 1:100 (300 ng/well). Doubling dilutions-— ^  
Incubate 37°C 2 hr.
Wash.
2. Add biotinylated antibody R 0B. Columns 2-9.
2 |
Initial dilution 1:50. Doubling dilutions S'
Incubate 37°C 30 min.
Wash.
3. Add Streptavadin peroxidase. 1:500 all wells.
Incubate 37°C 30 min.
Wash.
4. Add substrate. O.P.D. all wells.
Incubate 37°C in dark 40 min.
5. Stop with acid. Read 492 nm.
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Appendix 2.4
ELISA - Titration of D^ _ arnfieldi Antigen both Rotated and Non-Rotated
R 2 B Using Streptavadin Peroxidase at 1:500
All volumes 50 jil/well.
1. Coat plates arnfieldi antigen excluding column 12.
Initial dilution 1:50. Doubling dilutions 
Incubate 37°C 2hr.
Wash.
2. Add biotinylated antibody R2B. Plate 1 - rotated. R2B.
Plate 2 - non-rotated. R2B.
Initial dilution 1:50. Doubling dilutions 4" Columns 2-11. 
Incubate 37°C 30 min.
Wash.
3. Add Streptavadin peroxidase 1:500 columns 1-10.
Incubate 30 min.
Wash.
4. Add substrate O.P.D. all wells.
Incubate 37°C in dark 1 hr.
5. Stop with acid. Read 492 nm.
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Appendix 2.5
ELISA - Titration of D^ _ arnfieldi Antigen with Rotated R^B Using
Streptavadin Peroxidase at 1:500
All volumes 50 jil/well.
1. Coat plate arnfieldi antigen columns 3-12.
Initial dilution 1:50. Doubling dilutions.— >
Incubate 37°C 2 hr.
Wash.
2. Add biotinylated (rotated) antibody R^B columns 3-10.
Initial dilution 1:50. Doubling dilutions. >1'
Incubate 37°C 30 min.
Wash.
3. Add Streptavadin peroxidase 1:500 all wells.
Incubate 37°C 30 min.
Wash.
4. Add substrate. O.P.D. all wells.
Incubate 37°C in dark 1 hr 10 min.
5. Stop with acid. Read 492 nm.
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Appendix 2.6
ELISA - Titration of IK arnfieldi Antigen with Both R^B and R 2 B Using
Streptavidin Peroxidase at 1:1000
All volumes 50 /ll/well.
1. Coat plate IK_ arnfieldi antigen columns 3-12.
Initial dilution 1:50. Doubling dilutions.— ^
Incubate 37°C 2 hr.
Wash.
2. Add biotinylated antibody, columns 3-10. Plate 1 R^B.
Plate 2 R2B.
Initial dilution 1:50. Doubling dilutions. > 
Incubate 37°C 30 min.
Wash.
3. Add Streptavadin peroxidase 1:1000 all wells. 
Incubate 37°C 30 min.
Wash.
4. Add substrate. O.P.D. all wells.
Incubate 37°C in dark 1 hr.
5. Stop with acid. Read 492 nm.
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Appendix 2.7
ELISA - Titration of D^ _ arnfieldi Antigen with R^B Using
Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plate D^ _ arnfieldi antigen columns 3-12.
Initial dilution 1:50. Doubling dilutions.*-—^
Incubate 37°C 2 hr.
Wash.
2. Add biotinylated antibody (R^B). Columns 3-10 
Initial dilution 1:50. Doubling dilutions. 'I'
Incubate 37°C 30 min.
Wash.
3. Add Streptavadin peroxidase 1:1000 all wells.
Incubate 37°C 30 min.
Wash.
4. Add substrate O.P.D. all wells.
Incubate 37°C in dark 1 hr.
5. Stop with acid. Read 492 nm.
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Appendix 2.8
ELISA - Titration of arnf ieldi Antigen with both R^B and R 2 B Using
Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plate D^ _ arnfieldi antigen columns 3-12.
Initial dilution 1:50. Doubling dilutions.-— ^
Incubate 37°C 2 hr.
Wash.
2. Add biotinylated antibody columns 3-10. Plate 1 R^B.
Plate 2 R2B.
Initial dilution 1:25. Doubling dilutions. 4*
Incubate 37°C 30 min.
Wash.
3. Add Streptavadin peroxidase 1:1000 all wells.
Incubate 37°C 30 min.
Wash.
4. Add substrate. O.P.D. all wells.
Incubate 37°C in dark 1 hr.
5. Stop with acid. Read 492 nm.
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Appendix 2.9
ELISA - Titration of both R^ and R 2  with EL arnfieldi Antigen and both
R^B and R 2 B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plate antibody columns 3-10. Plate 1 R^
Plate 2 R2
Initial dilution 1:25. Doubling dilutions.— ^
Incubate 37°C 2 hr.
Wash.
2. Add D_^  arnfieldi antigen columns 3-12.
Initial dilution 1:50. Doubling dilutions.
Incubate 37°C 30 min.
Wash.
3. Add biotinylated antibody columns 3-10. Plate 1 R^B.
Plate 2 R2B.
Initial dilution 1:25. Doubling dilutions.— ^
Incubate 37°C 30 min.
Wash.
4. Add Streptavadin peroxidase 1:1000 all wells.
Incubate 37°C 30 min.
Wash.
5. Add substrate O.P.D. all wells.
Incubate 37°C in dark 40 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.10
ELISA - Titration of both R^ and R 2  with arnfieldi Antigen
and both R^B and R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates with antibody starting column 2. Plate 1 R ^ .
Plate 2 R2
Initial dilution 1:25. Doubling dilutions
Incubate 37°C 2 hr.
Wash.
2. Add D_;_ arnf ieldi antigen starting column 2.
Initial dilution 1:50. Doubling dilutions.'!'
Incubate 37°C 30 min.
Wash.
3. Add biotinylated antibody 1:50 all wells. Plate 1 R^B,
Plate 2 R2B
Incubate 37°C 30 min.
Wash.
4. Add Streptavadin peroxidase 1:1000 all wells 
Incubate 37°C 30 min.
Wash.
5. Add substrate O.P.D.
Incubate 37°C in dark 30 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.11
ELISA - Titration of with arnf ieldi Antigen in Bovine Serum
and R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plate antibody - R2.
Initial dilution 1:50. Doubling dilutions.— >
Incubate 37°C 2 hr.
Wash.
2. Add arnfieldi antigen in bovine serum. Starting column 2.
Initial dilution 1:5. Doubling dilutions. ^
Incubate 37°C 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:50. All wells.
Incubate 37°C 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark 30 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.12
ELISA - Titration of R^ and D^ _ arnfieldi Antigen in Bovine Serum with
R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 pl/well.
1. Coat plate antibody - ~ Not column 1. 1:50.
Incubate 37°C 2 hr.
Wash.
2. Add D_^  arnfieldi Antigen in bovine serum. Starting neat in column 2. 
Doubling dilutions— ^
Incubate 37°C 30 min.
Wash.
3. Add biotinylated antibody - R2B. 1:50. All wells.
Incubate 37°C 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark 30 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.13
ELISA - Titration of with arnf ieldi Antigen in Bovine Serum and
R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plate antibody - R^ - 1:100 starting column 2.
Incubate 37°C 2 hr.
Wash.
2. Add arnfieldi antigen in bovine serum. Columns 2 - 1 1 .
Initial dilution - neat column 2. Doubling dilutions— ^
Incubate 37°C 30 min.
Wash.
3. Add biotinylated antibody - R2B. 1:100. All wells.
Incubate 37°C 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark 45 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.14
ELISA - Titration of with IK arnfieldi Antigen and R^B Using
Streptavadin Peroxidase at 1:1000 or TMB
All volumes 50 jil/well.
1. Coat plate antibody ” ^2 ~ 1 1100- Starting column 2.
Incubate 37°C 2 hr.
Wash.
2. Add IK_ arnfieldi antigen. Columns 2-11.
Initial dilution 1:100. Doubling dilutions— ^
Incubate 37°C 30 min.
Wash.
3. Add biotinylated antibody - R2B 1:100. Columns 2-12.
Incubate 37°C 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells - plate 1 only. 
Incubate 37°C 30 min.
Wash.
5. Add substrate. All wells.
Plate 1 - O.P.D. Incubate 37°C in dark 30 min.
Stop with acid. Read 492 nm.
Plate 2 - T.M.B. Incubate 37°C 15 min.
Read 450 nm.
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Appendix 2.15
ELISA - Titration of with both Untreated and EDTA-Treated
D. arnfieldi Antigen and R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 ^ll/well.
Coat plate antibody - R£ - 1:100. Columns 2-12.
Incubate 37°C 2 hr.
Wash.
Add D_j_ arnfieldi antigen. Starting column 2 (neat).
Doubling dilutions— ^
Plate 1 - non-boiled Plate 2 - boiled with EDTA.
Incubate 37°C 30 min.
Wash.
Add biotinylated antibody - R2B - 1:100. All wells.
Incubate 37°C 30 min.
Wash.
Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C 30 min.
Wash.
Add substrate O.P.D.
Incubate 37°C in dark 40 min.
Stop with acid. Read 492 nm.
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Appendix 2.16
ELISA - Titration of with both Boiled and Non-Boiled arnfieldi
Antigen and R^B Using Streptavadin Peroxidase at 1:1000 and 1:5000
All volumes 50 jil/well.
1. Coat plate antibody “ ^2 ~ 1*100* Columns 2-12.
Incubate 37°C 2 hr.
Wash.
2. Add D_^  arnf ieldi antigen. Rows A - D non-boiled.
Rows E - H boiled.
Initial dilution neat - Doubling dilutions— ^
Starting columns 2-6 and 7-12.
Incubate 37°C 40 min.
Wash.
3. Add biotinylated antibody - R2B 1:50. Columns 2-11.
Incubate 37°C 40 min.
Wash.
4. Add streptavadin peroxidase. Columns 2-6 1:1000.
Columns 7-11 1.5000.
Incubate 37°C 40 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark 40 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.17
ELISA - Titration of with both Bovine Serum and Bovine Serum Plus
D. arnfieldi Antigen and R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plate antibody “ ^2 ” 1:100. Columns 2-12.
Incubate 37°C 2 hr.
Wash.
2. Add. Rows A, B, C, D bovine serum.
Column 2 - Initial dilution neat.
Doubling dilutionsr—>
Rows E, F, G, H arnfieldi antigen in bovine serum.
Column 2 - Initial dilution 1:100.
Doubling dilutions:— >
Incubate 37°C A0 min.
Wash.
3. Add biotinylated antibody - R2B 1:100.
Rows A - D Columns 2-6
Rows E - H Columns 2-12 
Incubate 37°C 40 min.
Wash.
4. Add streptavadin peroxidase 1:1000. Rows A - D Columns 2-9
Rows E - H Columns 2-12
Incubate 37°C 40 min.
Wash.
5. Add substrate. O.P.D. All wells.
Incubate 37°C in dark 40 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.18
ELISA - Titration of with both Bovine Serum and Bovine Serum Plus
D. arnfieldi Antigen and R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 ^il/well.
Coat plate antibody - R2 - 1:100. Columns 2-12.
Incubate 37°C 2 hr.
Wash.
Rows A - D. Add bovine serum.
Starting column 2 - Initial dilution neat.
Doubling dilutions*— ^ in 5% marvel.
Rows E - H. Add arnf ieldi antigen in bovine serum
Initial dilution column 2 1:100. Doubling dilutions— ^  in 5% marvel.
Incubate 37°C 40 min.
Wash.
Add biotinylated antibody - R2B - 1:100.
Rows A - D Columns 2-6.
Rows E - H Columns 2-12.
Incubate 37°C 40 min.
Wash.
Add streptavadin peroxidase 1:1000.
Rows A - D Columns 2-9.
Rows E - H Columns 2-12.
Incubate 37°C 40 min.
Wash.
Add substrate. O.P.D. All wells.
Incubate 37°C in dark 1 hr.
Stop with acid. Read 492 nm.
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Appendix 2.19
ELISA - Titration of with D_;_ arnf ieldi in Serum and Serum Only Using 
both 2.5% and 5% Marval as Diluting Agents and R2B Using 
Streptavadin Peroxidase at 1:1000 
All volumes 50 pl/well.
1. Coat plate antibody “ R2 “ 1 1100• All wells.
Incubate 37°C 2 hr.
Wash.
2. Add D^ _ arnfieldi antigen. Starting column 2.
Doubling dilutions— ^  in marvel to Column 11.
Rows A and B. Initial dilution 1:10 in serum. 2.5% marvel.
Rows C and D. Serum only. Initial dilution neat. 2.5% marvel.
Rows E and F. Initial dilution 1:10 in serum. 5% marvel.
Rows G and H. Serum only. Initial dilution neat. 5% marvel.
Incubate 37°C 30 min.
Wash.
3. Add biotinylated antibody - R^B. 1:100.
Rows A, B, E and F. Columns 2-11.
Rows C, D, G and H. Columns 2-6.
Incubate 37°C 30 min.
Wash.
4. Add streptavadin peroxidase. 1:1000.
Rows A, B, E and F. Columns 2-12.
Rows C, D, G and H. Columns 2-9.
Incubate 37°C 30 min.
Wash.
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5. Add substrate. O.P.D. All wells. 
Incubate 37°C in dark 30 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.20
ELISA - Titration of with IK arnf ieldi Antigen Plus Serum, Serum and
Marvel Alone Using Marval as a Diluting Agent and R^B Using
Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plate antibody - 
Incubate 37°C 2 hr.
Wash.
2. Rows A and B. Add IK_ arnf ieldi in serum.
Initial dilution Column 2 1:10 in serum.
Doubling dilutions in 2.5% marvel:— ^
Rows C and D. Add serum. Initial dilution column 2 neat.
Doubling dilutions in 2.5% marvelr ^
Rows E and F. Add marvel. Start column 3.
Incubate 37°C 30 min.
Wash.
3. Add biotinylated antibody - R£B - 1:100. Columns 2-12.
Incubate 37°C 30 min.
Wash.
4. Add streptavadin peroxidase. 1:1000. All wells.
Incubate 37°C 30 min.
Wash.
5. Add substrate. O.P.D. All wells.
Incubate 37°C in dark 30 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.21
ELISA - Titration of with Duplicate Serum Samples from Infected 
Animals and R^B Using Streptavadin Peroxidase at 1:1000 
All volumes 50 pl/well.
Coat plates antibody “ ^  - 
Incubate 37°C 2 hr.
Wash.
Add antigen - Plate 1.
Row A. Columns 2-10. D_j_ arnf ieldi antigen in bovine serum. Initial
dilution 1:10. Doubling dilutions— >
Rows B - H. Columns 2 and 3
Columns 4 and 5
Columns 6 and 7
Rows B - H. Columns 8 and 9
1:2 ) Serum samples from infected
) animals. Dilutions in 2.5%
1:4 ) marvel. Two wells for each
) sample at each dilution
1:8 )
1:2 ) Serum samples from infected 
) animals 
(Not Row F) Columns 10 and 11 1:4 )
Columns 12 and 2 and 3 (Plate 2) 1:8
Row H (Plate 1) Columns 8-12 no sample added.
Plate 2 Row A - Columns 2-10 - as plate 1
Rows B - D. Columns 4 and 5 
Columns 6 and 7 
Columns 8,9,10
Incubate 37°C 30 min.
Wash.
1:2 )
) Serum samples from 
1:4 ) infected animals as 
) before 
1:8 )
3. Add biotinylated antibody - R2B 
All wells bar column 10 plate 2. 
Incubate 37°C 30 min.
-  1:100
Wash.
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4. Add streptavadin peroxidase 1:1000. All wells bar column 12 Rows E -
H plate 1.
Incubate 37°C 30 min.
Wash.
5. Add substrate. O.P.D. All wells bar column 12 Rows A - D plate 1. 
Incubate 37°C in dark 30 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.22
ELISA - Titration of with Duplicate Serum Samples from Infected
Animals and R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody R2 1:100. All wells.
Incubate 37°C 2 hr.
Wash.
2. All dilutions in 2.5% marvel.
Row A. Starting column 2 (neat). Add D_j_ arnf ieldi antigen.
EDTA treated. Doubling dilutions— ^  to column 11.
Row B. Starting column 2 (neat). Add arnfieldi antigen.
) Serum samples from
dilutions ^ to col
- H. Columns 2-3 (neat)
Columns 4-5 1:2
Columns 6-7 1:4
Columns 8-9 (neat)
Columns 10- 11 1:2
- H. Columns 2-3 1:4
- F. Columns 4-5 (neat)
Columns 6-7 1:2
Columns 8-9 1:4
Incubate 37 C 30 min. 
Wash.
Two
) wells for each sample
)
 ) As above 
)
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3. Add biotinylated antibody - I^B 1:100. All wells. 
Incubate 37°C 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells. 
Incubate 37°C 30 min.
Wash.
5. Add substrate. O.P.D. All wells.
Incubate 37°C in dark 40 min.
6. Stop with acid. Read 492 nm.
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Appendix 2.23
ELISA - Titration of R^ with Serum from Possibly Infected Animals with
R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C. 2 hr.
Wash.
2. All dilutions in 2.5% Marvel.
Row A. Starting Column 2. Add D^ _ arnfieldi antigen (initial dilution 
1:10 in PBS). Doubling dilutions to Column 9 
Row B. Starting Column 2. Add arnfieldi antigen (initial dilution 
1:10 in horse serum). Doubling dilutions to Column 9:— ^  
Samples from possibly infected animals added as listed:- 
Plate 1, rows C-H, columns 2-7 - one animal per row.
Plate 1, rows C-H, columns 8-12 and Plate 2, rows C-H, columns 2-3 - 
one animal per row.
Plate 2, rows C-H, columns 4-8 - one animal per row.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
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5. Add substrate O.P.D. All wells. 
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.24
ELISA - Titration of with D^ arnfieldi Antigen, Following Various
Treatments and with Dilutions made in Marvel and Diluting Buffer, with R 2
Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plate antibody (R2) 1:100. All wells.
Incubate 37°C. 2 hr.
Wash.
2. Starting column 2, initial dilution 1:50. Doubling dilutions*—^  
to column 11.
Row A - D_j_ arnf ieldi antigen in PBS 
Row B - EDTA treated IL_ arnfieldi antigen 
Row C - Periodate treated D^ _ arnfieldi antigen 
Row D - Marvel only 
Row E - D^ arnfieldi antigen in PBS 
Row F - EDTA treated D^ arnfieldi antigen 
Row G - Periodate treated D^ arnf ieldi antigen 
Row H - Diluting buffer alone 
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
All dilutions in 
2.5% Marvel
All dilutions in 
diluting buffer
218
Appendix 2.24 (Cont'd)
5. Add substrate O.P.D. All wells. 
Incubate 37°C in dark, 30 min.
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Appendix 2.25
ELISA - Titration of with D;. arnfieldi Antigen in PBS
or Horse Serum Diluted in Marvel or Diluting Buffer 
with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
Coat plate antibody (R2) 1:100. All wells.
Incubate 37°C. 2 hr.
Wash.
Starting column 2. Initial dilution 1:10. Doubling dilutions 
to column 11.
Row A - D^ arnfieldi antigen in PBS
Row B & C - arnfieldi antigen in horse serum
Row D - Horse serum only
Row E - Dj_ arnf ieldi antigen in PBS
Row F & G - D_^  arnf ieldi antigen in horse serum
Row H - Horse serum only
Incubate 37°C, 30 min.
Wash.
Add biotinylated antibody (R2B) 1:100. All wells 
Incubate 37°C, 30 min.
Wash.
Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
Add substrate O.P.D. All wells.
Dilutions in 
2.5% Marvel
Dilution in 
diluting buffer
Incubate 37 C in dark, 30 min.
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6. Stop with acid. 
Read 492 nm.
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Appendix 2.26
ELISA - Titration of with arnfieldi Antigen in Horse Serum and Serum
Samples from Animals with R^B Using Streptavadin at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R£) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. All plates. Starting column 2, initial dilution 1:10. Doubling 
dilutions— -^ to column 11.
Row A - Horse serum with D_j_ arnf ieldi antigen.
Row B - Horse serum only.
Row C - Bovine serum only.
Rows D-H - Samples from animals - one animal per row.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.27
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated, 
from Animals with R2B Using Streptavadin Peroxidase at 1:1000 
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Starting column 2. Initial dilution 1:100. Doubling dilutions— ^
to column 11. All dilutions in 2.5% Marvel.
Row A - D^ _ arnfieldi antigen in horse serum.
Row B - Horse serum only.
Row C - Marvel only.
Rows D-H - Samples from sanimals - one animal per row.
Plate 1 - untreated samples.
Plate 2 - all samples treated with EDTA before use.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.28
ELISA - Titration of and Serum Samples from Donkeys with R^B
Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plate antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Starting column 2. Doubling dilutions — >  in 5% Marvel.
Row A - p_^  arnfieldi antigen in horse serum - initial dilution 1:10. 
Row B - Horse serum only - initial dilution 1:10.
Row C - Marvel 5%.
Row D-H - Samples from donkeys - neat.
Incubate 37°C, 40 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 40 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 40 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 40 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.29
ELISA - Titration of and Serum Samples from Animals with
Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Starting column 2. Doubling dilutions— >  Dilutions in 2.5% Marvel. 
Row A - D^ arnf ieldi antigen in horse serum. Initial dilution 1:10. 
Row B - Horse serum only. Initial dilution - neat.
Row C - Marvel only.
Row D-H - Samples from animals - one animal per row.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 run.
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Appendix 2.30
ELISA - Titration of and Serum Samples from Infected and Non-Infected
Donkeys with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 pl/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Starting column 2. Doubling dilutions— ^  Dilutions in 2.5% Marvel. 
Row A ~'D_j_ arnf ieldi antigen in horse serum. Initial dilution 1:10. 
Row B - Horse serum only. Initial dilution - neat.
Rows C-H Plate 1. Samples from donkey with patent infection.
Rows C-G Plate 2. Samples from donkey without patent infection.
Row H Plate 2. Sample from donkey with patent infection.
Samples start column 2, initial dilution - neat, one sample per row. 
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.31
ELISA - Titration of and Serum Samples from Animals with R^B
Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - arnfieldi antigen in horse serum. Initial dilution 1:10. 
Row B - Horse serum only. Initial dilution - neat.
Starting column 2. Doubling dilutions — >  column 11.
Dilutions in 2.5% Marvel.
Rows C-E ) Samples added, 3 of each columns 2-12 
)
Rows F-G ) excluding Plate 2 columns 10 & 11.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.32
ELISA - Titration of and Serum Samples from Animals with R^B
Using Streptavadin Peroxidase at 1:1000
All volumes 50 Jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Starting column 2.
Row A - D_^  arnfieldi antigen in horse serum. Initial dilution 1:10.
Row B - Horse serum only. Initial dilution - neat.
Doubling dilutions — ^  in 2.5% Marvel.
Rows C & D ) Samples in duplicate - one animal per column 
)
Rows E & F ) excluding columns 11 & 12, rows G & H, plate 5.
)
Rows G & H )
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.33
ELISA - Titration of and Serum Samples from Animals with R^B
Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - arnfieldi antigen in horse serum. Initial dilution 1:10. 
Row B - Horse serum only. Initial dilution - neat.
Starting column 2. Doubling dilutions— ^  in 2.5% Marvel. 
Row C & D )
) Samples in duplicate, one animal per column.
Row E & F )
)
Row G & H )
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.34
ELISA - Titration of and Serum Samples from Animals with R^B
Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R^) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - arnfieldi antigen in horse serum - Initial dilution 1:10. 
Row B - Horse serum only - Initial dilution - neat.
Starting column 2 - Doubling dilutions ^  in 2.5% Marvel. 
Row C & D )
) Samples in duplicate, one animal per column
Row E & F )
) excluding rows G & H, columns 5-12
Row G & H )
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R^B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.35
ELISA - Titration of with Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 ^ il/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - arnfieldi antigen in horse serum - Initial dilution 1:10. 
Row B - horse serum only. Initial dilution - neat.
Starting column 2 - Doubling dilutions— ^  in 2.5% Marvel. 
Rows C, E & G - Untreated serum samples
Rows D, F & H - Serum samples as above but EDTA treated.
Samples start column 2. 
indicates no sample.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6 . Stop with acid.
Read A92 nm.
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Appendix 2.36
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 ^ il/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A  - Eh_ arnfieldi antigen in horse serum. Initial dilution 1:10. 
Row B - Horse serum only. Initial dilution - neat.
Starting column 2. Doubling dilutions— ^  in 2.5% Marvel 
Rows C, E & G - Untreated serum samples.
Rows D, F & H - EDTA treated serum samples above.
Samples start column 2.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.37
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R^) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - D_j_ arnfieldi antigen in horse serum. Initial dilution 1:10. 
Row B - Horse serum only. Initial dilution - neat.
Starting column 2. Doubling dilutions— ^  in 2.5% Marvel.
Rows C, E & G. Untreated serum samples.
Rows D, F & H. EDTA treated serum samples as above.
Samples start column 2.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.38
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - D_j_ arnfieldi antigen in horse serum. Initial dilution 1:10. 
Row B - Horse serum only. Initial dilution - neat.
Starting column 2. Doubling dilutions— ^  in 2.5% Marvel. 
Rows C, E & G. Untreated serum samples.
Rows D, F & H. EDTA treated serum samples as above.
Samples start column 2.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.39
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated, 
from Animals with R^B Using Streptavadin Peroxidase at 1:1000 
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - arnfieldi antigen in horse serum. Initial dilution 1:10. 
Row B - Horse serum only. Initial dilution - neat.
Starting column 2. Doubling dilutions — -^  in 2.5% Marvel.
Rows C, E & G. Untreated serum samples
Rows D, F & H. EDTA treated serum samples as above.
Samples start column 2. Excluding Plate 2, rows G & H, 
columns 10 & 11.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.40
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - arnfieldi antigen in horse serum. Initial dilution 1:10. 
Row B - Horse serum only. Initial dilution - neat.
Starting column 2. Doubling dilutions in 2.5% Marvel.
Rows C, E & G. Untreated serum samples.
Rows D, F & H. EDTA treated serum samples as above.
Samples start column 2.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 392 nm.
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Appendix 2.41
ELISA - Titration of R^ and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - D_^  arnfieldi in horse serum. Initial dilution 1:10.
Row B - Horse serum only. Initial dilution - neat.
Starting column 2. Doubling dilutions— ^  in 2.5% Marvel. 
Rows C, E & G. Untreated serum samples.
Rows D, F & H. EDTA treated serum samples as above.
Samples start column 2. Excluding plate 2, rows E & F.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.42
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2 - 7 - D^ _ arnfieldi antigen. Initial dilution 1:10,
Doubling dilutions—-^ to column 11.
Columns 8 - 11- Horse serum only. Initial dilution - neat.
Doubling dilutions --->
Rows B, D & F - Untreated samples.
Rows C, E & G - EDTA treated samples.
Row H - Columns 2, 4, 6, 8, 10 & 12 - Untreated samples.
Columns 3, 5, 7, 9, 11 ~ EDTA treated samples.
Row A - Column 12 - EDTA treated sample.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
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Appendix 2.42 (Cont'd)
6. Stop with acid. 
Read 492 nm.
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Appendix 2.43
LISA - Titration of R and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coats plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-11 - arnfieldi antigen in horse serum.
Row B - Columns 2-11 - Horse serum only. Initial dilution - neat.
Rows C, E & G - Untreated samples excluding rows E & G, columns 10-12.
Rows D, F & H - EDTA treated samples excluding rows F & H, columns 10-12
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
Initial dilution 1:10. Doubling dilutions
Doubling dilutions
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Appendix 2.44
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated, 
from Animals with R^B Using Streptavadin Peroxidase at 1:1000 
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-9 arnfieldi antigen in horse serum.
Initial dilution 1:10. Doubling dilutions —■£* 
Rows B, D & F - Untreated samples. Starting column 2.
Rows C, E & G - EDTA treated samples. Starting column 2.
Row H - Columns 2, 4, 6, 8, 10 & 12 - Untreated samples.
Columns 3, 5, 7, 9, 11 - EDTA treated samples.
Row A - Column 11 - Untreated sample.
Columns 10 & 12 - EDTA treated samples.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.45
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
2. Row A - Columns 2-6 - arnfieldi in horse serum. Initial
dilution 1:10. Doubling dilutions— >  
Columns 7-11 - Horse serum only. Initial dilution - neat. 
Doubling dilutions *— ^
Rows B, D & F - Untreated samples.
Rows C, E & G - EDTA treated samples.
Row H - No samples.
Incubate 37°C, 30 min.
Wash.
3. Add biotintylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.46
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated, 
from Animals with R^B Using Streptavadin Peroxidase at 1:1000 
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-6 - D_j_ arnfieldi antigen in horse serum. Initial
dilution 1:10. Doubling dilutions— ^
Columns 7-11 - Horse serum only. Initial dilution - neat. 
Doubling dilutions — ^
Rows B, D fie F - Untreated samples.
Rows C, E f i e  G - EDTA treated samples.
Row H - Columns 2, 4, 6, 8 & 10 - Untreated samples.
Columns 3, 5, 7, 9 f i e  11 - EDTA treated samples.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.47
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-6 - arnfieldi antigen in horse serum. Initial
dilution 1:10. Doubling dilutions*— ^
Columns 7-11 - Horse serum only. Initial dilution - neat. 
Doubling dilutions— ^
Rows B, D & F - Untreated samples.
Rows C, E & G - EDTA treated samples.
Row H - Columns 2, 4, 6, 8, 10 & 12 - Untreated samples.
Columns 3, 5, 7, 9, 11 - EDTA treated samples.
Row A - Column 11 - Untreated sample.
Columns 10 & 12 - EDTA treated samples.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
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6. Stop with acid. 
Read 492 nm.
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Appendix 2.48
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated, 
from Animals with R^B Using Streptavadin Peroxidase at 1:1000 
All volumes 50 jil/well.
1. Coat plates antibody (l^) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-6 - D_;_ arnfieldi antigen in horse serum. Initial
dilution 1:10. Doubling dilutions— ^
Colums 7-11 - Horse serum only. Initial dilution - neat.
Doubling dilutions — >
Rows B, D & F - Untreated samples.
Rows C, E & G - EDTA treated samples.
Row H - Columns 2, 4, 6, 8, 10 & 12 - Untreated samples.
Columns 3, 5, 7, 9, 11 - EDTA treated samples.
Row A - Column 11 - Untreated sample.
Columns 10 & 12 - EDTA treated samples.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
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5. Add substrate O.P.D. All wells. 
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.49
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50jil/well.
1. Coat plates antibody (R^) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-6 - D^ arnfieldi in horse serum. Initial
dilution 1:10. Doubling dilutions— ^ 
Columns 7-11 - Horse serum only. Initial dilution - neat. 
Doubling dilutions— ^
Rows B, D & F - Untreated samples.
Rows C, E & G - EDTA treated samples.
Row H - Columns 2, 4, 6, 8, 10 & 12 - Untreated samples.
Columns 3, 5, 7, 9, 11 - EDTA treated samples.
Row A - Column 11 - Untreated sample.
Columns 10 & 12 - EDTA treated samples.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
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5. Add substrate O.P.D. All wells. 
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.50
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2 ) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-6 - D_;_ arnfieldi antigen in horse serum. Initial
dilution 1:10. Doubling dilutions— ^
Columns 7-11 - Horse serum only. Initial dilution - neat. 
Doubling dilutions —
Rows B, D & F - Untreated samples.
Rows C, E & G - EDTA treated samples.
Row H - Columns 2, 4, 6, 8, 10 - Untreated samples.
Columns 3, 5, 7, 9, 11 - EDTA treated samples.
Row A - Column 11 - Untreated sample.
Column 12 - EDTA treated sample.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2 B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
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5. Add substrate O.P.D. All wells. 
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.51
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (l^) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-6 - arnfieldi antigen in horse serum. Initial
dilution 1:10. Doubling dilutions — >
Columns 7-11 - Horse serum only. Initial dilution - neat. 
Doubling dilutions — >
Rows B, D & F - Untreated samples.
Rows C, E & G - EDTA treated samples.
Row H - Columns 2, 4, 6, 8, 10 & 12 - Untreated samples.
Columns 3, 5, 7, 9, 11 - EDTA treated samples.
Row A - Column 11 - Untreated sample.
Columns 10 & 12 - EDTA treated samples.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2 B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
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5. Add substrate O.P.D. All wells. 
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.52
ELISA - Titration of and D^ arnfieldi Antigen in Horse Serum and Marvel
with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R2 ) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-6 ) Horse serum starting columns 2 & 8. Initial
)
Columns 8-12 ) dilution - neat. Doubling dilutions
in 2.5% Marvel.
Rows B-H - Columns 2-6 - D_^  arnfieldi antigen starting column 2.
Initial dilution 1:2. Doubling dilutions— >  
in 2.5% Marvel.
Columns 8-12 - D^ arnfieldi antigen in horse serum starting
column 8. Initial dilution 1:2.
Doubling dilutions— ^  in 2.5% Marvel.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2 B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
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5. Add substrate O.P.D. All wells. 
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.53
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Donkeys with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 ^il/well.
1. Coat plates antibody (R2 ) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - D_^  arnfieldi antigen. Starting column 2. Initial dilution 1:10
Doubling dilutions— ^  in 1.25% Marvel.
Row B - Horse serum. Starting column 2. Initial dilution - neat.
Doubling dilutions — >  in 1.25% Marvel.
Row C - Columns 2-8 - Untreated donkey samples.
Row D - Columns 2-8 - EDTA treated donkey samples.
Rows E, F & G - No samples.
Row H - Horse serum. Starting column 2 - Initial dilution - neat.
Doubling dilutions — 1.25% Marvel.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2 B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
5. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
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6. Stop with acid. 
Read 492 nm.
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Appendix 2.54
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 |il/well.
1. Coat plates antibody (R2 ) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-5 - D^ arnfieldi antigen in horse serum.
Initial dilution 1:10.
Doubling dilutions-— ^ in 2.5% Marvel. 
Columns 6-9 - Horse serum. Initial dilution - neat.
Doubling dilutions— ^  in 2.5% Marvel.
Rows B, D & F - Untreated samples.
Rows C, E & G - EDTA treated samples.
Row H - Columns 2, 4, 6, 8, 10 & 12 - Untreated samples.
Columns 3, 5, 7, 9 & 11 - EDTA treated samples.
Row A - Column 11 - Untreated sample.
Columns 10 & 12 - EDTA treated samples.
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2 B) 1:100. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells.
Incubate 37°C, 30 min.
Wash.
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5. Add substrate O.P.D. All wells. 
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.55
ELISA - Titration of and Serum Samples, Untreated and EDTA-Treated,
from Animals with R^B Using Streptavadin Peroxidase at 1:1000
All volumes 50 jil/well.
1. Coat plates antibody (R9) 1:100. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Row A - Columns 2-8
Row B - Columns 2-8
Rows C, E & G - Columns 
Row A - Columns 9-12 
Rows D, F & H - Columns 
Row B - Columns 9~12 
Incubate 37°C, 30 min.
Wash.
3. Add biotinylated antibody (R2 B) 1:100. All wells. 
Incubate 37°C, 30 min.
Wash.
4. Add streptavadin peroxidase 1:1000. All wells. 
Incubate 37°C, 30 min.
Wash.
D. arnfieldi antigen. Initial dilution - neat
Doubling dilutions— ^ in 2.5% Marvel.
Starting column 2.
Horse serum. Initial dilution - neat.
Doubling dilutions — > in 2.5% Marvel.
Starting column 2.
2-12 )
) Untreated samples 
)
2-12 )
) EDTA treated samples 
)
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5. Add substrate O.P.D. All wells. 
Incubate 37°C in dark, 30 min.
6. Stop with acid.
Read 492 nm.
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Appendix 2.56
ELISA - Titration of D_;_ arnfieldi Antigen and or Serum from an Infected
Hare with anti-Rabbit or anti-Horse IgG Peroxidase
All volumes 50 ^ll/well.
1. Coat plates D_j_ arnf ieldi antigen - Columns 2-6 and columns 7-11.
Initial dilution 1:10. Doubling dilutions— ^
Incubate 37°C, 2 hr.
Wash.
2. Columns 2-6 - Add antibody (R^). Initial dilution 1:10.
Doubling dilutions— > starting row A, in 2.5% Marvel.
Columsn 7-11 - Add serum from a D^ arnfieldi infected mare.
Initial dilution 1:10. Doubling dilutions — >  
starting row A, in 2.5% Marvel.
Incubate 37°C, 30 min.
Wash.
3. Columns 2-6 - Add anti-rabbit IgG peroxidase 1:500.
Columns 7~9 - Add anti-horse IgG peroxidase 1:500.
Columns 10-11 - Add anti-horse IgG peroxidase 1:1000.
Incubate 37°C, 30 min.
Wash.
4. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
5. Stop with acid.
Read 492 nm.
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Appendix 2.57
ELISA - Titration of IK arnfieldi Antigen and Serum Samples, in
from Infected Animals with anti-Horse IgG at 1:500
All volumes 50 jil/well.
1. Coat plate IK_ arnf ieldi antigen 1:40. All wells.
Incubate R.T. overnight.
Wash.
2. Add samples as below. Initial dilution - neat. Doubling
dilutions ^  Starting rows A and E.
3.
4.
5.
Columns 2-4 
Columns 5-7 
Columns 8-10 
Columns 11-12 
Columns 2-4 
Columns 5-7 
Columns 8-10 
Columns 11-12 
Incubate 37°C, 30 min.
Wash.
Add anti-horse IgG 1:500. All wells. 
Incubate 37°C, 30 min.
Wash.
Add substrate O.P.D. All wells. 
Incubate 37°C in dark, 30 min.
Stop with acid.
Read 492 nm.
Rows A - D
One animal per group of three columns 
(except 11 & 12 when only 2 samples)
Rows E - H
One animal per group of three columns 
(except 11 & 12 when only 2 samples)
Triplicate,
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Appendix 2.58
ELISA - Titration of IK arnfieldi Antigen and Serum Samples, in Triplicate,
from Infected Animals with anti-Horse IgG at 1:500
All volumes 50 jil/well.
1. Coat plate IK_ arnfieldi antigen 1:40. All wells.
Incubate R.T. overnight.
Wash.
2. Add samples as below. Initial dilution 1:10. Doubling
dilutions ^  Starting rows A and E.
Columns 2-4 
Columns 5-7 
Columns 8-10 
Columns 11-12 
Columns 2-4 
Columns 5-7 
Columns 8-10 
Columns 11-12 
Incubate 37°C, 30 min.
Wash.
3. Add anti-horse IgG 1:500. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
5. Stop with acid.
Read 492 nm.
Rows A - D
One animal per group of three columns 
(except 11 & 12 when only 2 samples)
Rows E - H
One animal per group of three columns 
(except 11 & 12 when only 2 samples)
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Appendix 2.59
ELISA - Titration of arnfieldi Antigen and Serum Samples, in Triplicate,
from Infected Animals with anti-Horse IgG at 1:500
All volumes 50 jil/well.
1. Coat plate arnfieldi antigen 1:40. All wells.
Incubate R.T. overnight.
Wash.
2. Add samples as below. Initial dilution - neat. Doubling
dilutions Starting rows A and E.
Columns 2-4 
Columns 5-7 
Columns 8-10 
Columns 11-12 
Columns 2-4 
Columns 5-7 
Columns 8-10 
Columns 11-12 
Incubate 37°C, 30 min.
Wash.
3. Add anti-horse IgG 1:500. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
5. Stop with acid.
Read 492 nm.
Rows A - D
One animal per group of three columns 
(except 11 & 12 when only 2 samples)
Rows E - H
One animal per group of three columns 
(except 11 & 12 when only 2 samples)
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Appendix 2.60
ELISA - Titration of arnfieldi Antigen and Serum Samples, in
from Infected Animals with anti-Horse IgG at 1:500
All volumes 50 jil/well.
1. Coat plate EL_ arnfieldi antigen 1:20. All wells.
Incubate 37°C, 2 hr.
Wash.
2. Add samples as below. Initial dilution - neat. Doubling
dilutions 4^ Starting rows A and E.
Columns 2-4 
Columns 5-7 
Columns 8-10 
Columns 11-12 
Columns 2-4 
Columns 5-7 
Columns 8-10 
Columns 11-12 
Incubate 37°C, 30 min.
Wash.
3. Add anti-horse IgG 1:500. All wells.
Incubate 37°C, 30 min.
Wash.
4. Add substrate O.P.D. All wells.
Incubate 37°C in dark, 30 min.
5. Stop with acid.
Read 492 nm.
Rows A - D
One animal per group of three columns 
(except 11 & 12 when only 2 samples)
Rows E - H
One animal per groups of three columns 
(except 11 & 12 when only 2 samples)
Triplicate,
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